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 i 
 
Abstract 
 
Introduction and rationale: High flow nasal cannula therapy is being increasingly used as a 
form of respiratory support across the world. Its adoption and popularity have been rapid but 
little is known regarding its key mechanism of action even after more than a decade of its use. 
I conducted a proof of concept study of respiratory physiology during high flow therapy in 
preterm neonates.  
 
Methods: The study protocol involved measurement of nasopharyngeal airway pressures and 
gas concentrations as well as measurement of tidal breathing indices. A detailed descriptive 
review of clinical efficacy of high flow nasal cannula in preterm infants was performed. In 
order to identify the optimum measuring techniques, in this proof of concept study, three 
types of pressure measuring techniques, a gas analyser device and a non-invasive tidal 
breathing indices device were studied and the results are presented in this thesis. In addition, a 
detailed protocol for a larger randomised crossover study of respiratory physiology during 
continuous positive airway pressure of 6 cm H2O and high flow nasal cannula therapy ranging 
from 2-8 litres per minute flow was designed..  
 
Results: In this thesis, the results of a proof of concept physiological study have been 
presented. The results of the measurements performed in six babies of varying gestational age 
(less than 37 weeks of gestation) and birth weight are presented. Valid tidal volumes were 
measured in all babies, nasopharyngeal gas concentrations and pressure measurements in five 
and two babies respectively. There were no adverse events.  
 
Conclusions: It is feasible to measure nasopharyngeal air way pressures and gas 
concentrations as well as non-invasive tidal breathing indices in babies on high flow nasal 
cannula therapy safely. This study was successfully followed up by a larger randomised cross 
over study involving 45 infants with the same protocol.  
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 2 
 
1.1 Prevalence of HFNC use 
 
1.1.1 Definition 
 
In the Cochrane review of HFNC in neonates the following definition was used to identify 
relevant studies – ‘High flow nasal cannulae (HFNC) are small, thin, tapered binasal tubes 
that deliver oxygen or blended oxygen/air at gas flows of more than 1 L/min’(1). 
 
The flow rate is considered high flow when it is above that used in conventional low flow 
system. In LFNC system, the oxygen is not humidified or heated and is delivered by standard 
nasal cannulae (1-3). 
 
However, defining HFNC in absolute numbers without taking into account patient population 
that it is being used on is likely to be inaccurate. For example, a flow of 1-2 litres per minute 
in an older child or an adult may not be high flow. The flow has to be well above the 
inspiratory flow demands of a patient when in respiratory distress. The inspiratory flow 
demands rise significantly at times of respiratory distress.  
 
In the context of this study, as this study is in neonates, a definition of more than 1 litre per 
minute flow is used.  
 
1.1.2 History of HFNC usage 
 
The current modern high flow nasal cannula therapy systems have evolved over time. This 
was possible due to inventions that led to the development of apparatus adapted to heat and 
humidify air and to deliver heated and humidified air to the respiratory tract of a human 
patient. The integration of blenders that deliver varying concentrations of oxygen to the 
patient has also been crucial. There were a series of inventions in the 1970s that led to 
humidification of gases and in 1980s heating and humidification technologies were further 
improved (4). 
 
The delivery of oxygen and oxygen enriched air to the respiratory tract of a patient can cause 
discomfort. If this gas mixture also has low humidity it increases the respiratory irritation. The 
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respiratory irritation is worse when the oxygen and air mixture is administered over a long 
period of time (4). 
 
Some of the early examples of inventions that tried to overcome this problem include a device 
developed by Richard H Blackmer in 1981 that allowed oxygen enriching apparatus to 
increase or regulate the humidity of the air. The air supplied to the patient may be heated by 
circulation of warm air over delivery tubing, use of electric resistance heaters or circulating 
warm liquid co-linearly with the delivery tubing (4, 5). Similarly Fisher and Paykel Ltd 
developed a heating and humidification device in 1985. In their design, the humidifier has the 
ability to create a vapour pressure sufficient to cause water vapour and deliver at a desired 
temperature (6). 
 
Throughout the 1980s and 1990s, various companies and individual scientists developed 
heating and humidification devices for delivery of blended air/oxygen mixture to patients (4). 
Vapotherm produced the first Food and Drug Administration (FDA) approved device for 
delivering humidified high flow therapy in neonates in 2004. This device was called 
Vapotherm 2000i. This approval was for intended use to add moisture and to warm breathing 
gases for administration to patients, including neonates/infants and paediatric or adult patients 
(7). 
 
These Vapotherm units were withdrawn from the market in January 2006 following concerns 
due to Ralstonia infection in some US neonatal units. This was followed by a period of 
individual units putting together their own systems for delivery of heated, humidified gas 
using basic components of a humidifier, respiratory circuit, adapter and nasal cannula (7). 
 
This was followed by device produced by Fisher and Paykel Healthcare (Auckland, New 
Zealand). This device called RT329 Infant Oxygen Delivery System was able to deliver 
heated (37C) and humidified (44 mg/L) gas via nasal cannula at flow rates of up to 8 L/min 
(7). 
 
Depending upon the manufacturer the methods of heating and humidification of gases in 
various high flow devices vary. For example, heating method in Vapotherm is by having a 
tube structure where warm water compartment encircles the respiratory gas delivery tube 
whereas in Fisher and Paykel system a heated wire coil is used which extends to the end of 
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the circuit (7). Currently there are many commercial systems available manufactured by 
different companies such as Vapotherm, Fisher and Paykel, ResMed.   The relative merits of 
these devices need investigating.  
 
1.1.3 Use of HFNC in neonatal units 
 
The use of HFNC in neonatal units has been on the rise. The common reasons cited for the 
use of HFNC over CPAP has been increased patient comfort, easier to apply and reduction in 
nasal trauma and to provide positive airway pressure support. The increase in use predated 
completion of large clinical trials.  
 
In an online survey of 157 neonatologists in Australia and New Zealand in the year 2012, 27 
neonatal units were contacted (8). The response rate was 71% with 67% returning complete 
response to the questionnaire (8). 63% of the neonatal units at that time were using HFNC (8). 
57% of the neonatologists replied that there was no published data on safety and clinical 
usefulness of HFNC in neonates, however 15 of the 27 neonatal units covered in this survey 
had some local policy in place for using HFNC (8). Rain out of the circuit with fluid 
instillation into the upper airway was the most common problem reported(8). Most reported 
(86%) that it was easier to apply and 84% reported HFNC was better tolerated by the 
babies(8) than CPAP. Only 21% of the units used HFNC as primary support for RDS whereas 
62% were using as post extubation respiratory support (8). HFNC was used as a primary 
treatment for apnoea of prematurity in 58% of the units (8). Side effects including 
pneumothorax, hyperinflated lung fields, pulmonary haemorrhage, or feeding intolerance 
were not documented with HFNC use (8).  
 
In the USA, Hochwald and Osiovich performed a questionnaire survey of 97 academic 
neonatal units, 69% of the responders were using HFNC (9).  
 
In 2009, a telephone survey of senior nurses working in 214 UK neonatal units found 55% of 
the units using HFNC (10). The definition of HFNC was flow rate more than 1 litre per 
minute (10). However only 77% of these units were humidifying the gases before delivery as 
high flow (10). This reflects the evolution of high flow nasal cannula technology that earlier 
high flow gases were delivered without appropriate humidification or heating to appropriate 
temperature.    
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A telephone survey of 203 UK neonatal units was done in 2012 with 100% response rate (11): 
113 (56%) of the neonatal units use some form of HFNC (11), 42% of the units used either 
HFNC initially or CPAP followed by HFNC following extubation (11). HFNC was used only 
as a step down from CPAP in 58% of the units (11). Flow rate at commencement varied 
between with 60% of the units starting at  HFNC at 8 litres per minute and 30% of the units at 
5-6 litres per minute (11). Most units weaned off the HFNC once the flow rate was 2-3 litres 
per minute (11).  
 
A web based survey of 57 Level 2 and 3 neonatal units was done from November 2011 to 
May 2012 in the UK with 77% response rate (12). Among the responders 77% of the units 
used HFNC (12), 50% of the units did not have any guideline for use of HFNC (12). 
Vapotherm was the most commonly used device with 47% of the units using it whereas 
Fisher and Paykel bRT329 was used in 38% units (12). Indications included as an alternative 
to CPAP in 77%, for weaning CPAP in 71%, and for post extubation support in 53% (12). 
Gradual reduction in flow rate was the most common method of weaning where as one unit 
weaned by reducing the time spent on HFNC (12).  
 
It is evident from the series of surveys that the prevalence of use of HFNC is increasing in 
neonatal units. This increase in use is not based on irrefutable evidence of its safety and 
efficacy. The ease of administration and no reports of significant serious short term adverse 
events might have allowed its acceptance.  
 
Recent studies on HFNC use in neonates have not reported increased incidence of BPD but 
information about 'Severe BPD' is lacking. We examined the incidence of 'Severe BPD' by 
performing a retrospective audit of neonatal unit data from Royal Victoria Infirmary, 
Newcastle upon Tyne looking at the population of preterm babies less than 32 weeks’ 
gestation that required oxygen beyond the first 28 days of life (13). The aims of the audit were 
to examine trends in use of non-invasive respiratory support and respiratory outcomes in 
neonates <32 weeks’ gestation receiving non-invasive ventilation (NIV) and to identify 
association between type of non-invasive respiratory support and severe BPD. 
 
A total of 776 babies with <32 weeks’ gestation were admitted during the five-year period 
between January 2008 and December 2012 (13). Among these, 282 preterm babies required 
oxygen >28days of life (13). Out of these, 128 babies received CPAP ± BiPAP alone and 154 
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received HFNC ± CPAP.(13) The use of HFNC increased during this five-year period and 
that of CPAP as the sole non-invasive respiratory support decreased as illustrated in the 
Figure 1. 
 
 
 
 
 
 
Figure 1. Five-year trend in NIV use 
 
 
 
 
 
 
Figure 1 shows the increase in use of HFNC during the 5-year period associated with decline 
in use of CPAP alone as non-invasive therapy. 
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1.2 High Flow Nasal Cannula Device Set Up 
 
HFNC system is composed of humidification unit and flow driver and different types of 
heating system to deliver warmed, humidified blended air/oxygen mixture at variable flow 
rate and adjustable FiO2. These gases are heated to temperature close to 37˚C, humidified to 
100% relative humidity and delivered to the patient via nasal cannulae.  
 
Several manufacturers currently produce different HFNC circuits and devices, which vary in 
heating and humidification methods. 
 
The HFNC devices currently available in the market differ in their technology in different 
aspects of HFNC system but underlying principle is to administer the heated, humidified 
blended gas mixture at desired flow rate and FiO2. A schematic diagram of a HFNC device is 
shown in figure 2.  
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Figure 2. Schematic diagram of a HFNC device(2) 
 
 
 
 
 
 
Figure 2 shows components of a typical HFNC device. 
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1.3 Mechanisms of Action 
 
The following mechanisms of action of the heated, humidified high flow nasal cannula system 
have been suggested. It is important to note that the relative contribution of these mechanisms 
is not yet clearly elucidated. The possible role of these mechanisms has been either directly 
studied (14) or been extrapolated from similar studies done in animals and in vitro systems 
(14). 
 
1. Heating and humidification of gas 
2. Airway distending pressure 
3. Airway dead space wash out 
4. Effect on work of breathing 
5. Reducing metabolic demand 
 
1.3.1 Heating and humidification of gas 
 
It is a function of the upper airway particularly the nasal space to warm and humidify the 
inspired gas before delivery to lower airways. However, the inspiratory gas flows delivered by 
high flow systems are far higher than the inspiratory flows normally taking place in an infant 
with tidal breathing or even during respiratory distress. The anatomical capacity of the natural 
humidification and heating system thus is limited to meet the humidification requirements for 
higher inspiratory flows.  Consequently, the unhumidified and unheated gas flows can dry up 
the mucosa and result in mucosal injury and infection Kopelman (15). 
 
The clinical effectiveness of systems with heated and humidification gas delivery is also 
likely to be better compared to unheated and unhumidified system. In a crossover study of 30 
preterm infants, post extubation support with heated and humidified device (Vapotherm) fared 
better with no extubation failure compared to those receiving unheated and unhumidified high 
flow (16).  
 
The possible reason for this improved clinical effectiveness with heated humidified high flow 
system is likely because of its effects on pulmonary compliance and conductance. Saslow and 
colleagues compared 6 cm of H2O of conventional CPAP using standard humidification 
system with a high flow system delivering 5 L/min of heated humidified gas to infants. The  
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respiratory compliance profile was 1.03 ± 0.47 for HFNC whereas only 0.83 ± 0.49 ml/cm 
H2O / kg for CPAP (17). 
 
This improved respiratory compliance seen with HFNC system when compared to CPAP was 
seen despite CPAP achieving better oesophageal pressure (a surrogate for airway end 
expiratory pressure) profile (1.76± 1.46 vs 1.32 ± 0.77 cm H2O)(14, 17). Thus HFNC system 
achieved better respiratory compliance despite achieving less distending pressure possibly due 
to better conditioning of delivered gas (14).  This effect on compliance was observed in an 
earlier study in ventilated infants that even five minutes of ventilation with unheated and 
unhumidified gas resulted in significant reduction in pulmonary compliance and conductance 
(18).   
 
1.3.2 Airway distending pressure 
 
It is well established that the airway distending pressure is one of the main mechanisms of 
action of CPAP devices. That CPAP is effective in treating respiratory distress in infants was 
shown way back in 1971 (19). HFNC also delivers a certain amount of distending pressure to 
the airways as shown in several studies including in vitro studies (20-23) as well as a number 
of small clinical and interventional studies in humans (3, 17, 24-31). 
 
The distending pressure increases the Functional Residual Capacity (FRC). FRC is the 
volume of gas remaining in the lungs at the end of a normal expiration. At this lung volume 
the outward recoil of the chest wall and inward lung recoil are equal. FRC is reduced when 
the lungs are stiff and chest wall has low elasticity such as seen with preterm infants. Thus 
reduction in FRC means the baby is breathing from a lung volume which is closer to the 
closing volume. Since CPAP increases transpulmonary pressure there is increase in lung 
volume at the end of a normal respiration i.e., FRC. The increase in FRC in turn results in 
improved ventilation (32).  
 
The quantity of airway distending pressure achieved during HFNC is variable and 
unpredictable. This depends upon the quantity of leak at the nasal cannula –nares interface 
and at the mouth level. The flow rates used and size of the baby also influence the airway 
pressures measured during HFNC therapy.  
 
 11 
 
1.3.3 Airway dead space wash out 
 
The Carbon dioxide (CO2) removal is enhanced by enhancing the alveolar ventilation. The 
alveolar ventilation is determined by the minute volume which is calculated from the 
equation, 
Respiratory Minute Volume (MV) in litres (L) = Tidal Volume (TV) in litres X Respiratory 
Rate (f) 
Alveolar Minute Ventilation = (Tidal Volume – Dead space) X Respiratory Rate (f) 
Therefore, it is apparent that by reducing the dead space component, the alveolar ventilation 
can be improved.  
Since HFNC delivers gas flow in excess of inspiratory gas flow demands there is wash out of 
exhaled CO2 and enrichment of delivered O2 concentration in the upper airways and possibly 
further along the conducting airways. This effectively reduces dead space volume as there is 
clearance of CO2 from conducting airways allowing the alveolar ventilation with new gas 
mixture achieved by HFNC. Therefore, the efficiency of gas exchange improves. This results 
in lesser need for the infant to increase MV by increasing the respiratory rate. Clinically this 
has been observed by reduction in respiratory rate in several retrospective (33, 34) and 
prospective studies (31, 35).  
 
There is speculation that this improvement in ventilation is due to dead space wash out effect 
mainly and not due to distending pressure alone (22). In an animal study involving piglets 
with induced acute lung injury, HFNC administered within a range of 2-8 L/min, achieved 
improved ventilation and oxygenation. This effect was proportional to the flow levels used 
irrespective of pressures generated and higher leak resulted in better oxygenation (22).  
 
1.3.4 Effect on work of breathing 
 
Thoraco-abdominal asynchrony, Tidal volumes, pleural pressures (indirectly inferred by 
oesophageal pressures) measurements have been done to study the effects of HFNC and 
CPAP on respiratory mechanics and work of breathing (17, 30, 31, 36, 37).  
 
Locke et al demonstrated that as the flow rate increases there is a reduction in thoraco-
abdominal asynchrony (30). Since thoraco-abdominal asynchrony gives an estimate of work 
of breathing, increasing the HFNC flow rate resulted in reduction in work of breathing (38).  
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Boumecid demonstrated in 19 preterm infants that the thoraco-abdominal asynchrony seen in 
HFNC was comparable to that seen in constant-flow CPAP whereas variable – flow CPAP 
was better in improving thoraco-abdominal asynchrony (37).  
 
The tidal volume measured by respiratory inductance plethysmography during HFNC when 
compared to CPAP was similar as found by two different investigators (17, 37). Similarly a 
respiratory mechanics study by Lavizzari involved 20 preterm infants who required non-
invasive respiratory support within 96 hours after birth (36). They studied tidal volumes 
measured by respiratory inductance plethysmography, pleural pressures estimated from 
oesophageal pressures and also gas exchange during administration of a randomised sequence 
of CPAP at 2,4 and 6 cm H2O and HFNC at 2, 4 and 6 Litres per minute (36). Their study did 
not show any significant differences in breathing pattern, gas exchange or total work of 
breathing between HFNC and CPAP(36). Comparison of CPAP fixed at 6 cm of H2O was 
done with variable amounts of HFNC between 1-6 litres per minute flow rate was done by 
Lampland et al (31). They measured heart rate, respiratory rate, inspired oxygen 
concentration, and arterial oxygen saturation (31). They noticed increased oxygen 
requirements, increase in respiratory rate and also some apnoea events when HFNC flow rates 
were 1-2 litres per minute (31).  
 
In a randomised crossover study in infants with evolving or established BPD, Shetty et al 
studied effects of HFNC and CPAP on work of breathing, thoracoabdominal asynchrony and 
oxygenation (39).  They studied 20 infants (median gestational age of 27.6 weeks (range 24.6-
31.9 weeks) at a median postnatal age of 30.9 weeks (range 28.1-39.1 weeks) (39). Infants 
were studied on 2 consecutive days (39). On the first study day, they were randomised to 
either CPAP or HHFNC each for 2 h, the order being reversed on the second day (39). The 
pressure time product of the diaphragm (PTPdi) was used to infer the work of breathing (39).   
There were no significant differences in the work of breathing on CPAP versus HFNC as the 
mean PTPdi 226 (range 126-294) was similar to HFNC mean PTPdi  224 cm H2O/s/min 
(95% CI for difference: -27 to 22; p=0.85) (range 170-318) (p=0.82) (39).  
 
In a single centre, prospective study involving children less than 3 years of age, relationship 
between HFNC and effort of breathing was studied. The effort of breathing was estimated by 
measuring percent change in pressure rate product (PRP) (40). They used different levels of 
flow rates at 0.5, 1.0, 1.5, and 2.0 L/kg/minute based on body weight (40). In 21 patients with 
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49 episodes they reported that increasing flow rates resulted in a significant difference in the 
percent change in PRP from baseline (of 0.5 L/kg/minute). The highest change was seen at 
flow rate of 2.0 L/kg/min (-21%) (40). Further, this effect was particularly significant in 
children less than 8 kg in weight.  
 
1.3.5 Reducing metabolic demand 
 
The inspired air is warmed to 37˚C and humidified to 100% relative humidity by the nasal 
passages (14). There is energy cost to this process of conditioning the gas before delivery to 
lower airways (14). The nasal passages do capture moisture and heat from expired gas for 
recycling with subsequent inspirations (14). However as this is not 100% efficient system, 
there is metabolic energy expenditure by nasal mucosa to warm and humidify the inspired gas 
to ideal conditions (14). In an adult breathing at 12 breaths per minute with 500ml tidal 
volume in an environment of 21˚C temperature and 50% relative humidity will spend an 
additional 156 calories per minute to warm and humidify the inspired air to ideal condition 
(14). HFNC by delivering gases warmed to 37˚C and humidified to 100% relative humidity 
reduce the metabolic cost to the baby (14).  
 
1.4 Effects of HFNC on Airway Distending Pressures  
 
1.4.1 Airway pressure - Principle factors 
 
Airway pressure due to HFNC is determined by three principle factors (41): 
 Flow  
 Anatomical dimensions   
 The leak –Around nasal prongs & mouth   
A schematic representation of the resistors in series and pressure compartments that can be 
identified is shown in figure 3.  
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Figure 3. Schematic representation of HFNC(41) 
 
 
 
 
Figure 3 illustrates the two resistors and two pressure compartments in the circuit - patient 
HFNC system applied to patient. Resistor (R1) is the nasal cannula and therefore pressure 
compartment (P1) is the patient circuit(41). Resistor (R2) represents the components resistive 
to gas release from the patient’s nose (around the cannula) and mouth and therefore pressure 
compartment (P2) is the pressure in the nasopharynx (41). 
 
Unlike CPAP, High flow nasal cannula is an open system. Gas flow delivered to a patient via 
nasal cannula and the cannula prongs should not occlude the nares and where the patient’s 
mouth should not be actively closed (41). The reason for this is explained by the 
understanding of resistance locations and pressure segments in the whole HFNC and patient 
airway continuum. The pressure in each compartment is a function of the resistor(s) that lie in 
series downstream from that compartment (41). Therefore, circuit pressures will always be 
substantially greater than pressure in the nasopharynx (41).  
 
1.4.2 Pressure in the Device Circuit 
 
Nasal cannula outer diameter is very small in the range of 2-3.7 mm (2). Therefore, this offers 
very high resistance to airflow. Therefore to achieve high flows into the patients airway the 
circuit pressure needs to achieve high levels up to 3 to 4 PSI range (41). It has been shown 
that limiting the pressure by pressure limiting valve (PLV) limits the ability to deliver higher 
flows (31). It is not possible to transfer the same amount of high pressure into the patient’s 
airway because of the nasal cannula resistor which is upstream to airway. The key findings of 
role of pressure limiting valve in HFNC device is shown in figure 4.  
                              
 
Airway Tubing & Flow driver           
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Figure 4. Effect of pressure limiting valve in HFNC device (31) 
 
 
 
Figure 4 shows the data from Lampland et al(31) using a Fisher and Paykel HFNC system 
with and without a pressure limiting valve (PLV) set to 45 cmH2O noted that with the 
pressure limiting valve in place, the system does not permit more than 2 L/min to pass 
through the cannula regardless of the flow entering the humidifier(31, 41). 
 
 
1.4.3 Anatomy of upper airway 
 
The nostrils and nasal cavities are the first anatomical points through which HFNC is 
delivered. It is therefore important to study the distribution and velocity of the airflow in the 
nasal cavity. In order to understand this phenomenon, knowledge of nasal anatomy and its 
geometrical influence has to be understood.  
 
The nasal cavity has tortuous passages that form a large surface area and are lined with 
mucosa (42). The nasal cavity extends from nasal vestibule till the beginning of nasopharynx. 
This is actually two separate airways partitioned by the nasal septum within the nasal cavity 
(42). The nasal vestibule is the area enclosed by the external cartilages of the nose and is lined 
with small, filtering hairs (42). The turbinates (or concha) are long, narrow and curled bone 
shelves that protrude into the nasal cavity, creating a large surface area and forming the 
inferior, middle and superior airways and meatus passageways (42). The nasal valve occurs 
just posterior of the nasal vestibule and is the region of smallest cross-sectional area (See 
figure number 5) (42). 
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These cross-sectional areas at the nasal valve has been found to be 0.54–1.21 cm2 measured 
by Ozcan Cakmak et al (43). They determined this from their study on 25 healthy adults using 
CT scan data. However the nasal valve size is not constant but constantly changing with the 
nasal cycle with changes in the surrounding erectile tissues (44). The nasal valve leads into 
the nasal cavity expanding both in height and in cross sectional area. The relative anatomy of 
both half of nasal cavity is similar although they are not symmetric in dimensions (42). The 
right side tends to be larger in cross sectional area (42). The cross sectional area of the right 
nasal cavity 7.2 cm posterior of the external naris is 30% larger than on the left (42).  
 
In a study examining the dimensions of human nasal cavity using CT scan data of 30 healthy 
adults reported that the internal volume of middle region of the left and right nasal cavities 
vary by up to 65% (45). The cross-sectional area narrows down to 1.1 cm2 in the oropharynx. 
The oropharynx size depends upon the position of soft palate (42).  
 
Since the nasal passages have complex geometry and inaccessible passageways, it is difficult 
to study flow pattern within nasal cavities. However the flow patterns can be studied using in 
vitro artificial nasal models (42). Using computational models, Wolf et al (46) found that on 
inspiration, maximum velocities of 6–18 ms-1 were measured at the nasal valve, 2 ms-1 in the 
main passage and 3 ms-1 in the nasopharynx (46). Largest flow was through the middle 
airway. During expiration, maximum velocities of 3–6 ms-1 were measured in the nasal valve 
and velocity of 1–2 ms-1 throughout the nasal cavity (46).  
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Figure 5. Coronal cross sections of nasal cavity with respective locations illustrated on 
the sagittal view(42) 
 
 
 
 
 
 
 
Figure 5 shows a series of anatomical areas of the nose starting from nares anteriorly and 
proceeding posteriorly. The corresponding anatomical areas are depicted in sagittal view. 
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In infants and children nasal cavity measurements have been made using CT scan. Likus et al 
examined the CT scans of 180 Polish Caucasian children (83 girls and 97 boys) with age 
range of birth to 3 years, with normal development and with no evidence of craniofacial 
abnormalities in the age range of birth to 3 years (47).  The children were divided into 
following groups  
A: 0–3 months (23 children: 13 females and 10 males) 
B: 4–6 months (35 children: 20 females and 15 males) 
C: 7–12 months (53 children: 27 females and 26 males) 
D: under 2 years of age (13–24 months) (42 children: 14 females and 28 males) 
E: under 3 years of age (25–36 months) (27 children: 9 females and 18 males). 
They measured several nasal dimensions, of particular importance to this study were, firstly, 
anterior bony width between the two maxillary ridge called as piriform aperture (ABW) and 
this refers to site of nasal valve, secondly, nasopharynx vertical distance between posterior 
vomer and cranial base (NVD) which relates to nasopharyngeal size and finally, bony choanal 
aperture width between both pterygoid processes in posterior nasal cavity called choanal 
aperture (BCAW)  which relates to any possibility of resistance in series further down in the 
nasal cavity. These nasal dimensions are illustrated in figure 6.  
 
The results for above three parameters are shown in table 1 (47), 
 
Table 1. Nasal cavity dimensions at nasal valve region (ABW)(47) 
 
 
Group ABW  
[mm] 
BCAW  
[mm] 
Nasopharynx  
NVD [mm] 
A 14.87 ± 1.62 16.86 ± 2.16 21.06 ± 3.48 
B 15.60 ± 1.15 16.70 ± 1.26 24.86 ± 2.66 
C 17.11 ± 1.27 17.77 ± 1.45 25.60 ± 2.67 
D 18.46 ± 1.35 19.26 ± 1.47 25.62 ± 2.40 
E 18.87 ± 1.28 20.65 ±1.53 26.18 ± 3.27 
 
Table number 1 shows the typical nasal cavity dimensions seen in various age groups of 
children from 0-36 months of age. 
 
 
 19 
 
Figure 6. CT scan image of nasal cavity in a 4 month old normal child(47) 
 
 
 
 
Figure number 6 shows CT scan image of a 4-month-old child with identification of the 
important structures in nasal anatomy. 
  
There is progressive growth in the nasal cavity dimensions with age but it is not uniform or 
linear (47). In a study on 39 infants, using continuous wide-band noise acoustic rhinometry, 
using a specific probe optimized for infants examined at infancy and 1 year of age, the nasal 
dimensional growth and maturation was reported by Djupesland et al (48). During the first 
year of life, the acoustically determined dimensions of the nasal airways increased 
significantly (48). The total minimal cross-sectional area increased by 67% (0.21 cm2-->0.35 
cm2)(48), the volume of the anterior 4 cm of the nasal airway by 36% (1.80 cm3-->2.44 cm3) 
and the distance to the minimum cross-sectional area by 19% (0.78 cm-->0.93 cm) (48).  
 
During inspiration, the air flow velocity is higher initially and its path of flow is mainly 
through the lower half of the nasal cavity. Therefore, the olfactory grove which is located in 
 
 
 
 
 
 
ABW – Anterior bony 
width 
 
BCAW – Bony choanal 
aperture width 
 
NVD – Nasopharynx 
Vertical Distance 
 
RABW – Right 
anterior bony width 
 
LABW – Left anterior 
bony width 
 
RPBW – Right 
posterior bony width 
 
LPBW – Left posterior 
bony width 
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the upper portion of the nasal cavity receives air flows with lower velocity (49). The sniffing 
manoeuvre alters this flow and directs increased air flow towards the upper portion of the 
nasal cavity.   
 
The narrowest part of the nasal passage relevant to air flow resistance is at the functional 
nasal valve in the anterior nasal cavity and therefore it is a major determinant of flow (49). 
The posterior cavity, however is wider and circular. The expiratory flow in the nasal cavity is 
along the turbinates (49). 
 
The relationship of nasal air flow is linear to the nasal cavity volume and area (49). The nasal 
tissues, however, cause dynamic changes to the nasal resistance which affects flow. This is 
due to a number of factors including collapse of soft tissues and downstream resistance of the 
lower airways (49).  
 
The neonates are obligate nasal breathers supplemented by oral breathing during sleep (49). 
Primary oronasal breathing occurs normally with crying and returns to uninterrupted nasal or 
some combination of oronasal (49).  
 
A premature infant’s skin is especially susceptible to injury from nasal interface devices (49). 
Researchers have used to different scoring systems based on site of nasal trauma. The damage 
may occur at any of these sites including the nares, intranasal septum, the septum’s anterior 
tip (columella), or philtrum (49).  
 
In summary, the nasal and nasopharyngeal airway anatomy of preterm, infants and adults 
poses a physiologically complex pattern of airway resistance.  
 
1.4.3 Effects of mouth position on nasopharyngeal pressure 
 
When the HFNC circuit is connected to the patient with the nasal interface there are mainly 2 
sites which allow leak. First is at the nasal cannula and nare interface and second is at the 
mouth. It has been shown in studies on CPAP that pharyngeal pressures drop when the mouth 
is open (50).  
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Kubicka et al studied delivered oral cavity pressures during HFNC flow rate range of 1-5 
litres per minute in 27 infants (3). Small (outer diameter: 0.2 cm) cannulae were used for all 
infants and prescribed flow rate was opportunistically studied with no changes made for the 
study (3). In their study infants (postmenstrual age: 29.1–44.7 weeks; weight: 835–3735 g; 
flow rate: 1–5 L/minute), no pressure was generated with the mouth open at any flow rate (3). 
With the mouth closed, the oral cavity pressure was related to both flow rate and weight. For 
infants of <1500 g, there was a linear relationship between flow rate and oral cavity pressure 
(3). They concluded that firstly, their technique of measuring oral cavity pressure can estimate 
the level of continuous positive airway pressure and secondly, continuous positive airway 
pressure generated with heated, humidified, high-flow nasal cannula treatment depends on the 
flow rate and weight(3). According to their data, the more smaller infants when their mouths 
were closed had clinically significant and unpredictable levels of continuous positive airway 
pressure during high flow therapy (3).   
 
In the study by Arora et al involving 25 (mean 78.1 [SD 30.9] days; weight 5.3 [SD 1.1] kg) 
patients with bronchiolitis, nasopharyngeal pressures were measured at varying flow rates of 
HFNC(28). They found that nasopharyngeal pressures increased linearly with flow rates up to 
6 L/min (28). Nasopharyngeal pressure increased by 0.45 cm H2O for each 1 L/min increase 
in flow rate (28). There were significant differences between pressures in open and closed 
mouth states for flow rates up to 6 L/min (28). At 6 L/min, the pressure in open mouth state 
was 2.47 cm H2O and that in closed mouth state was 2.74 cm H2O (P<0.001)(28).  
 
In a lung model study, two HFNC devices Vapotherm 2000i and Fisher-Paykel were studied 
to understand the relationship between the device, intraprong, and proximal airway pressures 
and the flow values. Fisher-Paykel system had a pressure release valve (23).  
A paediatric size cannula of 2-mm inner diameter was used in a lung model and the device, 
intraprong, and proximal airway pressures at random flow values between 0 L/min and 12 
L/min with an FIO2 of 0.21 were measured under simulated minimal and moderate nares-
prong leak as well as varying mouth leak (23). 
 
Irrespective of leak, all the three pressures increased with increasing flows with both devices 
(23). Under conditions of minimal leak and flow rates <8 L/min, the Fisher-Paykel device 
generated larger pressures than the Vapotherm device although this was not seen at higher 
flows because of pressure release valve (23).  The intra prong pressures were about 1/5th to 
 22 
 
1/3rd  (between 22% and 27% and 20% and 32% ) of the corresponding device pressure value 
for Fisher-Paykel and Vapotherm (23). There was further reduction in proximal airway 
pressure downstream by about 20% to 30% relative to the intraprong pressure values with the 
two devices (23). Interestingly, the device pressure was not affected by nares-prong leaks or 
mouth leak (23).  However, the increase in leak at nares or mouth caused reduction in 
intraprong and proximal airway pressures (23). The authors concluded that HFNC may 
deliver uncontrolled continuous positive airway pressure to infants (23).  
 
However, the results of some studies evaluating mouth position and effects on airway 
pressure are in conflict with the results of above studies. Wilkinson et al. studied pharyngeal 
pressure in 18 preterm neonates (median gestational age 34 weeks, weight 1.619 kg) during 
high flow therapy (27). A catheter-tip pressure transducer was introduced into the 
nasopharynx (27). Flow was sequentially increased to a maximum of 8 litres per minute and 
decreased to a minimum of 2 litres per minute (27). There was a strong association between 
pharyngeal pressure and both flow rate and infant weight (P<0.001, r20.61), but not mouth 
closure (27). They concluded that high flow nasal cannulae at flow rates of 2 to 8 litres per 
minute can lead to clinically significant elevations in pharyngeal pressure in preterm infants 
(27). Flow rate and weight but not mouth closure are important determinants of the pressure 
transmitted (27). They felt that the amount of nasal gas leakage with HFNC was more 
important than the degree of mouth leak, particularly in comparison to the tightly fitting nasal 
prongs used with CPAP, which allow very little gas to escape from the nostrils (2, 27). 
 
1.4.4 Effects of flow rate on nasopharyngeal pressure 
 
CPAP machines are capable of varying the flow delivered to achieve set amount of pressure 
when the circuit has varying amounts of leak. Generally, the flow to the magnitude of around 
8 litres per minute is used to achieve a CPAP of about 5-6 cm H2O. Thus, this implies that 
varying amounts of flow can have varying amount of pressure generation downstream in the 
airways. This aspect has been looked in more detail with respect to HFNC by various 
investigators.  
 
In an animal study, Frizzola et al studied effects of flow rate on the tracheal pressures (22).  
Neonatal piglets (n=13; 2-6kg) were injured with IV oleic acid and supported with HFNC at 2 
-8 L/minute (22). Tracheal pressures were recorded by transmural catheters (22). Oxygenation 
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and tracheal pressures increased in a flow dependent manner and at 8L/minute, tracheal 
pressures did not exceed 6±1 cmH2O (22). 
Kubicka et al studied oral cavity pressures during HFNC flow rate range of 1-5 litres per 
minute in 27 infants (3). Small (outer diameter: 0.2 cm) cannulae were used for all infants and 
prescribed flow rate was opportunistically studied with no changes made for the study (3). In 
their study infants (postmenstrual age: 29.1–44.7 weeks; weight: 835–3735 g; flow rate: 1–5 
L/minute), under the conditions of mouth open no pressure was generated irrespective of the 
flow rate (3). The oral cavity pressure was related to flow rate and weight of the infant when 
the mouth was closed. The relationship was linear between flow rate and oral cavity pressures 
for infants <1500 grams (3). 
 
Lampland et al conducted both in vitro and in vivo study of effects of HFNC flow rate on the 
airway pressures (31).  In the in vitro part, the HFNC pressure and flow was measured with 
varying degrees of leak and with and without the use of a pressure-limiting valve (31). In the 
in vivo part, they measured end expiratory oesophageal pressures in 15 newborns on NCPAP 
6 cm H2O and then on HFNC at 6 L/minute, with flow decreased by 1 L/minute every 30 
minutes (31). In the in vitro study, in the absence of leaks, the pressures were limited by the 
pressure-limiting valve only at flows > 2 L/minute (31). With leaks of 30% and 50%, 
delivered pressures were always < 3 cmH2O(31). They found wide variation in intrapatient 
and interpatient results (31). The end expiratory oesophageal pressures were similar with 
CPAP and HFNC (31).  
 
Spence et al studied intra pharyngeal pressures (IPP) in 14 infants in an observational study 
on a sample of stable term and preterm infants who were being treated either with NCPAP or 
with HFNC (26) with 6 babies were studied on both (26). Two infants only had IPP measured 
on CPAP, and six infants had IPP measured on HFNC (26). IPPs were recorded for 2 to 3 min 
or until airway pressure and infant were stabilized at each level NCPAP of 2, 4 and 6 cm H2O 
and HFNC of 1, 2, 3, 4 and 5 l/min
 
average pressures were documented over the 2 to 3 min 
observation period at each NCPAP and HFNC level and a single value was recorded (26). 
Infants’ mouths were kept closed by gentle chin support and/or pacifier placement (26).  
A Viasys 5 French Tracheal Catheter (PN 10635, Viasys Healthcare, Yorba Linda, CA, USA) 
was introduced to the posterior pharynx through the infant’s nares or mouth for measuring 
pressure (26). Depth of insertion was estimated by measuring the distance between the corner 
of the nare and the ear lobe (26). The catheter was connected to a pressure-measuring device 
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(Viasys avea ventilator) and IPP was recorded continuously (26). The Viasys Infant Flow 
CPAP System was the primary device used for this study (26). HFNC was delivered via 
Fischer & Paykel (Fisher & Paykel Healthcare Inc. Irvine, CA, USA) humidification system 
and Salter brand infant nasal cannula (26). All the infants had the ‘infant size’ prongs from 
Salter (26). Except for one patient, HFNC consistently generated a significant amount of 
CPAP: the average IPP (cm of H2O) for flow rates of 1, 2, 3, 4 and 5 litres per minute was 
1.7±0.3, 1.7±0.2, 2.6±0.3, 3.8±0.4 and 4.8±0.5 respectively (26).  In one patient, flows at 1to5 
LPM generated an IPP of <2cmH2O (26). This study did not find a correlation between the 
size of the baby and the IPP generated at each flow rate, as it was not powered to detect this 
correlation if any (P = 0.707) (26).  
 
In another study involving 16 VLBW infants over 3 days of age, range of airway pressures 
with Optiflow HFNC device was studied (51). Both pharyngeal and oesophageal pressures 
were measured using a 6Fr solid state manometric catheter (Unisensor, NH) with dummy in 
and out for mouth leak evaluation (51). The infants characteristics at study entry were age of 
mean (SD)) 36(22) days, gestationa age 27(2) wks, Birth weight 850 (220) g and FiO2 
26(6)% (51). At the 7L/min flow rate, the end inspiratroy and end expiratory pressures (cm 
H2O) for pharyngeal and oesophageal measurment were 5.5 (4.6, 6.7), 6.5 (5.4, 7.6), 2.2 (1.0, 
3.3) and 13.3 (10.6, 14.2) respectively (51).  There was a significant relation 
between  flow and pharyngeal pressure although flow rates greater than 4 L/min had little 
additional effect on pharyngeal pressure (51). Their conclusion was that alteration of flow has 
a significant effect on pharyngeal but not oesophageal pressure (51). This is difficult to 
explain apart from any possibility of methodology of pressure measurement being the cause 
of their finding.  
 
1.4.5 Effects of nasal cannula size on nasopharyngeal pressure 
 
The nasal cannula and nares interface is a site for leak in the HFNC circuit when applied to 
the patient. Therefore, relative size of nasal cannula to the nare diameter is of practical 
relevance. Some of the earliest studies of oesophageal pressures during high flow therapy 
have shown that larger nasal cannula tends to produce higher pressures (2, 30).  
Nasal cannula outer diameter (OD) is specified by manufactures(2). In general, the OD is 
around 2.4 mm in premature and new born neonates, and 2.4 to 3.7 mm in infant and 
paediatric patients (2, 49). Locke et al. measured oesophageal pressure produced with varying 
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OD of nasal cannulae (2, 30). The 3 mm OD nasal cannula delivered higher pressures with a 
mean of 9.8 cm H20 at a flow of 2L/min in infants who were 30 weeks’ gestation at 28 days 
of age(2, 30). In contrast, the 2 mm OD cannula, did not deliver any pressure (30). One 
possible explanation for this is there may be increase in leakage of flow around the smaller 
cannulae (2). It is important to note that this study dates back to 1993 and the high flow 
device was not a standardised equipment capable of heating and humidifying to optimum 
conditions (30).  
 
The ratio of nasal cannula to the nasal opening is more important than the absolute size of the 
cannula (30). The entire nasal passage is important in the development of positive end-
distending pressure (30). Both anatomic and physiologic factors can affect the nasal gas flow 
pattern and turbulence will cause resistance to gas flow similar to a mechanical occlusion of 
the nasal passage (30).  
 
Since size of nares is proportional to the size of the baby, baby’s weight influences the likely 
pressures delivered to the airways (2).  
 
Volsko et al in an in vitro study described the relationship between the pressure generated at 
the airway opening and flow through a nasal cannula using a simulated infant model (21). A 
range of nare sizes including small, medium and large were drilled into a plastic fixture (21). 
A lung simulator was used to simulate spontaneous breathing (21). A range of tidal volumes 
from 3 mL to 12 mL were delivered by adjusting the amplitude in a simulated respiratory 
wave form (21). The simulated lung model had a lung compliance and resistance set at 0.5 
mL/cm H2O and 125 cm H2O/L/s, respectively (21). They optimally sized cannulae for 
premature, infant and paediatric nares to ensure that they were not occluded (2, 21).  The 
prong occlusion of the nares did not exceed 50% (21). A flow rate range of 2– 6 L/min in 1-
L/min increments was used (21). They recorded Mean airway pressure and percent change in 
tidal volume (VT) (21). The greatest effect on tidal volume was seen with the premature 
cannula (21). The least effect on pressure and VT change occurred with the infant cannula 
(21). The differences in spontaneous tidal volume across all flows were negligible (21). The 
maximum pressure generated was 2 cm H2O, which was not clinically significant (2, 21). 
These findings were similar to Locke’s study on infants using 2 mm OD nasal cannula (2, 30).  
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Using a simulated in vitro system Sivieri et al. measured proximal airway pressures delivered 
by a HFNC system while varying flow and ratio of cannula to nares size. Airway pressure 
increased progressively with increased flow and with nasal prong to nares ratio (20). They 
concluded that safe and effective use of HFNC requires careful selection of appropriate nasal 
prongs for the individual infant even with an integrated pressure limiting valve (20). 
 
1.4.6 Summary of effects of HFNC on airway pressures 
 
The physiology studies looking at airway pressures have been summarised in the table 
number 2. The relationship of airway pressures to other parameters can be summarised as 
follows,  
 
1. When compared to CPAP the airway pressures (oesophageal, nasopharyngeal, oral) 
are similar to, or less than, those usually set with CPAP (3, 21, 26, 27, 38). However 
the pressures measured with older HFNC devices recorded higher airway pressures 
beyond the pressures usually used in CPAP therapy (30).  
2. The flow rate positively correlates with pressure; airway pressures increasing with 
increasing flow (3, 22, 26, 31, 38, 52). 
3. The airway pressures increase with decreasing infant weight (3, 27, 38). 
4. There is significant inter-patient variability in airway pressures mainly due to varying 
leak at the mouth and nose (3, 20, 23, 31, 38). 
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Table 2. Summary of studies examining airway pressures during HFNC 
 
Study n Weight 
(grams) 
Flow 
(L/min) 
Conclusions of Airway 
Pressure 
Relevant 
Circumstances 
Locke(30) 
 
Pediatrics 
 
1993 
13 Mean 
1,377 
0.5-2 No pressure generation with 
smaller prongs at any flow 
rate 
Larger prongs deliver 
increasing pressure with 
increasing flow 
Unheated and 
unhumidified 
Mean 
oesophageal 
pressure of 
9.8 cm H2O at 2 
L/minute 
 
Sreenan(24) 
 
Pediatrics 
 
2001 
40 1,260 1–2.5 Flow rate required to 
generate similar oesophageal 
pressure as generated by 
NCPAP of 6 cm H
2
O 
increases with increasing 
infant weight 
Unheated, 
humidified 
 
Oesophageal 
pressure 
Volsko(21) 
 
Respir Care 
 
2011 
Lung 
model 
 
 
1000 
 
>2 Highest &lowest airway 
pressure 
Mean airway pressure 
 
 
Positive 
expiratory 
pressure with all 
cannula sizes 
 
Saslow(17) 
 
J Perinatol 
 
2006 
18 580 – 
1990 
3 - 5 Not more than CPAP of 6 cm 
H
2
O 
Oesophageal 
pressure 
Pyon(53) 
 
PAS (abstract) 
 
2008 
8 < 2000 6 - 8 Not more than CPAP of 6 cm 
H
2
O 
Oesophageal 
pressure 
Lampland 
J(31) 
 
Pediatr 
 
2009 
15 1324 ± 
424 
1 - 6 Similar to CPAP of 6 cm H
2
O Oesophageal 
pressure 
Spence(26) 
 
J Perinatol 
 
2007 
14 1589+/-
170 
Up to 5 Intrapharyngeal pressure 4.8± 
0.5 cm H
2
O at 5 LPM 
Mouth closed 
800 g (high pressures) 
2100g (low pressures) 
 
Study weight 
1589±170 
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Study 
(cont) 
n Weight 
(grams) 
Flow 
(L/min) 
Conclusions of Airway 
Pressure 
Relevant 
Circumstances 
Wilkinson(27) 
 
J Perinatol 
 
2008 
18 534 - 
1868 
2 - 8 Mean pharyngeal pressure of 
5.3 cm H
2
O at 5 L/m 
No effect of 
mouth position 
on pressures. 
Study weight 
1.619 kg (0.816 
to 4.400). 
Kubicka(3) 
 
Pediatrics 
 
2008 
27 835 – 
3735 
 
1 - 5 Highest oral cavity pressure 
recorded was 4.8 cm H
2
O 
Mouth closed 
Snug nasal 
prongs 
2 babies <1000 g; 
(900g & 835g) 
Collins(29) 
 
Journal of 
Paediatrics 
and Child 
Health 
 
2013 
9 - 2-8 Nasopharyngeal pressures 
measured 
 
Comparison of 2 HFNC 
systems 
 
2-6 l/min – no difference 
 
7 l/min - VAPO-
4.7 (2.2) 
F&P - 4.23 (2.2) 
 
8 l/min - VAPO -
4.9 (2.2) 
F&P- 4.1 (2.3) 
 
Arora et 
al(28) 
 
 
 
2012 
 
25 
 
weight, 
5300 
[SD 
1100]  
Up to 
6L/kg/min 
Acute bronchiolitis -
Prospective, observational 
study Heated humidified 
HFNC system. 
Linear increase in NP 
pressures with flow rates up 
to 6 L/minute but with 
significant differences 
between pressures in open 
and closed mouth states. 
Bronchiolitis severity scores 
improved significantly 
Nasopharyngeal 
(NP) pressures 
Vital signs 
Bronchiolitis 
severity scores 
Oxygen 
saturation  
 
 
Mile´si et 
al(54). 
 
2013 
 
  21 - 1, 4, 6 and 
7L/kg/min 
Pharyngeal pressure (PP) and 
oesophageal pressure (Pes) 
measured simultaneously. 
 
Flow >2 L/kg/minute 
generated a mean PP >4 cm 
H2O. 
Significant reduction in 
respiratory rate noted with 
increase in flow from 
baseline to maximal flow 
rate. 
Prospective 
observational 
study Heated and 
humidified 
HFNC (RT329 
system with 
MR850 
humidifier, 
Fisher and 
Paykell) 
 29 
 
1.5 Measuring Airway Pressure 
 
The most popular devices currently used for medical pressure measurement are based on 
catheters and guidewires (55). 
 
1.5.1 Types of pressure measuring technology 
 
 Air filled balloons 
 Fluid (Saline/Water) filled Catheter  
 Air charged catheter  
 Solid state Catheter with inbuilt transducer  
 Optical fibre pressure sensor 
 
The air-filled balloon pressure sensor is less expensive compared to other sensors (56). 
However, they do not last long and performance may alter with repeated use and cleaning 
(56). The performance is also affected by the dimensions of the balloon which determines the 
efficiency with which pressure signal is transmitted to the external pressure transducer (56). 
The balloon volume needs to be monitored to maintain optimum performance (56). Since the 
transducer is externally located it is difficult to use this device for ambulatory pressure 
monitoring (56) 
 
Although air-charged catheters are less expensive, fluid-filled catheters have relatively more 
stable response (55). Cooper et al compared the efficiency in pressure transduction of air 
charged and water filled catheters for urodynamic pressure measurement (57). The catheters 
were exposed to sudden change in pressure. During this time, they assessed frequency 
response of the two systems. In addition, they also measured the response of the catheters to 
movement artefacts and different gravity effects by changing the height of the catheter tips to 
different levels (57). 
 
Water-filled catheters do not attenuate the pressure signal as much as the air-charged catheters 
because water is not compressible (57). However, the column of water in the tube can vibrate 
and cause peak pressure amplification (57). Since air is compressible, it results in  attenuation 
of the pressure signals (57). Thus while the water filled catheter may affect mainly higher 
frequencies, the air-charged systems attenuate lower frequencies as well (57).  Unlike the 
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water filled catheters, air-charged catheters are less affected by movement and gravity effects 
(57).  
 
The length of the water filled catheter is inversely related to frequency response of the whole 
system. The wider the diameter, more will be the attenuation of the natural frequency of the 
water column itself (55).  
 
Solid state catheter with inbuilt transducer at the tip is next in the development of the pressure 
transducers. A schematic diagram is shown in the figure 7.  Although these pressure 
guidewires are a further improvement and alternative to catheters they are more expensive 
(55). Guidewires and catheter pressure transducers are known as electro-mechanical pressure 
transducers (55). The pressure-sensing device can be a part of a catheter containing multiple 
channels to perform other functions (55). 
 
Figure 7. Sensor attached to the side of a catheter (from Gaeltec Ltd) at its distal end 
 
 
 
 
 
 
Figure 7 showing the side wall mounted pressure transducers at the distal end of the catheter. 
 
An example of solid state guide wire with pressure sensors was used by Pavel Mazmanyan et 
al whilst measuring airway pressures during HFNC and CPAP in infants (58). This Mikro-
Cath pressure catheter is said to deliver accurate data for analysis of airway pressures. The 
advantage is these provide continuous, real-time data. The catheter is used for monitoring 
pressures as a minimally invasive device but it can be used only for less than 24 hours with 
body contact.  
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These catheters have several advantages. Pressure is measured at the site of interest, can be 
measured in ambulatory patient, it is not influenced by gravity and the movement of the 
subject does not give rise to significant motion artefacts unlike a fluid filled catheter.  
 
The main disadvantages are that they need re-calibration, are fragile and expensive. The 
salient features of the measurements from the solid-state catheters and fluid filled catheters 
are shown in table 3.  
 
Table 3. Solid-state pressure sensor compared to traditional Fluid-filled pressure 
measurements (55) 
 
 
Solid state guide wire technology Fluid filled catheter 
Accurate dP/dt Unreliable dP/dt 
True pressure signal Pressure signal needs augmentation- 
overshoot and resonance possibilities 
No time delay in signal conduction Time taken for signal transmission 
Not affected by movements Motion artefacts are frequent 
True pressure readings in any height in fluid 
No effect of gravity before or after 
calibration 
Gravitational effects can cause change in 
baseline with change in height of catheter 
after calibration 
 
Table 3 shows the differences between solid-state and fluid-filled pressure measurements 
 
 
Optical fibre sensors are more recent improvement over catheter based sensors. Since they are 
very small they are useful for medical applications. The optical fibres made up of silica glass 
have about 125-micron diameter. Optical fibres of even 80 microns diameter are now 
available (55).  
 
They can be used even when tight bending is needed. The bend – insensitive fibres are 
capable of transmitting signals through tight bends. A single catheter can hold multiple 
numbers of optical fibre pressure sensors enabling multiple type of applications or 
measurements (55).  
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Another distinct advantage is that optical fibre sensors can be built in a way that they are able 
to detect different signal types such as strain or pressure, temperature at multiple points along 
the length of the optical fibre.  These multiple points can detect either single type or different 
types of physical parameters (55)  
 
Finally, these fibres are extremely stable over long periods of recording. The sensor 
prototypes are quoted as having a stability of 1 mm Hg/hour and the commercially available 
sensors come with a stability of 3 mmHg/28 days (55).   
 
1.5.2 Technical requirements for airway pressure sensors  
 
Range of a pressure sensor can be defined as the difference between the maximum and 
minimum value that can be measured by that sensor in the site of interest (55).  
 
Since the pressure range is different in different body systems the appropriate site-specific 
pressure sensor with the capability to measure pressure should be used. For example, the left 
ventricular pressure range is 0 -150 mm Hg (0 - 203.9 cm H2O) whilst that in intra cranial site 
is only  0 -7.5 mm Hg (0 – 10.1cm H2O) (55).  
 
Similarly, the pressure range varies at different sites in the respiratory system. The intra 
alveolar and intra tracheal pressures change dynamically as well and can reach to levels of –
75 mmHg (101.9 cm H2O) (55). Pressure ranges vary based on the application needs and 
condition of the infant’s breathing, for example, in a spontaneously breathing infant to that in 
a ventilated infant (59). A European Task Force set up to provide guidance on standards for 
Infant Lung Function Testing recommended following pressure ranges shown in table  
4 (59). 
 
Accuracy of the sensor requirements depends on the area of interest to be measured. The 
clinical relevance of magnitude of changes in pressure readings on organ function or disease 
state assessment (55). For example, a small pressure error in reported pressures in left 
ventricular pressure may not affect clinical judgement whereas similar range of error in 
intracranial pressure would affect clinical decision making.  
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The sampling rate is defined as the number of measurements obtained per second. The 
sampling rate of a pressure signal is determined its waveform and periodicity (55). A system 
should be able to record at least double the highest frequency present in the signal so that all 
the data in the signal can be reproduced accurately (55). In the case of the medical sensors, the 
general recommendation is that they should acquire 5–10-times more samples than the highest 
frequency of the pressure wave that is being measured (55). 
 
The linearity of a pressure sensor should be within 1% of the reading or 1.01 cm H2O 
whichever is greater (59). It is important to note that the linearity is a different concept from 
accuracy. A pressure sensor can have acceptable linearity being consistently inaccurate. It is 
possible to apply correction if there is linearity.  
  
Table 4. Pressure ranges normally encountered during pulmonary function tests in 
infants and young children (59) 
 
 
Pressure Transducer Pressure range kPa 
Oesophageal pressure -5 to 5 
Airway opening pressure -10 to 10 
Plethysmographic box pressure (100 L) -0.1 to 0.1 
Jacket Pressure (forced flows) 0 to 15 
 
The Table 4 shows pressure range in various pulmonary function tests in infants and young 
children 
 
1.5.3 Other factors affecting sensor performance 
 
The physical characters of the catheter that cause damping effect on the pressure signal 
include its own elasticity, mass and friction. The catheter has a natural frequency that will 
affect the sensor performance in the sensors located within the catheters (55). The main effect 
will be on the frequency response of the sensor equipment (55).  
   
The sampling site should not be affected by eddies or current effects. These currents will 
particularly affect the lateral pressure measurements (59). Another significant factor is the 
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Bernoulli effect which is greater when the diameter of the tube is small such as seen in infants 
(59).  
 
The common reasons for baseline instability of the equipment include drift of transducers 
(intrinsic property of the material of the transducer) and sensitivity to temperature, position 
(gravity, e.g. water filled catheter systems) and other changes in environmental conditions 
(59). Baseline instability is crucial for calibration and measurement procedures (e.g. when 
using catheter tip transducers for oesophageal manometry) and must be specified by the 
manufacturer (59).  
 
1.5.4 Principles of Pressure Sensors 
 
There are two main types of pressure measurement sensors namely strain gauge transducer 
and diaphragm displacement sensors.     
 
The strain gauge transducers change their output in response to the strain (pressure changes) 
(55). Their working principle is governed by the following relation between sensitivity 
(Gauge factor GF) and relative change in resistance (∆R/R) and relative change in length 
(∆L/L), also called as strain ε (55). A schematic representation of this principle is shown in 
the figure number 8.  
   
GF = ∆R/R / ∆L/L= ∆R/R / ε (55)  
 
The technology in diaphragm displacement sensors is  known as micro electro mechanical 
systems (MEMS) technology (55). These sensors have a very thin structure which deforms 
and has a flat surface called as diaphragm. The diaphragm is located in a sealed cavity (55). 
The diaphragm deforms when the pressure impacting on its surface changes. The principle 
mechanism of this type of diaphragm sensors can be capacitance based or based on a 
piezoelectric transducer (55). At baseline, the cavity has an initial volume (V0) and pressure 
(P0). Then a change in pressure (∆P) causes the medium inside the cavity to compress or 
expand (∆V) depending on the direction of pressure change. This is possible because medium 
is enclosed in the cavity (55). A schematic representation of this principle is shown in the 
figure number 9. 
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 Figure 8. Schematic representation of a piezo resistive sensor (55) 
 
 
 
 
Figure 8 shows a schematic diagram of a piezo resistive type of sensor with change in 
dimension under the influence of a strain (or pressure) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L refers to the length of the 
sensor element 
 
∆L refers to the change in length 
of the sensor element on 
application of strain (or pressure) 
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Figure 9. Schematic representation of a diaphragm displacement sensor (55) 
 
 
 
 
Figure 9 shows a schematic diagram of a diaphragm displacement sensor depicting the 
volume change in sensor cavity when diaphragm is displaced due to the pressure differential 
applied on its surface. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
V0 - Initial volume of the 
sensor cavity 
 
P0 - Initial pressure in the 
sensor cavity 
 
∆P - Change in pressure on 
the diaphragm of the sensor 
 
∆V – Change in the volume 
of the cavity 
 
D- Diaphragm of the sensor 
 
 
∆P 
D 
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1.5.5 Types of airway pressure measurements 
 
The airway pressures can be reported at different points in the waveform. Some authors have 
reported the end expiratory pressure whereas some other studies have reported mean airway 
pressures.   
 
1.5.6 Practical challenges in pressure measurement in neonates 
 
1. Size of nasopharyngeal airway smaller and therefore need smaller calibre diagnostic 
instruments. 
 
2. The neonates typically have less reserve in terms of maintaining adequate gas exchange and 
decompensate quickly, therefore interventional studies are riskier and difficult to perform. 
 
3. Since neonates feed relatively frequently time window for performing measurements is 
small and for the same reason prolonged airway pressure measurement is difficult.  
 
4. The fidelity of data acquired and that used for reporting needs to be defined strictly with 
clear criteria.  
 
5. The motion artefacts are a significant practical problem due to neonates crying, moving and 
secretions if any.  
 
6. Calibration requirements: Any interruptions in measurements due to neonate requiring care, 
desaturations would mean that recalibration of the measuring equipment may be required. 
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1.6 Effects of HFNC on Washout of Airway Dead Space 
 
1.6.1 Airway dead space wash out effect and its impact on CO2 removal 
 
The minute ventilation consists of alveolar ventilation and dead space ventilation. By flushing 
the dead space/ expired CO2 off and enriching it with set FiO2 the dead space can be reduced 
and alveolar ventilation can form a greater proportion of the minute ventilation. This results in 
improved efficiency of respiratory efforts to achieve adequate gas exchange.  
 
Tracheal gas insufflation (TGI) method can be used to promote CO2 elimination (60-64). In 
experimental animal models TGI reduces dead space and promotes pulmonary gas exchange 
and reduces ventilator pressure and volume requirements (65, 66). Studies evaluating acute 
lung injury using modified endotracheal tubes designed to reduce physiological dead space 
during mechanical ventilation in animal models, noted that compared to conventional 
mechanical ventilation the requirement for pressure and volume were less with reduction in 
dead space strategy (67, 68). The markers of lung and systemic inflammation were also 
reduced.  
 
Nakos et al studied effects of TGI in spontaneously breathing patients with COPD (69). These 
patients had been weaned from mechanical ventilation (69).  The study had two groups, one 
with oral tracheal tube and a second with tracheostomy (69). They found that the tidal volume 
(VT), minute volume (MV), PaCO2, and dead space volume VD/VT were dependent on the 
flow rates used via oral-tracheal tube (69). The distal catheter position was better in terms of 
efficacy than the proximal position. The TGI gas delivery through tracheostomy tube was less 
effective compared to oral tracheal tube (69). They concluded that reduction in CO2 levels 
reduced the VT needed and this in turn reduced the work of breathing required to achieve the 
VT and MV (69). . 
 
The physiologic effects of TGI was further studied by Miller et al in an acute lung injury 
model involving neonatal piglets. The piglets (n=19, Weight 2.4±0.4 kg) were spontaneously 
breathing and were supported with CPAP of 5 cm H2O. The aim of the study was to 
understand TGI effects on gas exchange and pulmonary mechanics (70). The acute lung 
injury was induced by intravenous oleic acid administration. They were given either CPAP 
and TGI (n=9) or CPAP alone (n=10) (70). The target SaO2 of >93% was maintained by 
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increments in FiO2 by 0.05 every 15 min during the study.  Apart from vital signs, they 
recorded the following parameters namely, arterial blood gases, pulmonary mechanics, and 
Thoraco abdominal motion (TAM) (70). The group receiving TGI achieved better 
oxygenation and CO2 removal compared to the control (70). Consequently, the pH was also 
higher and closer to the baseline value in TGI group. The oxygen requirement noted by the 
FiO2 titration data showed that TGI group required lesser oxygen supplementation by 4 hours 
into the study. They also required lower minute ventilation (MV)  and showed greater 
compliance compared to the control group (70). The resistance and TAM were similar 
between the two groups (70). They concluded that the use of TGI with CPAP in the treatment 
of acute lung injury results in better gas exchange and improved pulmonary mechanics (70). 
In this study, the piglets were intubated and therefore application of TGI was done through 
endotracheal tube. Therefore if one were to achieve TGI by some other means than by 
endotracheal intubation then that would result in improved ventilation and CO2 clearance and 
reduced need for mechanical ventilation (14).  
 
Dewan and Bell studied the effects of airway dead space wash out in 10 patients of COPD on 
respiratory support with trans tracheal catheters (TTC) by administering low flow and high 
flow oxygen and assessing effects on dyspnoea and exercise tolerance (71). The study 
protocol involved four sessions of modified progressive treadmill tests on two separate days 
(71). Two tests were performed when the patients receiving Low Flow Trans Tracheal 
Oxygen (LFTTO) and  High Flow Trans Tracheal Oxygen (HFTTO) and other two tests were 
done when the patients were receiving low flow nasal prong (LFNP) and high flow nasal 
prong (HFNP) oxygen (71). Equivalent oxygen saturation was achieved by adjusting the flow 
rate (71). The exercise distance with HFTTO was 2.5 times greater than with LFTTO and 
HFNP was 2.38 times greater than with LFNP (p<0.005) (71). Interestingly, there was no 
significant difference in exercise distance and dyspnoea scores with HFTTO as compared 
with HFNP and LFTTO compared with LFNP (71). They concluded that the exercise 
tolerance was greater with the use of high flow oxygen irrespective of the route when 
compared to low flow oxygen (71). The maximum exercise tolerance was not improved by 
Trans Tracheal oxygen as compared to nasal prong oxygen when the oxygen saturations were 
maintained similar (71). 
 
Holleman-Duray et al showed in their neonatal study which incorporated an early extubation 
protocol that infants extubated to high flow therapy from a significantly greater ventilator rate 
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compared to other non-invasive support modes (33± 8 vs 28 ±8 breaths per minute; p<0.05) 
(72). This indicates that the babies requiring higher respiratory rate to achieve adequate MV 
for satisfactory gas exchange were able achieve satisfactory ventilation by increasing alveolar 
ventilation fraction with high flow therapy because of airway dead space wash out effect (72).  
 
1.6.2 Airway dead space wash out effect and its impact on oxygenation 
 
Chatila et al conducted a prospective but non randomised and non-blinded study in 10 patients 
with COPD and compared the effects of high flows of humidified oxygen (HFO) to 
conventional low flow oxygen (LFO) delivery at rest and during exercise (73). All the patients 
had advanced airflow obstruction but were clinically stable with no evidence of exacerbation 
(73). Baseline recording was done on rest and then patients exercised on a cycle ergometer for 
up to 12 min starting on LFO first (73). They had a period of rest followed by exercise when 
using the high-flow oxygen (HFO) system. The HFO was delivering 20 L/min and was 
adjusted to deliver similar FiO2 as that of LFO system (73). They measured the work of 
breathing, tidal volume, respiratory rate, inspiratory time fraction, rapid shallow breathing 
index and pressure-time product from a pulmonary mechanics monitor (73). The patients 
whilst receiving HFO exercised longer and reported less dyspnoea with better breathing 
pattern compared to when on LFO (73). Although the FiO2 was maintained equivalent when 
on HFO and LFO, the exercise period with HFO achieved higher oxygenation (73). 
They concluded that high flows of humidified oxygen by enhancing oxygenation improved 
exercise performance in patients with COPD and severe oxygen dependency (73). 
 
In studies with in vitro models, airway oxygen fractions were higher with the HFNC versus 
non-rebreathing masks (14, 74). This is likely due to the effect of a high flow on the upper air 
way dead space, with the high flow of oxygen 'washes out' the end-expiratory gas containing 
reduced O2 and higher CO2 content(54). In the next breath, the lower airways receive gas with 
higher oxygen concentration because of this washout effect (54).  
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1.6.3 Methods of measuring airway gas concentrations 
 
Airway gas concentration can be measured by sampling the air by a catheter and analysing it 
with a gas analyser. The sampling can be continuous or intermittent. Commercial gas 
analysers with high degree of accuracy are available. These are generally electronic analysers 
that can perform rapid and continuous gas analysis.  
 
Broadly gas analysers can be classified into O2 analysers, CO2 analysers and multiple gas 
analysers. These devices can be incorporated in a single unit which can be used for gas 
analysis in clinical and research setting.  
 
Oxygen analyser types include those using paramagnetic technique, galvanic technique and 
polarographic technique. 
 
Paramagnetic technique is based on the principle that oxygen has a free electron which makes 
it to be attracted towards a magnetic field (75). These analysers are made up of two 
compartments, one for sampling and other acts a reference compartment (75). They are 
separated by a pressure transducer (75). When the expired gas is channelled through the 
sampling compartment it is subjected to an electromagnetic field which agitates the oxygen 
molecules (75). At the same time the reference compartment receives room air with 21% 
oxygen (75). Thus a differing concentration of oxygen creates a differing partial pressure and 
this is picked up by the pressure transducer and is converted to a DC voltage (75). This is  
proportional to the concentration of oxygen (75).  
 
Galvanic technique is based on chemical properties of the oxygen molecules. Oxygen is made 
to diffuse across the membrane and an electrolyte solution (Potassium hydroxide) to a cathode 
made up of gold or silver and the anode is usually lead (75, 76). Depending on the partial 
pressure of oxygen an electrical current is generated which gives quantitative estimation of 
oxygen concentration (75). They have a response time of approximately 20 seconds with an 
accuracy of 3% (75). These devices do not need water vapour trap as they are not affected by 
water vapour. However, the limitation is limited life of electrolyte solution which is affected 
by the oxygen over time.  
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In the polarographic technique current flows between a silver cathode and a platinum anode 
(75). The oxygen molecules move across a Teflon membrane (75). An external current is 
required to drive the cathode reaction, hence the name polarographic (76). 
  
CO2 analyser types include Infrared absorption spectroscopy, refractometry, piezoelectric 
absorption, Raman scattering and mass spectrometry. 
 
Infrared absorption spectroscopy is based on the principle that molecules having dissimilar 
atoms absorb infrared radiation in a unique way specific to that molecule (75). In doing so, 
energy is generated which causes molecular vibration (75). This vibration has a specific 
frequency which is dependent upon the molecular mass and atomic bonding of the molecule 
of the gas (75). Thus the absorption of infrared by a specific molecule occurs at a specific 
wavelength and this obeys ‘Beer-Lambert law’ (75). According to Beer-Lambert law there is 
a logarithmic dependence between the transmission of light through a substance and the 
concentration of that substance (75). The infrared absorbance peaks for carbon dioxide with 
this technique is located at the 4-5 μm range (75). The device has a set of narrow band filters 
set in chopper wheel assembly through which infrared radiation is focussed (75). The specific 
infrared rays filtered are captured or detected by photocells or thermopiles, amplified and 
signal is processed giving quantitative output of the levels of gas being analysed (75).  
The device can be set as a mainstream or as side stream to the ventilation channel (75). The 
mainstream attachment does not require gas sampling but the side stream requires gas 
sampling (75). Water trap is required in both set up as water vapour affects analysis (75). The 
sampling rate in side stream set up should be at around 50-250 ml/min (75).  
 
Refractometry technique  is based on the physical principle of refraction of a monochromatic 
light through the gas medium being analysed (75). There are calibrated refractometers 
(example, Rayleigh) which have a series of prisms which split the light source through 
sampling and control tubes (75). Different gases produce specific pattern of refraction and 
from this their type and concentration can be determined (75). This type of device is typically 
used for anaesthetic gases such as halothane but can be used for other gases including CO2 
(75). However, these do not give breath to breath analysis (75).  
 
Piezoelectric absorption analysers are based on the resonance property of a piezoelectric 
compound such as quartz (75). Two quartz crystals (one coated with silicone based oil and 
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other remains uncoated) are mounted between electrodes (75). The oil-coated quartz crystal 
absorbs the gas being analysed and changes the resonant frequency in proportion to the 
concentration of gas present (75). Although these devices have a fast response time they are 
limited by inability to differentiate individual gases (75). 
 
Raman scattering phenomenon is used in another type of CO2 analysers. The scattering of 
light on contact with object is been theorised by two principles, first is called Rayleigh 
scattering and the second called Raman Scattering. This technique uses Raman scattering 
principle where an intense, coherent and monochromatic light interacts with the gas molecule 
being analysed, gets scattered (75). During this process, some of the light's energy is either 
absorbed or release of the energy as a photon with a different wavelength (75). This leads to 
change in the wavelength due to transformational shift in the gas molecule (75). The scattered 
light is passed through a series of narrowband filters onto a photo-detector followed by signal 
processing unit (75). Since the filters are specific for the gas to be analysed, the concentration 
of gas can be determined (75). This technique is fast and can analyse multiple gases with good 
accuracy (75).  
 
Mass spectrometry is mainly a research tool but it is highly accurate. In this technique, a 
sample of the gas to be analysed is drawn into a low pressure chamber which is connected to 
another chamber subjected to vacuum pressure (75). The gas molecules get ionised due to this 
exposure to pressure change and they are accelerated by a cathode plate (75). These ionised 
molecules have different mass and charge based on the type of gas (75). They are separated 
by exposure to electromagnets or fixed magnets (75). They are filtered by narrow band filters 
and trapped by photovoltaic receptors, the electrical signal is amplified and processed into a 
quantitative estimate of the gas being analysed (75). The response time is long so it is not 
suitable for continuous inline monitoring but they are very accurate (75).  
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1.7 Effects of HFNC on Tidal Volume  
 
1.7.1 Tidal volume and minute volume importance for ventilation 
 
Minute volume is the amount of gas inhaled or exhaled from a person's lungs in one minute. 
If both tidal volume (VT) and respiratory rate (ƒ or RR) are known, minute volume can be 
calculated by multiplying the two values.  
MV = TV X f 
Blood carbon dioxide (PaCO2) levels vary inversely with minute volume. Minute volume 
generally decreases when at rest, and increases with exercise. Minute volume comprises the 
sum of alveolar ventilation and dead space ventilation, 
 V= VA   + VD 
Where VA is alveolar ventilation and VD represents dead space ventilation. 
Tidal ventilation parameters have been used to assess the impact of HFNC on work of 
breathing (10). Non-invasive methods of lung function assessment in preterm and term infants 
can be done by tidal breathing measurements. This can help in management of respiratory 
support.  
  
1.7.2 Tidal volume measurement studies during HFNC 
 
Saslow et al studied eighteen preterm neonates <2.0 kg on HFNC and NCPAP support in a 
random order(17). A ventilator was used to deliver 6 cm H2O of NCPAP with nasal 
prongs(17). High-flow nasal cannula therapy was delivered with Vapotherm (VAPO) at 3, 4 
and 5 l/min (17). Tidal ventilation was measured using respiratory inductance 
plethysmography which was calibrated with face-mask pneumotachography (17). The 
oesophageal pressure was measured to generate estimation of transpulmonary pressure (Ptp). 
The sampling frequency of data was at 100 Hz. The outcomes measured included tidal 
volume (ml/kg), respiratory rate, lung compliance, phase angle and end distending 
pressure(17). The tidal volume range they noted with high flow therapy (VAPOTHERM) and 
CPAP are shown in table 5 (17).  
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Table 5. The tidal volumes during CPAP and HFNC in the study by Saslow et al(17) 
 
 
Respiratory support levels Tidal volumes (mean±s.d.)     n=18 
NCPAP 6 3.53±1.92 
VAPOTHERM 3 3.15±1.36 
VAPOTHERM 4 3.08±1.35 
VAPOTHERM 5 3.21±1.31 
 
 
Table 5 shows the mean tidal volumes observed during HFNC and CPAP in 18 preterm 
neonates. 
 
Boumecid et al studied thirteen infants (GA=29 ±1 Weeks; BW=1350±350 g) at a post-natal 
age of 3±1 days on three respiratory support devices each for 30 minutes in random order 
(37). The respiratory support modes were variable flow NCPAP generator (Infant-Flow, EME 
Tricomed, UK) at a pressure of 5 cm H2O, a conventional constant-flow NCPAP (Baby-
Flow, Draeger, Germany) at a pressure of 5 cm H2O with gas flow rate 10 l/min and nasal 
cannulae (length=1 cm, internal diameter=1.5 mm; Kendal, Germany) connected to an air-O2 
blender-flow meter (Sechrist, France) with flow rate of 2 l/min (37). They used respiratory 
inductive plethysmography (Respitrace Plus, Sensor Medics, USA) and obtained Tidal 
volume (VT), rib cage contribution to the VT (%RC), phase angle between abdominal and 
thoracic motions (h), respiratory rate (RR), and inspiratory times (Ti) (37). Mean tidal 
volume, VT, measured from the flow- volume loops was higher during variable-flow than 
during either constant-Flow NCPAP or during nasal cannulae (p<0.05) (37). 
 
Lavizzari et al conducted a randomised crossover trial in 20 preterm infants (gestational age: 
31±1 weeks) with mild-moderate RDS requiring non-invasive respiratory support within 96 h 
after birth (36). Infants were exposed to a randomised sequence of CPAP and HFNC at 
different settings (2, 4 and 6 cmH2O for NCPAP and 2, 4, 6 L/min for HFNC) to enable 
comparison at the same level of retropharyngeal pressure (Prp) (36). A 6 Fr feeding catheter 
with four side holes at the distal extremity was inserted in the pharynx and connected to a 
pressure transducer to measure retropharyngeal pressure (Prp) (36). To avoid occlusions of 
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the catheter by secretions, a 40 mL/h airflow produced by a micro infuser was applied at the 
inlet of the catheter (36). 
Tidal volume was measured from respiratory inductance plethysmography and they found that 
the VT was similar in the two modalities as shown in table 6 (36).  
 
Table 6. The tidal volumes in mL at equal distending pressures - Lavizzari et al(36) 
 
Respiratory support Prp=2 cm H2O Prp=4cm H2O 
CPAP 5.77 (4.76; 6.75) 6.89 (4.33; 8.41) 
HFNC 5.29 (3.46; 7.95) 7.54 (3.97; 10.17) 
 
Table 6 shows the tidal volumes at equal distending pressures during HFNC and CPAP in 20 
preterm infants. 
 
 
1.7.3 Methods of measuring tidal volume 
 
The pneumotachometer is currently the most accepted device to measure tidal breathing (77). 
However, this requires application of a face mask over the face which has been shown to alter 
the respiratory parameters. In a physiology study on 10 normal, sleeping term infants aged 1-4 
days, investigators studied the effects of application of pneumotachograph in addition to full 
face mask compared to facemask rim alone on the tidal volume and respiratory rate. The tidal 
volume and respiratory rate were determined by a transthoracic impedance pneumograph 
(78). There was a significant reduction in respiratory rate both in quiet sleep (12%) and during 
rapid eye movement sleep (17%) with face mask rim alone. When the complete face mask 
plus pneumotachograph  was applied, the respiratory rate reductions were 10% in quiet sleep 
and 14% in rapid eye movement sleep (78). Tidal volumes on the other hand showed increase 
in both types of instrumentation and quantitatively the increase in tidal volumes were of 
similar magnitude to respiratory rate reduction (78). They concluded that the change in 
respiratory pattern was due to trigeminal stimulation from the face mask used (78).  
 
Respiratory inductance plethysmography (RIP) provides a non-invasive measurement of lung 
volume using recording bands around the thorax and abdomen. In its simplest form it involves 
inductance coils placed around the child’s chest and abdomen and changes in the impedance 
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of the coils are proportional to changes in the volume of the chest and abdomen and the sum 
of the two impedances is proportional to lung volume (79). 
RIP is based upon the two-compartment model of thoraco abdominal movement during 
respiration (80). The valid measurements are obtained when initial calibration is done 
accurately, the body movements are stable and changes in respiratory movements are 
recorded accurately (80). Measurement errors occur when there is displacement of transducer 
bands and when body position changes (80). RIP detects changes in the volume of the chest 
and abdomen during inspiration and expiration, which can be used to measure tidal volume 
(80). 
 
Saslow et al used RIP in 18 preterm neonates <2.0 kg, when they studied in a random order 
on HFNC or CPAP support (17). CPAP at 6 cm H2O with nasal prongs was delivered by a 
ventilator while HFNC was by Vapotherm (VAPO) at 3, 4 and 5 l/min flow rates (17). Tidal 
ventilation was obtained using respiratory inductance plethysmography by recording chest 
wall and abdominal movements (17). They used respiratory inductance plethysmography 
(RIP) bands (Respibands Plus, Sensormedics Corp., Yorba Linda, CA) placed around the 
infant’s rib cage and abdomen(17). Calibration was done by direct comparison of volume 
changes measured by face-mask pneumotachography (Hans Rudolph Inc., Kansas City, MO) 
(17). No differences were found in the work of breathing for all settings (17). 
 
In study of 13 premature infants (GA=29 ±1) weeks; BW=1350±350 g) at a post-natal age of 
3±1 days Boumecid et al used Respiratory Inductance Plethysmography (RIP) when they 
compared variable flow CPAP to constant flow CPAP and nasal cannula (at a flow rate of 2 
l/min) (37). They used Respitrace Plus for RIP and calibrated it using face mask 
pneumotachography (37). The RIP was useful in obtaining the respiratory parameters and 
allowed the authors to make comparison between variable flow CPAP and constant flow 
CPAP as well as nasal cannula therapy (37). They found that mean tidal volume was higher 
during variable-flow compared to other modes in their study (37). 
 
Lavizzari et al studied 20 preterm infants between 28+0 and 32+6 weeks gestational age (GA) 
and postnatal age <96 h receiving either NCPAP or HFNC for mild to moderate RDS(36). 
They used RIP to calculate tidal volumes (36). Tidal changes were computed from the 
abdominal (AB) and thoracic (RC) displacements measured by respiratory inductance 
plethysmography (RIP) (36). The calibration was done comparing with a face-mask 
 48 
 
pneumotachography over several spontaneous breaths (36). Using this RIP method, they did 
not find any statistically significant differences in breathing pattern, gas exchange, lung 
mechanics and total WOB in either mode of respiratory support (36).  
 
Volusense is a recently developed system using electromagnetic inductive plethysmography 
technique for evaluating tidal breathing indices in infants. Respiratory measurements are 
derived from changes in electromagnetic inductance in a wrap-around vest worn by the baby. 
The vest is disposable and used for one patient only to avoid cross-infection. The vest is made 
from soft elastic. The vests contain thin conductive coils that are isolated. Thorax and 
abdominal volumes and volume changes are measured and stored digitally. This allows 
measurement of tidal volume, respiratory rate and tidal flow volume loops non-invasively and 
without application of masks or instrumentation of the infant’s airway. The calibration is done 
with a pretested and validated cylinder provided with the device (24-26). This has been 
recently validated as reliable as pneumotachography and safe in babies of gestation 28 weeks 
and above (24, 26). The technique is therefore ideal for measuring the effects of HFNC and 
CPAP on tidal breathing indices non-invasively and may improve our understanding of its 
mechanism of action. It may also allow us to detect the effects of varying pressure on 
Functional Residual Capacity (FRC) baseline and improve understanding of the role of 
pressure on recruitment of lung volume. 
 
Using a device employing this new technique of electromagnetic inductance plethysmography 
(EIP), Pickerd et al measured tidal breathing in 49 healthy spontaneously breathing infants 
between 32 and 42 weeks postconceptional age (PCA) (81). They noted that the tidal 
volume/kg  and minute volume decreased with advancing PCA (81). In another study using 
similar electromagnetic inductive plethysmography technique, tidal ventilation and breathing 
pattern were measured and compared simultaneously with pneumotachography in 43 infants 
either receiving no respiratory support or continuous positive airway pressure (CPAP) 
(82).Twenty-three infants were receiving CPAP (gestational age 28 ± 2 weeks, mean ± SD) 
and 20 were breathing spontaneously (gestational age 34 ± 4 weeks)(82). The two methods 
were in reasonable agreement, with VT (r2 = 0.69) ranging from 5 to 23 ml (4–11 ml kg−1) 
with a mean difference of 0.4 ml and limit of agreement of −4.7 to + 5.5 ml (82). 
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1.8 HFNC – Summary of Literature Review  
 
1.8.1 Summary of physiology studies 
 
In summary, the use of HFNC is an increasing trend across the world. The device set up has 
basic components of humidification, air and oxygen blender and a flow driver delivering 
conditioned gases via nasal cannulae. There are some evidences in support of various 
proposed mechanisms of action in the form of in vitro and in vivo physiology studies in 
animals and humans. The measurement techniques differ greatly in their working mechanism, 
accuracy and applicability to the intended study question. Various investigators have 
conducted focussed research on respiratory physiology parameters. The conditions of study, 
equipment used and methods employed differ and making inference is difficult. The 
physiology studies are listed in table 7.  
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Table 7. List of physiology studies evaluating respiratory parameters and HFNC 
mechanisms 
 
 
Study 
Year 
Number  
Setting Type 
of subjects 
Age/gestatio
nal age (GA) 
and weight 
Study type 
and design 
Respiratory 
support 
devices used 
Outcomes 
measured 
Findings Additional 
informatio
n 
Locke et 
al(30) 
 
  
1993  
 
 
n = 13 
 
 
NICU 
Preterm 
infants Mean 
GA 30 weeks, 
mean birth 
weight 1,377 
g 
Observational 
study 
Unheated and 
unhumidified 
HFNC (Salter 
Labs) 
Oesophageal 
pressure 
Ventilatory 
patterns with 
respiratory 
inductance 
plethysmograph
y 
No pressure 
generation 
with smaller 
prongs at any 
flow rate 
Larger 
prongs 
deliver 
increasing 
pressure with 
increasing 
flow 
Mean 
pressure of 
9.8 cm H2O 
at 2 
L/minute 
Flow rates 
0.5–2 L/ 
Minute 0.2 
and 0.3 cm 
prongs 
Sreenan 
et al(24)  
 
 
2001 
 
 
n = 40 
NICU 
Preterm 
infants Mean 
GA 28.7 
weeks, mean 
study weight 
1,260 g  
Observational 
study 
Unheated, 
humidified 
HFNC (Salter 
Labs) vs. 
NCPAP 
(Infant Star)  
Treatment of 
Apnoea of 
Prematurity 
(AOP)  
 
Oesophageal 
pressure  
No 
difference in 
efficacy of 
treatment for 
AOP  
 
Salter Labs 
‘infant’ size 
prongs used  
 
Low flow 
rates used 
at 1–2.5 L/ 
minute  
Saslow et 
al(17) 
 
 
2006  
 
 
n = 18  
NICU 
Preterm 
infants Mean 
GA 28.2 
weeks, mean 
study weight 
1,542 g  
Observational 
crossover 
study Heated 
and 
humidified 
HFNC 
(Vapotherm 
2000i) vs. 
NCPAP 
(Infant Bird 
Ventilator)  
Work of 
breathing 
Respiratory 
inductance 
plethysmograph
y Respiratory 
rate 
Oesophageal 
pressure  
No 
difference 
noted 
between two 
modalities. 
Oesophageal 
pressure was 
significant 
only at 5 
L/minute of 
HFNC  
Used flow 
rates 
ranging 
from 3–5 
L/minute  
Spence et 
al(26) 
 
 
2007  
 
 
n = 14  
NICU 
Preterm 
infants 
Median study 
GA 30 weeks, 
median study 
weight 1,589 
g  
Observational 
study Heated 
and 
humidified 
HFNC 
(Fisher and 
Paykell) and 
NCPAP 
(Infant Flow)  
Pharyngeal 
pressure  
Pharyngeal 
pressure 
increases 
with 
increasing 
flow  
‘Infant’ size 
Salter 
prongs were 
used 
 51 
 
Study 
Year  
number 
(cont) 
Setting Type 
of subjects 
Age/gestatio
nal age (GA) 
and weight 
Study type 
and design 
Respiratory 
support 
devices used 
Outcomes 
measured 
Findings Additional 
informatio
n 
Kubicka 
et al(3) 
 
 
2008  
 
 
n = 27  
NICU 
Preterm 
infants GA 
range 25–40 
weeks, birth 
weight 605–
3,657 g  
Observational 
study Heated 
and 
humidified 
HFNC 
(Vapotherm 
2000i or 
Fisher and 
Paykell 
RT329)  
Oral pressure  No pressure 
generated 
with mouth 
open  
When mouth 
in closed 
position 
pressure 
increases 
with flow in 
infants < 
1,500 g 
  
Flow rates 
1–5 
L/minute, 
0.2 cm 
prongs 
More 
mature and 
larger 
infants 
included in 
study 
Wilkinso
n et 
al(27)  
 
 
2008  
 
 
n = 18  
NICU 
Preterm 
infants 
Median GA 
27.1 weeks, 
median birth 
weight 944 g  
Observational 
study Heated 
and 
humidified 
HFNC 
(Fisher and 
Paykell 
RT329)  
Pharyngeal 
pressure  
Pharyngeal 
pressure 
increases 
with 
increasing 
flow but 
decreases 
with 
increasing 
weight  
Included 
extremely 
premature 
infants 
Higher 
flows up to 
8 L/minute 
Mouth 
position is 
irrelevant 
Lamplan
d et 
al(31)  
 
 
2009  
 
 
n = 15  
NICU 
Preterm 
infants Mean 
GA 29.5 
weeks, mean 
birth weight 
1,324 g  
Observational 
study Heated 
and 
humidified 
HFNC 
(Fisher and 
Paykell 
RT329) vs. 
NCPAP 
(Draeger 
Babylog 
8000)  
Physiological 
parameters 
including heart 
rate, respiratory 
rate, FiO2, 
PaO2 RDS 
scoring system 
Oesophageal 
pressure  
As flow rate 
decreases 
respiratory 
rate increases 
As flow rate 
increases 
oesophageal 
pressure 
increases  
Fisher and 
Paykell 
neonatal 
size prongs 
of 0.24 cm 
used  
Slightly 
higher flow 
rates 
studied 1–6 
L/minute 
Corley et 
al(35)  
 
 
2011  
 
 
n = 20  
ICU Mean 
age 65.3 
years, weight 
93.3 kg  
Post cardiac 
surgery adult 
patients  
Prospective 
interventional 
study LFNC 
vs. HFNC  
Electrical 
impedance 
tomography  
Respiratory rate  
Borg scores  
Significant 
correlation 
between 
airway 
pressures and 
end 
expiratory 
lung 
impedance 
 
A trend 
towards 
HFNC 
improving 
subjective 
dyspnoea 
scoring 
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Study 
Year  
number 
(cont) 
Setting Type 
of subjects 
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Volsko et 
al(21) 
 
 
2011  
 
 
Simulatio
n model 
Laboratory 
based study 
Active 
simulator 
lung model  
Observational 
study Lung 
model 
simulated a 
sick neonate 
of 
approximatel
y 1 kg with 
lung 
compliance 
0.5 mL/cm 
H2O and 
resistance 
125 cm 
2O/L/s  
Highest and 
lowest airway 
pressure  
Mean airway 
pressure  
VT drop  
Flows of >2 
L/minute 
generated 
positive 
expiratory 
pressure with 
all cannula 
sizes  
Cannulae 
used were 
(Comfort 
Flow 
models) 
Premature 
Infant  
Infant 
Arora et 
al(28)  
 
 
2012  
 
 
n = 25  
 
PICU Mean 
age 78.1 [SD 
30.9] days; 
weight, 5.3 
[SD 1.1] kg  
Acute 
bronchiolitis 
Prospective, 
observational 
study Heated 
humidified 
HFNC 
system  
Nasopharyngeal 
(NP) pressures 
Vital Signs 
Bronchiolitis 
severity scores 
Oxygen 
saturation  
Linear 
increase in 
NP pressures 
with flow 
rates up to 6 
L/minute but 
with 
significant 
differences 
between 
pressures in 
open and 
closed mouth 
states 
Bronchiolitis 
severity 
scores 
improved 
significantly  
No effect of 
gender or 
weight 
noted on 
generated 
pressure 
Mile´si et 
al(54) 
 
 
 2013  
 
 
n = 21  
PICU  
 
Infants < 6 
months old  
 
Acute RSV 
bronchiolitis  
Prospective 
observational 
study Heated 
and 
humidified 
HFNC 
RT329 
system 
Fisher and 
Paykell 
Pharyngeal 
pressure (PP) 
and 
oesophageal 
pressure (Pes) 
measured 
simultaneously  
Flow >2 
L/kg/minute 
generated a 
mean PP >4 
cm H2O  
Significant 
reduction in 
respiratory 
rate noted 
with increase 
in flow  
Measured at 
flows of 1, 
4, 6 and 7 
L/minute 
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Sivieri et 
al(20)  
 
2013  
 
Simulatio
n model  
Laboratory 
based study  
Observational 
study  
 
HFNC 
(Fisher & 
Paykel 
system with 
integrated 
pressure 
relief valve)  
 
In vitro 
evaluation of 
effect of 
nasal prong-
to-nares ratio 
and mouth 
leak on 
airway 
pressures 
generated by 
HFNC device  
Cannula and 
airway 
pressures  
 
Cannula and 
mouth leak 
flows  
For all ratios 
mouth open 
6 L/minute 
flow 
pressures 
were < 1.7 
cm H2O  
 
Ratios <0.9 
mouth closed 
airway 
pressure was 
<10 cm H2O  
 
Ratios >0.9 
50% mouth 
leak airway 
pressure rises 
to 18 cm 
H2O at 2 
L/minute 
flow  
 
24 cm H2O 
at 6 L/ 
minute flow 
(pressure 
relief valve 
limited)  
Neonatal 
and infant 
sized nasal 
prongs (3.0 
and 3.7 mm 
outer 
diameter)  
 
Seven sizes 
of 
simulated 
nares 
(range: 3-7 
mm internal 
diameter)  
 
Nasal 
prong-to-
nares ratio 
range (0.43 
to 1.06) 
Collins et 
al(29) 
 
2013 
 
n=9 
 
 
NICU 
 
 
mean 
gestational 
age at birth 
of 27.4 
completed 
weeks (SD 
1.5) and 
birthweight 
1139 g (SD 
253). 
 
 
Observational 
study 
 
 
 
HFNC 
Devices 
 
Fisher & 
Paykel 
 
Vapotherm 
 
 
Pharyngeal 
pressure 
measurements 
recorded with 
both HFNC 
devices at flow 
rates of 2–8 
L/min. 
There was no 
difference in 
pharyngeal 
pressures 
recorded 
between 
devices at 
flow rates of 
2–6 L/min;  
measured 
pressure was 
linearly 
associated 
with flow 
(R2 = 0.9).  
 
The 
pressure 
limiter 
valve of the 
Fisher & 
Paykel 
device 
attenuated 
the 
pharyngeal 
pressures at 
flows of 7 
and 8 
L/min.  
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Parke et 
al(83) 
 
2013 
 
 
n=15 
 
 
Adults 
 
Age 59.5 
±10.6 years 
Weight 85.1 
±17 kg 
 
Cardiac post-
operative 
patients 
RT033/ 034 
Optiflow 
nasal 
cannula, 
MR880 
heated 
humidifier, 
and RT241 
heated 
delivery tube, 
Fisher & 
Paykel 
 
The pressure 
transducer - 
Nasopharyng
eal catheter 
connected to 
a differential 
transducer 
Nasopharyngeal 
pressure 
measurements 
at gas flows of 
30, 40, and 50 
L/min 
mean ± SD 
nasopharyng
eal airway 
pressures 
were 1.5 ± 
0.6, 2.2 ± 
0.8, and 3.1 
± 1.2 at 30, 
40, and 50 
L/min  
The 
expiratory 
pressure 
during 
HFNC was 
higher than 
the mean 
pressure 
previously 
reported for 
nasal high 
flow. 
Shetty et 
al(39) 
 
2016 
 
 
n=20 
 
 
Median 
gestational 
age of 27.6 
weeks (range 
24.6–31.9 
weeks)) 
 
Studied at a 
median 
postnatal age 
of 30.9 weeks 
(range 28.1– 
39.1 weeks). 
Randomised 
crossover 
trial 
 
HFNC - 
Fisher and 
Paykel using 
optiflow 
neonatal and 
infant nasal 
prongs 
WOB assessed 
by measuring 
the pressure 
time product of 
the diaphragm 
(PTPdi).  
 
Thoracoabdomi
nal asynchrony 
(TAA)  
 
SaO2  
 
no 
significant 
differences 
in the results 
on CPAP 
versus 
HHFNC 
mean PTPdi  
mean TAA  
mean SaO2  
Oesophagea
l (Poes) and 
gastric 
(Pgas) 
pressures 
were 
measured 
using a dual 
pressure 
transducer 
tipped 
catheter 
(Gaeltec). 
Frizzola 
et al 
 
2012 
 
 
Animal 
Study 
 
n=13 
Neonatal 
piglets (n=13; 
2-6kg) were 
injured with 
IV oleic acid 
and supported 
with HFNC at 
2 through 8 
L/min. 
Treatment 
order 
randomised 
 
Vapotherm 
2000i  
 
CPAP 
VIP Bird 
infant 
ventilator  
Tracheal 
pressures 
Respiratory 
parameters –  
respiratory rate 
and relative 
tidal volume 
 
CO2 levels 
PaO2 levels 
were measured 
CO2 trended 
downward in 
a flow 
dependent 
manner 
independent 
of leak. 
Double 
prong (low 
leak) had 
greater 
impact on O2 
At 8L/min, 
tracheal 
pressures 
did not 
exceed 6±1 
cm H2O. 
Single 
prong(high 
leak) 
greater CO2 
removal 
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Moller et 
al(84) 
 
 
2015 
 
 
 
Anatomic
al Model 
study 
 
 
 
Models 
1st - simple 
tube model 
consisting of 
a nozzle to 
simulate the 
nasal valve 
area, 
connected to 
a cylindrical 
tube to 
simulate the 
nasal cavity. 
 
The second 
anatomically 
representative 
upper airway 
model (from 
CT-scan 
images)  
HFNC at 
rates of 15, 
30, and 45 
l/min 
 
 
 
Tracer gas 
clearance 
investigated 
The tracer gas 
clearance was 
determined 
using dynamic 
infrared 
CO2 spectrosco
py and 81mKr-
gas radioactive 
gamma camera 
imaging. 
There was 
complete 
tracer-gas 
removal 
from the 
nasal cavities 
within 1.0 s. 
The level of 
clearance in 
the nasal 
cavities 
increased by 
1.8 ml/s for 
every 1.0 
l/min 
increase in 
the rate of 
NHF 
For both 
models, the 
anterior 
compartme
nts 
demonstrate
d faster 
clearance 
levels (half-
times < 0.5 
s) and the 
posterior 
sections 
showed 
slower 
clearance 
(half-times 
< 1.0 s). 
Moller et 
al(85) 
 
2016 
 
 
n=10 +3 
 
 
Observational 
study 
10 healthy 
adult 
volunteers 
And 3 
tracheotomise
d patients 
Scintigraphy 
with 
81mKrypton 
(81mKr) gas 
during a 
breath-
holding 
manoeuvre 
with closed 
mouth and 
in 3 nasally 
breathing 
tracheotomise
d patients by  
 
 
HFNC rates 
of 15, 30, and 
45 l/min.  
 
 
. 
Volumetric 
capnography 
and oximetry 
through 
sampling CO2 
and O2 in the 
trachea and 
measuring the 
inspired volume 
with inductance 
plethysmograph
y 
 
decrease in 
81mKr gas 
clearance 
half-time 
with an 
increase 
of HFNC 
flow rate in 
the nasal 
cavities  
 
Tracheal gas 
showed an 
HFNC 
dependent 
decrease of 
inspired CO2 
that 
correlated 
with an 
increase of 
inspired O2 
 
NHF clears 
upper 
airways of 
expired air. 
 
The dead 
space 
clearance is 
flow and 
time 
dependent, 
and it may 
extend 
below 
the soft 
palate. 
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Miller et 
al(70) 
 
2004 
 
Animal 
Study 
 
n=19 
 
Spontaneousl
y breathing 
neonatal pigs 
(2.4_0.4 kg) 
 
Induced lung 
injury 
Randomised 
controlled 
 
randomized 
to receive 
CPAP with 
TGI (TGI; 
n=9) or 
CPAP alone 
(control; 
n=10) 
arterial blood 
gases, 
pulmonary 
mechanics, and 
thoracoabdomin
al 
motion (TAM) 
were evaluated 
30 min after 
injury and at 1-
hr intervals for 
4 hr 
TGI group  
PaCO2 was 
lower  
while the 
oxygenation 
indices were 
greater  
pH was 
greater  
 
ventilation 
was 
accomplishe
d with a 
lower minute 
ventilation 
(MV) 
Examined 
role of TGI 
(wash out 
effect) 
 
HFNC was 
not studied 
 
 
 
Resistance 
and TAM 
were 
similar 
between 
groups. 
Chang et 
al(52) 
 
 
2011 
 
In-Vitro 
study 
 
 
 
 
To study the 
effect of flow 
on 
temperature, 
humidity, 
device 
pressure, and 
resistance 
Nasal cannula 
(NC), 
continuous 
positive 
airway 
pressure 
(CPAP), and 
high-flow 
nasal cannula 
(HFNC) 
 
Flow ranges 
(0-3 L/min 
and 0-8 
L/min) 
Effect of flow 
on temperature, 
in humidity, 
pressure and 
resistance 
For all 
devices at 0-
3 L/min, 
there was a 
difference 
(p<0.01) in 
temperature, 
humidity 
pressure and 
resistance as 
a function of 
flow. 
 
For HFNC 
and CPAP at 
0-8 L/min, 
there was a 
difference 
(p<0.01) in 
temperature, 
in humidity, 
pressure and 
resistance as 
a function of 
flow. 
 
 
Gas 
delivered 
by HFNC 
was more 
humid than 
NC and 
CPAP.  
 
Higher 
pressure 
and 
resistance 
was 
delivered 
by the 
HFNC 
system  
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Sivieri et 
al(86) 
 
 
2017 
 
 
In-Vitro 
study 
Premature 
infant lung 
model 
 
Piston 
cylinder lung 
simulator, 
having a 
fixed volume 
of 30 ml and 
a 4.8 ml dead 
space, 
simulated 
spontaneous 
breathing 
(6.5 ml tidal 
volume, Rate 
50/min, Ti 
0.5 sec) 
Fisher & 
Paykel 
cannulas (2.8 
and 3.2mm 
O.D.)  
 
Infant-Flow 
NCPAP 
cannulas (3.4 
and 4.1mm 
O.D. 
 
Simulated 
airways with 
either 3.5 or 
4.5mm I.D. 
nares. 
 
 
The lung was 
primed with 5% 
CO2. 
 
Washout times 
were 
determined at 
HFNC settings 
of 3, 4, 5, 6, and 
8 L/min and 
NCPAP at 3, 4, 
5, 6, and 8 cm 
H2O with 
simulated open 
and closed 
mouth  
conditions and 
full and half 
inserted HFNC 
prongs 
Overall 
combined 
mean 
washout 
times for 
NCPAP with 
mouth closed 
were 
significantly 
longer than 
HFNC over 
all five 
pressure and 
flow device 
settings. 
 
CO2 washout 
times 
decreased as 
flow or 
pressure 
device 
settings were 
increased.  
Simulated 
mouth 
opening 
was a 5mm 
I.D. side tap 
below the 
nasal 
interface. 
 
There were 
negligible 
differences 
in washout 
times 
between 
NCPAP and 
HFNC with 
mouth 
open. 
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1.9 Concerns with HFNC Therapy 
 
1.9.1 Delivery of airway pressure – unmonitored and unpredictable 
 
Some of the earlier studies on high flow therapy documented delivery of inadvertently high 
mean airway pressures when nasal cannula diameter 0.3 cm was used in neonates (30). 
Studies of airway pressures since have not consistently identified dangerously high pressures 
(3, 17, 27, 31). However there is wide variation in the techniques and protocol used to 
measure pressures (2).  
 
1.9.2 Microbial colonisation of delivery systems 
 
In 2005 there were reports of Ralstonia species infection in the neonatal units using 
Vapotherm 2000i (87, 88). This was noted to be due to the humidification system used in the 
HFNC units. Since then strict infection prevention measures such as disposal of humidifier 
fluid routinely and standardised cleaning of equipment has made these systems safer. 
However, as HFNC circuit contains moist, humidified system, continued vigilance and strict 
adherence to cleaning must be followed to avoid infections.   
Shoemaker et al noted increased gram-negative infections in their observational study (89). 
 
1.9.3 Effects on lung volumes 
 
Long term effects of inadequate lung expansion or over distension due to effects on end 
expiratory lung volume (EELV) –does it increase incidence of CNLD? Inadequate end 
expiratory pressure may lead to reduction in end expiratory lung volume or Functional 
Residual Capacity. This can lead to atelectasis and can give rise to atelectotrauma. It is 
possible that in the presence of atelectasis lung units that are still recruited may in advertently 
receive a greater proportion of tidal volume and become over distended. 
 
On the contrary, over distension can lead to volutrauma. Dreyfuss et al studied this 
phenomenon of volutrauma in rats with or without strapped chests (90). This allowed limiting 
the thoracoabdominal movements (90). They compared the consequences of normal tidal 
volume ventilation in mechanically ventilated rats at a high airway pressure (HiP-LoV) with 
those of high tidal volume ventilation at a high (HiP-HiV) or low (LoP-HiV) airway pressure 
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(90). An application of PEEP (10 cm H2O) and its effects on both oedema and lung 
ultrastructure was also studied (90). In rats with low tidal volumes (VT) there was no cases of 
pulmonary oedema, even when high airway pressures were used (90). The lungs from the rats 
submitted to high volume ventilation had significant permeability type pulmonary oedema 
(90). This oedema was more pronounced in LoP-HiV rats and it was markedly reduced by 
application of PEEP (90).   
 
Both these phenomena are harmful to developing lung tissue. It is not known; however exact 
dose-response value for these adverse effects to occur during HFNC. Whether transient 
elevations or drop in airway pressures have any clinic-pathological effects is unknown.  
 
1.9.4 Effects of noise 
 
The noise levels produced vary with the type of machine used. It also depends upon the flow 
driver and the way the system is built. It also depends upon the flow rate used during therapy.  
 
Roberts CT et al performed a study in 21 infants to determine whether HFNC (n=21) was 
noisier than bubble CPAP n=13) (BCPAP) for preterm infants (91). They measured noise 
levels within the external auditory meatus (EAM) with a microphone probe tube connected to 
a calibrated digital dosimeter (91).. HFNC flow rate range was 2–5 L/min, and BCPAP 
pressures were 5–7 cm of water using 6–10 L/min of gas flow (91). There was no evidence of 
a difference in average noise levels measured at the EAM for HFNC compared to 
BCPAP(91). HFNC was quieter than BCPAP only at low frequency (500 Hz), mean (95% CI) 
3.0 (0.3 to 5.7) dBA (91). Noise increased with increasing BCPAP gas flow (p=0.007), but 
not with increasing set pressure (91). There was a trend to noise increasing with increasing 
HFNC gas flows (91). They concluded that HFNC are not noisier than BCPAP for preterm 
infants at the gas flow range that they studied.  
 
An In-Vitro study was done to record the noise levels produced by Fisher & Paykel NHF™ 
and Vapotherm Precision Flow®) and one CPAP device (Dräger Babylog® 8000 plus in the 
oral cavity of newborn manikin model in an incubator in a quiet environment (92). HFNC 
flows of 4-8 l/min and CPAP pressures of 4-8 cm H2O with CPAP flow at 8 l/min was used 
(92). Vapotherm HFNC generated the highest noise levels, measuring 81.2-91.4 dB(A) with 
increasing flow (92). Fisher & Paykel HFNC noise levels were between 78.8 and 81.2 dB(A) 
 60 
 
(92). The CPAP device generated the lowest noise levels between 73.9 and 77.4 dB(A)(92). 
Thus in this study both HFNC devices generated higher noise levels than the CPAP device 
(92).  
 
1.9.5 Possibilities of air leak syndromes 
 
A case series with HFNC including one involving pneumocephalus, pneumo orbitis and scalp 
emphysema raised concerns with air leak syndromes (93). Since there have been few more 
case reports of air leak (94, 95). However, this has not been supported by further larger 
clinical trials involving HFNC (96-98).  
 
1.9.6 Monitoring while on HFNC 
 
Delayed recognition of a deteriorating patient with progressive respiratory failure may occur 
due to the ability of the HFNC system to give up to 100% oxygen without necessarily 
improving ventilation and CO2 removal. However, not much has been published in neonatal 
or paediatric literature regarding the likely short term adverse events due to HFNC apart from 
few case reports. This may be because there is no clear evidence as to how to wean, escalate 
or stop high flow therapy (99). A Cochrane systematic review in 2015 failed to identify any 
relevant studies evaluating discontinuation of HFNC in preterm infants (99). Therefore, any 
adverse event may not be appreciated as due to the way HFNC as administered or prescribed 
to the neonate. In the adult ICU however, there have been some observational and 
retrospective data regarding possible delays in intubation due to reliance on HFNC 
contributing to mortality (100, 101).  
 
1.10 HFNC - Gaps in knowledge 
 
Although various mechanisms of action for HFNC in neonates have been proposed the 
relative contributions of these mechanisms is not well understood. In addition there are a 
number of factors influencing the measurements of physiology parameters depending on the 
technique used making comparisons and inferences of earlier studies particularly difficult.  
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1.10.1 Airway pressure measurement during HFNC therapy 
 
The magnitude of pressure generated in the airway varies depending upon the site of 
measurement, measurement technique used and the fidelity of the data acquired and used to 
report the pressures. Thus clinicians and researchers are still not clear as to the pressure 
effects of HFNC on the airway. Therefore it is important to identify appropriate and fit for 
purpose techniques and record accurate pressure measurements in the airway.  
 
1.10.2 Nasopharyngeal gas concentrations during HFNC therapy 
 
Dead space wash out effects of HFNC in human patients has not been unequivocally 
answered. The proposed evidences have largely been drawn from tracheal insufflation studies 
and animal models. Thus recording airway gas concentrations at various stages of respiratory 
cycle gives clarity regarding any role for dead space wash out mechanism for HFNC.  
 
1.10.3 Tidal volume changes during HFNC therapy 
 
The tidal volume measurement is challenging as application of pneumotach devices on the 
face to capture tidal breathing results in alternation in respiratory rate and depth. Thus non-
invasive techniques are needed which can continuously measure changes in tidal volumes 
with changes in HFNC therapy. However, measuring techniques involving conventional 
plethysmography equipment are cumbersome. Therefore a simple, minimally invasive device 
is needed. Although it has been shown that following initiation of HFNC there is 
improvement in respiratory rate and heart rate parameters in children with respiratory distress 
it is not clear whether this effect is due to effects on the tidal volumes.  
 
1.10.4 Gaps in knowledge regarding HFNC clinical application 
 
There is currently no consensus and evidence basis for the treatment initiation parameters 
such as HFNC flow levels and whether to wean oxygen or flow as well as the rate of weaning 
to be employed. The influence of different pathologies and population for which it is being 
used also needs to be studied.  
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Chapter 2. Aims 
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The work presented in this thesis was a proof of concept study for a larger randomised 
crossover study to investigate respiratory physiology during high flow nasal cannula therapy 
in preterm neonates. 
   
In order to evaluate the respiratory physiology, various parameters had to be measured. This 
included nasopharyngeal pressures, nasopharyngeal space oxygen and carbon dioxide 
concentration, tidal volumes and measures of gas exchange such as transcutaneous carbon 
dioxide levels and transcutaneous oxygen saturation. I investigated the feasibility and 
accuracy of methods to measure these parameters in preterm neonates during high flow 
therapy. In parallel I designed and developed the protocol for the randomised crossover study 
and successfully applied for ethical approval.  
 
Therefore, the specific aims of my project were to,  
 
1. Perform a descriptive review of available evidence for clinical efficacy and safety of high 
flow nasal cannula therapy in preterm neonates 
 
2. Assess the range, accuracy and feasibility of three different types of nasopharyngeal 
airway pressure measuring techniques in preterm neonates during high flow therapy 
 
3. Assess the feasibility and accuracy of airway gas concentration assessment in preterm 
neonates during high flow therapy 
 
4. Assess the feasibility and accuracy of measuring tidal volumes in preterm neonates during 
high flow therapy using Volusense equipment 
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Chapter 3. Descriptive Review of Key Outcomes with High Flow Nasal 
Cannula Therapy in Preterm Infants  
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3.1 Introduction 
 
In preterm infants, Respiratory Distress Syndrome (RDS) is an important clinical entity 
requiring intensive care support. The disease has a wide spectrum in severity and therefore 
different levels of respiratory support may be required. It is important to identify optimum 
respiratory support which is safe in the short term as well as long term and efficacious in 
terms of clinical outcomes. This is particularly important at present because it is evident from 
surveys that a significant number of neonatal units and clinicians have reported existence of 
equipoise when deciding between CPAP and HFNC.  
 
HFNC was initially used as a post extubation respiratory support or while weaning from 
CPAP. However, as experience with its use increased with time, neonatal units started using it 
as primary respiratory support following birth or when RDS set in. This clinical application 
was not preceded by well conducted clinical trials. Since the first paper on its use as primary 
respiratory support was presented by Nair et al in an academic meeting in 2005 there have 
been several studies examining the clinical efficacy and safety of HFNC in neonatal 
population.  
 
In this chapter, a descriptive review of these studies followed by a table listing the key 
features of each study is presented. A discussion on the current evidence for and against its 
use as respiratory support in various clinical situations has been presented.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 66 
 
3.2 Background 
 
3.2.1 Definitions 
 
In this review following definitions were used, 
Preterm infants – Infants born at gestation less than 37 weeks completed. 
 
HFNC therapy – Treatment with heated, humidified air/oxygen mixture with flow rates more 
than 1 litre per minute.  
 
CPAP therapy – Treatment with a device delivering air/oxygen mixture via a nasal interface 
which maintains a continuous positive airway pressure.  
 
BPD – NIH definition – Infants requiring oxygen at 28 days of life and further classified 
according to gestation at birth and oxygen/positive pressure requirement as shown in table 8.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 67 
 
Table 8. Bronchopulmonary Dysplasia Definition(102) 
 
 
Gestational 
Age 
<32 wk ≥32 wk 
Time point of 
assessment 
36 wk PMA or discharge to home, 
whichever comes first 
>28 d but <56 d postnatal age or 
discharge to home, whichever comes 
first 
 
Treatment with oxygen > 21% for at least 28 d plus 
Mild BPD 
Breathing room air at 36 wk PMA or 
discharge, whichever comes first 
Breathing room air by 56 d postnatal 
age or discharge, whichever comes first 
Moderate BPD 
Need * for <30% oxygen at 36 wk 
PMA or discharge, whichever comes 
first 
Need * for <30% oxygen at 56 d 
postnatal age or discharge, whichever 
comes first 
Severe BPD 
Need * for ≥30% oxygen and/or 
positive pressure, (PPV or NCPAP) at 
36 wk PMA or discharge, whichever 
comes first 
Need * for ≥30% oxygen and/or 
positive pressure (PPV or NCPAP) at 56 
d postnatal age or discharge, whichever 
comes first 
  
 
Table 8 shows the current consensus definition of BPD(102) 
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3.2.2 Rationale 
 
This review is relevant because of the widespread use of HFNC despite it being just over a 
decade old therapy. This has the implications for lung health of the individual patient as well 
as implications for health care burden for family and health care providers because of unclear 
risks for efficacy in the short term and bronchopulmonary dysplasia in the long term. This is 
particularly relevant for extremely low birth weight infants.  
 
Pathophysiology in BPD can be considered in three areas as lung parenchymal disease, 
pulmonary vascular disease and airways disease.  
 
In BPD, pulmonary gas exchange is abnormal due to changes in lung parenchyma. The 
changes include alveolar simplification and abnormal development of the pulmonary vascular 
bed (103). The lung parenchyma shows different areas of hyperinflation, atelectasis and 
fibrosis. This results in increased dead space, abnormal lung resistance and compliance in a 
patchy distribution, V/Q mismatch and intrapulmonary shunting (104-106). The differences in 
pulmonary resistance and compliance in different lung units results in differences in 
ventilation causing ventilation inhomogeneity.  
 
The main features of pulmonary vascular abnormality seen in BPD are poor growth of 
pulmonary vascular bed and inflammation due to endothelial cell dysfunction (103).  
This results in poor gas exchange. Pulmonary hypertension develops over time when this 
process is severe (103). 
 
Increased airway obstruction is seen in BPD due to airway remodelling, decreased airway and 
alveolar growth, and mechanical ventilation associated complications such as tracheomalacia, 
bronchomalacia, and stenosis of glottis, sub glottis and trachea. Airway obstruction leads to 
air trapping (107). Pulmonary mechanics are also altered because of reduction in the lung 
parenchymal elastic framework. This results in reduced airway support and allows airway 
closure and collapse of alveoli. These changes result in overall reduced lung compliance and 
reactance whilst increasing pulmonary resistance (108, 109). 
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3.3 Aims and Outcomes 
 
3.3.1 Aims 
 
The aim of this review is to present an up to date evidence regarding the efficacy and safety of 
HFNC as respiratory support for preterm infants (<37 weeks’ gestational age at birth), when 
compared with other modes of non-invasive respiratory support.  
 
3.3.2 Outcomes 
 
Main outcomes of interest are treatment failure as defined by study criteria (failure of 
extubation), mortality, nasal trauma, BPD, air leak syndromes, length of respiratory support, 
duration of oxygen therapy and duration of hospitalisation. 
 
3.4 Methods 
 
3.4.1 Search strategy  
 
I searched the following electronic databases Ovid Medline, EMBASE, HMIC and CINAHL 
as well as The Cochrane Library. In addition, the references from the extracted articles were 
cross checked for further articles. All languages were included during the search for articles. 
The study types searched included Cochrane Reviews, Systematic Reviews, Meta-Analyses, 
Controlled Clinical Trials, and Randomized Controlled Trials. The key words used in earlier 
Cochrane Review and another earlier meta-analysis done by Kotecha et al were used for the 
search and are listed below (1, 110). 
 
Key words used as in the study by Kotecha et al - Non-invasive ventilation, CPAP, 
continuous positive airway pressure, nasal cannula, nasal prong, oxygen inhalation therapy, 
high-flow, high-flow therapy, Infant, Low Birth Wt., Infant, Extremely Low Birth Wt., Infant, 
Premature, Premature Birth, Fetal Growth Retardation, Birth Wt., Low Birth Wt., IUGR, 
Randomized Controlled Trials, Random Allocation, Double-blind Method, Single Blind 
Method, clinical trial, controlled clinical trial, multicentre study (110).  
Key words used as in the Cochrane review- infant or newborn or neonate or neonatal or 
premature or very low birth weight or low birth weight or VLBW or LBW (1). 
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In this review, I included prospective, randomized controlled trials involving preterm infants 
born at <37 weeks’ gestational age. Studies involving both term and preterm babies were 
included but only preterm data was taken into consideration. Trials were included if 
participating infants received non-invasive respiratory support, and randomly assigned to 
HFNC or any other form of non-invasive respiratory support as primary respiratory support 
after birth, after extubation from mechanical ventilation or while weaning from non-invasive 
respiratory support.  
 
3.4.2 Selection of studies 
 
A total of 35 studies published as full text articles (24, 29, 91, 96-98, 111-139) and 2 studies 
as abstracts (140, 141) were extracted from the literature search. Among these, five articles 
were used for qualitative analysis only such as for review of other clinical outcomes (118, 
133, 137-139). A total of 20 studies published as full-text articles (96-98, 113, 114, 116-118, 
122-132, 134) and 2 studies published as abstracts (140, 141) with treatment failure data were 
included in the final review. Of the studies published as abstracts, one study evaluated HFNC 
as primary support but was terminated early and the data was extracted from previous reviews 
(1, 110, 140, 142) and in another study only abstract data was used to review HFNC as 
weaning mode (141). Both these abstracts were included because data needed for the review 
question was available.  
 
All included studies compared HFNC with CPAP, except 2 studies of which one compared 
HFNC with Nasal Intermittent Positive Pressure Ventilation (NIPPV) (126) and Nasal 
Intermittent Mandatory Ventilation (NIMV) in the other (123). All the studies involved 
preterm infants who were <37 weeks’ gestation except in 2 studies which included both term 
and preterm infants but stratified data of only preterm babies were included in the analysis 
(97, 111).  
 
One study compared HFNC with CPAP both as a primary mode of respiratory support and as 
post extubation respiratory support and stratified data for primary outcomes were available for 
both uses and therefore this study was included review questions (97). Thus, 6 studies were 
included for examining HFNC as primary respiratory support (97, 122, 127, 130, 131, 140) 
and 11 studies were included for examining HFNC as post extubation respiratory support (96-
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98, 111, 112, 116, 117, 124, 125, 128, 132). Google Translate was used for an automated 
translation from Chinese to English (Google Inc, Mountain View, CA). Characteristics and 
clinical details of all the included studies are presented in table 9.  
 
3.4.3 Statistical analysis 
 
Although this was a descriptive review, I calculated risk ratio for various outcomes using the 
data from included studies. I used Review Manager (RevMan) version 5.3 (The Nordic 
Cochrane Centre, The Cochrane Collaboration, 2014, Copenhagen, Denmark) for statistical 
analysis. The data was extracted for each intervention group and Risk Ratios (RR) was 
calculated, along with 95% confidence intervals (CIs). Significance was set at P<0.05.  
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Table 9. List of studies included in HFNC clinical efficacy review 
 
 
 
Study name Study 
Type 
Study population 
n 
Comparison Outcomes 
Yoder 
2013 
RCT Primary n=141 
Post extubation  
n= 291 
HFNC vs 
CPAP 
Treatment failure 
Subgroup -Primary support  
Extubation failure 
Subgroup – Post extubation  
Nair 
2005 
RCT n=67 HFNC vs 
CPAP 
Treatment failure requiring intubation 
Iranpour 
2011 
RCT n=70 HFNC vs 
CPAP 
Treatment failure requiring intubation 
Lavizzari 
2016 
RCT n=316 HFNC vs 
CPAP 
Treatment failure requiring intubation 
Shin 
2017 
RCT n=87 HFNC vs 
CPAP 
Treatment failure requiring intubation 
Roberts 
2016 
RCT n=564 HFNC vs 
CPAP 
Treatment failure requiring intubation 
Kugelman 
2011 
RCT n=76 HFNC vs 
NIPPV 
Treatment failure requiring intubation 
Iranpour 
2016 
RCT n=60 HFNC vs 
NIMV 
Total respiratory support 
Respiratory support after 1st day 
Collins 
2013 
RCT n=132 HFNC vs 
CPAP 
Extubation failure in the first 7 days after 
extubation 
Manley 
2013 
RCT n=303 HFNC vs 
CPAP 
Treatment failure within 7 days of 
randomisation 
Liu 
2014 
RCT n=255 HFNC vs 
CPAP 
Extubation failure in the first 7 days after 
study entry 
Mostafa-
Gharehbaghi 
2014 
RCT n=85 HFNC vs 
CPAP 
Re-intubation within 3 days of study 
entry 
Chen 
2015 
RCT n=66 HFNC vs  
CPAP 
Extubation failure within 7 days 
Chen  
2016 
RCT n=129 HFNC vs 
CPAP 
Extubation failure within 7 days 
Kang 
2016 
RCT n=161 HFNC vs 
CPAP 
Treatment failure within 7 d after 
extubation 
Kadivar 
2016 
RCT n=54 HFNC vs 
CPAP 
Remaining extubated for at least 3 days 
after INSURE method.  
Soonsawad 
2017 
RCT n=49 HFNC vs 
CPAP 
Extubation failure within 3 days after 
endotracheal tube removal 
Elkhwad 
2017 
RCT n=60 HFNC vs 
CPAP 
Failure of extubation within 5 days of 
initial extubation 
Abdel Hady 
2011 
RCT n=60 HFNC vs no 
HFNC 
Duration of oxygen 
Requirement 
Badiee 
2015 
RCT n=88 HFNC vs 
CPAP only 
Duration of oxygen 
Requirement 
Soonsawad 
2016 
RCT n=101 HFNC vs 
CPAP only 
Time, it took to wean off the use of the 
CPAP or HFNC devices 
Bao 
2017 
RCT n=82 HFNC vs 
LFNC 
Rate of one time successful weaning of 
CPAP 
TOTAL  3297 
 
  
 
Table 9 shows the list of studies included in this review and key characteristics. 
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3.5 Primary respiratory support for RDS - HFNC versus CPAP 
 
3.5.1 Descriptive review of studies evaluating HFNC for primary respiratory support 
compared to CPAP 
 
I identified 6 RCTs addressing this question in this review. 3 studies were small trials and 3 
studies had large number of infants. Overall 1245 babies have been studied. A brief 
description of these studies is followed by a meta-analysis of the primary outcome of 
treatment failure. The treatment failures in the studies were defined by need for intubation and 
mechanical ventilation.   
 
A study by Yoder et al consisted of essentially two subgroups- one subgroup where HFNC 
was used as primary support for respiratory distress and compared with CPAP, and other 
subgroup where HFNC was used as post extubation support and compared with CPAP in its 
efficacy against treatment failure (97). Over all 432 term and preterm infants of more than 28 
weeks' GA who were planned to receive non-invasive respiratory support either as primary 
support after birth or as post extubation support were enrolled onto the study (97). Among the 
study patients, 351 infants were preterm and rest were term babies (97). The primary support 
subgroup had 125 preterm infants and post-extubation subgroup had 226 preterm babies(97).  
The respiratory support provided by HFNC was in the range of 3 to 5 L/min or nasal CPAP 
was 5 to 6 cmH2O and this was administered after randomisation (97). The primary outcome 
was defined as the need for intubation based on pre-determined criteria, within 72 hours of 
commencing the treatment allotted by randomisation with either HFNC or CPAP (97).   
There was no significant difference in the primary outcome between CPAP and HFNC. More 
infants in the HFNC group crossed over to the alternative treatment after 72 hours. Any type 
of positive pressure requirement was shorter for CPAP group as compared to HFNC group 
but there was no difference in time to wean to room air or BPD rate.  
They concluded that in infants >28 weeks’ gestational age, HFNC appears to have similar 
clinical efficacy and safety to CPAP as a mode of non-invasive respiratory support. 
The study had prespecified criteria for intubation and used random number generation and 
opaque sealed envelopes for randomisation but the study was non-blinded. The risks for bias 
include, non-blinded study, selective reporting of outcomes, and loss of power when making 
subgroup analysis of preterm babies from the whole study group which had both term and 
preterm babies. 
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Nair et al conducted a single-centre study looking at HFNC efficacy as a primary support for 
respiratory distress in preterm infants (140). They enrolled 67 preterm infants of mean (range) 
32 (27-34) weeks gestational age and mean birth weight of 1700 grams with respiratory 
distress in the first six hours after birth (140). They were randomised to HFNC (mean flow 
rate was 5 to 6 L/min) or CPAP (pressures of 5 to 6 cmH2O) (140). The primary outcome was 
pre-determined with set criteria and was met if the infant required intubation due to 
respiratory failure (140). They found that 4/33 (12.1%) in HFNC group and 4/34 (11.7%) in 
NCPAP group ended up with treatment failure as per their pre-determined criteria in the trial 
(p= 0.96).  
 
This was one of the first studies which looked at HFNC as primary support for RDS in 
neonates. The study was well structured with pre specified criteria (140). In addition unlike 
some other studies during the same time, the Vapotherm units used in the study were modern 
and delivered both heated as well as humidified gas (140).  However, the study had to be 
stopped early due to reports of infection with Ralstonia species in other neonatal units using 
Vapotherm device for delivery of HFNC (1). The study was unpublished but was presented in 
Paediatric Academic Society meeting (1, 140). The recruited infant numbers did not reach the 
power to discriminate superiority of HFNC over CPAP (1). The study did not examine the 
extremely premature babies or VLBW babies (140).  
 
The risks of bias include non-blinded study, the Vapotherm device was provided by the 
company.  
 
In a single centre study by Iranpour et al conducted in a University Hospital in Iran, 70 
preterm infants of 30 to 35 weeks' gestation were enrolled at 24 hours of age. The inclusion 
criteria was presence of ongoing features of respiratory distress and oxygen requirement 
(122). Infants were then randomised to either HFNC (gas flow 1 to 4 L/min) or to continuing 
nasal CPAP (6 cmH2O)(122). In this study they also used INSURE (Intubation, Surfactant 
administration, Extubation) technique if the infants met prespecified criteria and this was done 
either before or after randomisation as per infants clinical requirement (122).       
They found that there was no difference in failure of treatment. In addition, there were no 
differences in death, duration of hospitalization, duration of improvement of respiratory 
distress, chronic lung disease (CLD) and pneumothorax. There was less nasal trauma in 
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HFNC group (P<0.0001). They concluded that HFNC was as effective as CPAP in the 
management of RDS in premature neonates more than 30 gestational weeks.  
This study was a prospective randomised trial with clear segregation of two treatment arms 
and included complications data such as nasal trauma and air leak episodes. The 
randomisation process was unclear and criteria for treatment failure/intubation was not stated. 
This was a non-blinded study. The HFNC flow rates were much lower than conventionally 
used at present. Despite this, the HFNC arm did not show poorer primary outcome compared 
to CPAP. The use of INSURE treatment might have altered the course of RDS and might 
have changed the respiratory support requirement significantly. In addition, the pre-treatment 
of 24 hours duration with nasal CPAP might influence the subsequent lung compliance due to 
CPAP effects on end expiratory lung volume.   
 
The risks of bias in this study includes unclear randomisation process where information 
about sequence generation being not available. This results in selection bias. The criteria for 
treatment failure or re intubation was not specified resulting in performance bias.  
 
Ciuffini et al in 2013 at halfway stage and Lavizzari et al on completion in 2016 published 
their single centre study of 316 preterm infants, mean (range) gestational age of 33 (29-36) 
weeks and mean birth weight of 1900 grams with mild to moderate respiratory distress after 
birth (119). Infants were randomised to receive HFNC (flow rates of 4 to 6 L/min) or nasal 
CPAP (pressures of 4 to 6 cmH2O). The primary outcome was the need for intubation within 
72 hours of life, based on a prespecified criteria (119). At halfway stage of the recruitment, 
they found that 11/85 (12.9%) in HFNC group and 5/92 (5.43%) in NCPAP group ended up 
with intubation within 72 hours of enrolment into the trial (p= 0.11) (119).  
The study used block randomisation method with sealed envelopes. They had pre-specified 
criteria for intubation. The study included infants who had INSURE technique who may have 
a different course of RDS compared to other infants without surfactant. The study was 
published prior to completion full trial of planned study population of 316 infants and this 
was a non-blinded study. 
 
The completed trial was then published by the same group Lavizzari et al in 2016 as a 
randomized, clinical, non-inferiority trial (127). The treatment arms were HFNC on one arm 
and CPAP/biphasic positive airway pressure (BiPAP)in the other am (127). The primary 
outcome was treatment failure within 72 hours, defined by the need for mechanical ventilation 
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127). The non-inferiority margin was set at 10% (127).  The study was done between 2012 
and 2014 (127).   
 
Their study objective was to determine whether HFNC provides respiratory support as a 
primary approach with efficacy levels of being non-inferior to nasal continuous positive 
airway pressure (CPAP) or bi-level CPAP (BiPAP) in preterm neonates (127). 
The inclusion criteria were preterm in the gestational age 29+0 to 36 +6 presenting with mild 
to moderate RDS requiring non-invasive respiratory support(127). Pre specified criteria for 
starting non-invasive respiratory support were in place in the protocol (127). The study arms 
were HFNC at flow rates of 4 to 6 L/min or CPAP/BiPAP at pressures of 4 to 6 cm H2O 
(127). 
 
They recruited a total of 316 infants with 158 in the HFNC group (mean [SD] GA, 33.1 [1.9] 
weeks; 52.5% female) and 158 in the CPAP/BiPAP group (mean [SD] GA, 33.0 [2.1] weeks; 
47.5% female) (127). The primary outcome failure of treatment was seen in 17 out of 158 
infants in HFNC group (10.8%) and 15 out of 158 infants in CPAP/BiPAP group (9.5%). The 
95% CI of risk difference was −6.0% to 8.6%; P = .71 (127). In this study, the use of HFNC 
was noninferior to CPAP with regard to the primary outcome because the upper 95% 
confidence limit (8.6%) was below the non-inferiority margin of 10%, and the lower 95% 
confidence limit (−6.0%) was below 0% (127). The result was similar when applying a per-
protocol analysis (127).  
 
Since their findings were in agreement within the limits of non-inferiority margins set 
initially, they concluded that HFNC showed efficacy and safety similar to those of 
CPAP/BiPAP when applied as a primary respiratory support to mild to moderate RDS in 
preterm infants older than 28 weeks’ gestational age (127). 
 
This study achieved total study numbers as per their sample estimates and used pre-specified 
and standardised criteria for study entry. The non-inferiority margin of 10 percentage points 
allows reasonable degree of certainty to claim non-inferiority of one treatment compared to 
the other.  
 
This study also used INSURE (intubation, surfactant treatment, and extubation) treatment and 
this did not amount to treatment failure. Moreover, the surfactant administration was 
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common, occurring in >40% of infants in both treatment groups. They did not report the age 
at randomisation and the respiratory support data before entry to the study was not explicitly 
stated. The risks of bias in this study include non-blinded study affecting performance bias.  
 
Shin et al conducted a randomised controlled trial involving 87 preterm infants with 
gestational age range of 30 - 35 weeks with respiratory distress within 24 hours after birth 
(131). The primary outcome was defined as the need for intubation or mechanical ventilation 
due to treatment failure (131). The treatment failure included any of the following: respiratory 
acidosis at maximum setting of the allocated device [flow 7 L/min or PEEP 7 cmH2O]), 
degree of hypoxia (defined by FiO2>0.4 to maintain SpO2 88 to 94%) or frequency and 
severity of apnoea (>2–3 episodes of apnoea/hour requiring repeated stimulation or bag-and-
mask ventilation) despite optimising therapy delivery either during HFNC or during CPAP 
(131).  The primary outcome events in HFNC was 16 out of 42 neonates and in CPAP was 9 
out of 43 neonates reached treatment failure criteria (Risk difference 17.17 [−1.90–36.23]; P = 
0.099) (131). The most frequent reason for treatment failure was hypoxia (p=0.020) seen 
predominantly in HFNC group (131). The authors concluded that their study did not support 
the noninferiority of HFNC compared to CPAP as an initial management of respiratory 
distress in premature infants at between 30 and 35 weeks gestational age (131). 
 
The randomization was performed by using computer-generated random-number followed by 
sequentially numbered sealed opaque envelopes. Babies who received intubation and 
surfactant were excluded and criteria for treatment failure was explicitly stated.  
This was a non- blinded study with small study numbers, therefore it is possible that it did not 
have the power to identify effectiveness between two modalities of respiratory support.  
 
Roberts et al conducted a multicentre, randomized, noninferiority trial, where 564 preterm 
infants (gestational age, ≥28+0 weeks) with early respiratory distress were studied with one 
arm being nasal high-flow therapy and the other arm being nasal CPAP (130). The primary 
outcome was treatment failure within 72 hours after study entry (130). In this non inferiority 
trial the margin was 10 percentage points and it was determined by the absolute difference in 
the risk of the primary outcome (130). CPAP rescue provided to HFNC arm in case of failure 
and if CPAP also failed, they were mechanically ventilated (130).  
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Treatment failure was observed in 71 of 278 infants (25.5%) in the HFNC group and in 38 of 
286 infants (13.3%) in the control group (risk difference, 12.3 percentage points; 95% 
confidence interval [CI], 5.8 to 18.7; P<0.001) (130). The rate of intubation within 72 hours 
and rate of adverse events was similar between two groups (130). Since the treatment failure 
rate was 25.5% in HFNC group they concluded that when used as primary support for preterm 
infants with respiratory distress, HFNC results in higher treatment failure compared to CPAP 
(130).  
 
This study also did not adopt INSURE treatment and the randomisation process was robust. 
Trial recruitment was stopped early after review by safety monitoring committee. In order to 
achieve 90% power, the study needed 750 infants to identify non-inferiority of HFNC over 
CPAP. The risks of bias are non-blinded study, allowed CPAP cross over from HFNC and 
therefore could have affected secondary outcomes.  
 
These 6 studies have been summarised in table 10.  
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Table 10. Summary of clinical studies comparing HFNC versus CPAP as primary 
respiratory support 
 
 
 
Author, 
date, 
Country 
Publication 
journal 
Study 
population 
Type of 
study 
 
 
Primary 
outcome 
Results 
Events/Tota
l 
Additional 
information 
Yoder et 
al(97) 
 
2013 
 
USA 
 
Pediatrics 
141 neonates 
in primary 
support arm 
– 28–42/40 
gestational 
weeks, 
birth weight 
≥1000 g 
 
125 babies 
were preterm 
 
Multi-centre 
RCT 
Unblinded  
 
 
Extubation 
failure any 
time after 
initiation of 
study 
support 
HFNC – 
6/58 
 
 
 
CPAP- 
 9/67 
Pre-
intervention 
respiratory 
support also 
included 
neonates who 
were initially 
on non-
invasive 
support 
 
Pre-extubation 
caffeine use 
was not 
standardised 
Nair et 
al(140) 
 
2005 
 
USA 
 
PAS 
meeting 
unpublished 
67 preterm 
infants 
 
27 to 34 
weeks' 
gestational 
age (GA) 
mean GA of 
32 weeks and 
birth weight 
of 1700 
grams  
 
 
 
Single centre 
RCT 
Unblinded 
 
 
HFNC: 
Vapotherm 
5 to 6 L/min 
 
CPAP: 
bubble 
CPAP,  
Hudson 
prongs, 5 to 6 
cmH2O 
Respiratory 
failure 
requiring 
intubation, 
based on 
prespecifie
d criteria 
(pH ≤ 7.25 
and 
PaCO2 ≥ 60 
mmHg , or 
FiO2 > 
0.70, or 
severe or 
frequent 
apnoea) 
HFNC 4/33 
 
CPAP 4/34 
Vapotherm 
units were 
recalled 
following 
reports of 
Ralstonia 
infection – 
therefore 
study ended 
prior to full 
recruitment 
 
Randomisatio
n was 
standardised 
with Sealed 
envelopes and 
Stratified into 
27 to 30 
weeks' and 31 
to 34 weeks' 
gestation. 
Permuted 
block 
randomisation 
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Author, 
date, 
Country 
Publication 
journal 
(Cont) 
Study 
population 
Type of 
study 
 
 
Primary 
outcome 
Results 
Events/Tota
l 
Additional 
information 
Iranpour et 
al(122) 
 
2011 
 
Iran 
 
Archives of 
Disease in 
Childhood. 
70 preterm 
infants 
 
30–35 weeks 
gestation 
 
 
RCT 
 
 
Group1 
(CPAP) 
received 
NCPAP from 
birth and  
Group 2 
(HFNC) 
received 
CPAP for the 
first 24 hours 
after birth, 
then standard 
HFNC 
Rates of 
treatment 
failure (and 
need for 
intubation) 
within 
seven days 
of trial 
entry 
HFNC 0/35 
 
CPAP 0/35 
 
Lavizzari et 
al(127) 
 
2016 
 
Italy 
 
JAMA 
Pediatrics 
 
316 infants 
with 158 in 
the HFNC 
group (mean 
[SD] GA, 
33.1 [1.9] 
weeks; 
and 158 in 
the 
CPAP/BiPA
P group 
(mean [SD] 
GA, 33.0 
[2.1] weeks;  
randomized 
clinical non-
inferiority 
trial 
 
The babies 
were 
randomised 
to either 
HFNC at 4 to 
6 L/min or 
CPAP/BiPA
P at 4 to 6 
cm H2O  
 
  
 
Treatment 
failure 
within 72 h, 
defined as 
the need for 
mechanical 
ventilation 
HFNC 
17/158 
 
CPAP  
15/158 
In the CPAP 
group, infants 
were shifted to 
BiPAP in the 
case of more 
than 4 
episodes 
of apnoea per 
hour or more 
than 2 
episodes per 
hour requiring 
positive 
pressure 
ventilation or 
if deemed by 
clinicians 
because of 
increased 
work of 
breathing. 
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Author, 
date, 
Country 
Publication 
journal 
(Cont) 
Study 
population 
Type of 
study 
 
 
Primary 
outcome 
Results 
Events/Tota
l 
Additional 
information 
Shin et 
al(131) 
 
2017 
 
South Korea 
 
J Korean 
Med Sci 
87 preterm 
infants 
 
30 weeks and 
less than 35 
weeks of ges-
tational age 
 
Single centre 
RCT 
 
HFNC  
Flow of 5 
L/min 
initially and 
adjusted 
between 3–7 
L/min  
 
CPAP- 
PEEP of 5 
cmH2O 
initially and 
adjusted be-
tween 4–7 
cmH2O  
Pre-
specified 
treatment 
failure 
criteria 
HFNC 
16/42 
 
CPAP  
9/43 
HFNC  
Optiflow 
System  
Fisher & 
Paykel 
Optiflow   
 
CPAP  
Infant Flow 
CPAP system 
or Millennium 
ventilator  
 
Short binasal 
prongs with 
different sizes 
according to 
weight 
Roberts et 
al(130) 
 
2016 
 
Internationa
l trial 
 
The New 
England 
Journal of 
Medicine 
564 infants 
included in 
the analysis 
 
HFNC 278 
CPAP 286 
RCT 
 
HFNC 
Optiflow 
Junior 
Fisher and 
Paykel or 
Precision 
Flow 
Vapotherm 
device. 
 
Initial gas 
flow of 6 to 8 
LPM  
 
CPAP 
ventilator, an 
underwater 
“bubble” 
system, or a 
variable-flow 
device. 
 
 
 
Pre-
specified 
treatment 
failure 
criteria 
HFNC 
71/278 
 
CPAP 
38/286 
HFNC 
The size of the 
nasal cannulae 
was 
determined 
according to 
the 
manufacturers 
instructions  
 
CPAP 
short binasal 
prongs 
or a nasal 
mask 
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3.5.2 Results and discussion: 
 
I performed a meta-analysis of the primary outcomes of all the available studies to date up to 
January 2018. This is summarised in a Forest plot in figure 10.  
When the later studies are taken into account, the updated pooled analysis shows that CPAP is 
better than HFNC in primary respiratory support in terms of the primary outcome of treatment 
failure (defined by individual studies at different timescales). This is consistent with the meta-
analysis presented by Roberts et al excluding the relatively smaller Shin et al study (131, 
142).   
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Figure 10. Forest plot of comparison: HFNC versus CPAP soon after birth for primary 
respiratory support in RDS, Outcome: Treatment failure as defined by the studies. 
 
 
 
 
 
 
Figure 10 shows risk ratio with 95% confidence intervals in brackets when comparing HFNC 
versus CPAP as the primary respiratory support mode for RDS in preterm neonates. 
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When HFNC was compared with CPAP as a primary respiratory support mode in preterm 
neonatal respiratory distress there was increased risk of treatment failure as shown in the 
Forest plot figure 10 with RR 1.57 95% CI (1.20, 2.05)].  
 
The studies by Yoder et al (97), Nair et al (140), Iranpour et al (122) and initial publication of 
the part of the study by Lavizzari group (119) were systematically reviewed and meta-
analyses was published by different investigators in 2015 (110) and 2016 (1). They found no 
differences in treatment failure, intubation, or other clinical outcomes.  Subsequently there 
have been further larger studies published by Lavizzari et al (127), Shin et al (131) and 
Roberts et al (130). These later studies are larger, more rigorous in terms of statement of 
criteria for treatment interventions and were pre-registered as clinical trials reducing the 
reporting bias.  
 
The Cochrane review in 2016 presented their meta-analysis from studies up to 2016 (1). They 
found a cumulative risk ratio of 1.30 (0.73, 2.34) based on 439 patients from 3 trials with 211 
patients in HFNC arm and 228 patients in CPAP arm (1). They concluded that for preterm 
infants needing primary respiratory support after birth, there were no differences in the rates 
of primary or secondary outcomes between HFNC and CPAP (1).  
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3.6 Primary Respiratory Support for RDS in Neonates – HFNC versus NIPPV 
 
HFNC has been compared with bi-level type of pressure support devices. There have been 2 
RCTs comparing HFNC to other bi-level type of non-invasive respiratory support as primary 
respiratory support after birth in preterm infants.  
 
3.6.1 Descriptive review of studies evaluating HFNC for primary respiratory support 
compared to NIPPV 
 
In this single-centre, prospective, randomized, controlled, pilot study, Kugelman studied 76 
preterm infants (gestational age <35 weeks, weight >1000 g) with RDS comparing HFNC 
with NIPPV for primary respiratory support after birth (126). Infants were treated with either 
HFNC (starting gas flow 1 L/min, increased up to 5 L/min as required) or synchronised 
NIPPV (positive inflation pressure 14 to 22 cmH2O, positive end-expiratory pressure 6 
cmH2O, rate 12 to 30 inflations per minute) (126). The primary outcome was the proportion 
of infants who failed non-invasive respiratory support and needed endotracheal intubation or 
were switched to another form of non-invasive respiratory support (126).  
A total of 76 infants participated in the trial (38 in each treatment group) (126). The type of 
respiratory support mode was associated with duration of the non-invasive support. The BPD 
rates were similar between the two groups (126). Nasal trauma was not recorded and air leak 
was reported in 2 patients receiving HFNC (126). The study did not include ELBW babies.  
The risks of bias include being a non-blinded study the equipment was supplied by 
Vapotherm company. The randomisation sequence generation method was not described.   
 
The study by Iranpour et al compared Nasal Intermittent Mandatory Ventilation (NIMV) to 
HFNC in preterm infants with RDS after the first 24 hours of life (123). Those requiring 
NIMV respiratory support more than one day and showed the signs of respiratory distress 
were randomized into two groups of NIMV and HFNC (123). There were 30 infants in each 
group (123). All patients with RDS were treated with NIMV for the first day (123). They 
evaluated the rates of chronic lung disease, mechanical ventilation, failure to treatment, the 
time to establish full enteral feeding and the mortality rate (123). No incidence of treatment 
failure, chronic lung disease, mechanical ventilation or endotracheal intubation was observed 
in either group (123). Nasal mucosal damage was mainly seen in NIMV group (123). In view 
of the favourable complications profile, they concluded that HFNC was more tolerable than 
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NIMV in the treatment of RDS in premature neonates ≥30 weeks when initiated after the first 
24 hours of life (123). 
 
The study employed simple randomisation to allocate the study groups. The administration of 
surfactant with INSURE method might affect the results although there was no statistical 
significant difference in its use between the two groups. The minimum respiratory flow rate of 
oxygen was 2 L/min and the optimum was calculated based on the patient’s weight [0.68W 
(kg) + 0.92] formula from Sreenan et al study (24). The NIMV device characteristics were not 
specified.  
 
3.6.2 Results and discussion 
 
The above two studies have been summarised in table 11. The primary outcome and events 
per study arm has been extracted from the studies. I performed a risk ratio analysis using the 
data from above two studies shown in figure 11.  
 
When HFNC was compared with NIPPV as a primary respiratory support mode, there was no 
significant increased risk of treatment failure, RR 0.85 95% CI (0.44, 1.65).  
 
Cochrane review took into account data from one study and reported that there was no 
difference between HFNC and NIPPV in rates of treatment failure, death or CLD (1, 126). 
Also, from the same study it was noted that infants randomised to HFNC spent a longer 
period of time receiving non-invasive respiratory support (median 4 days vs median 2 days, P 
< 0.01) (1, 126).  
 
Since then there has been one more study from 2016 which did not find any further 
differentiating data with regards to primary outcome of treatment failure as defined by the 
study (123).  
 
Since there were no events relating to death, CLD or treatment failure in either arm of 
treatment in the study by Iranpour et al, there was no difference between HFNC and NIPPV in 
rates of treatment failure, death or CLD.  
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Table 11. Summary of clinical studies comparing HFNC versus NIPPV as primary 
respiratory support for RDS in preterm neonates 
 
 
 
 
Author, 
date, 
Country 
Publication 
journal 
 
 
Study 
population 
 
Type of 
study 
Level of 
evidence 
Equipment 
 
 
Primary 
outcome 
 
Results 
Events/Total 
 
Additional 
information 
Kugelman et 
al(126) 
 
2015 
 
Israel 
 
Pediatric 
Pulmonology 
76 neonates  
 
Gestational 
age <35 
weeks, 
mean 33 
weeks and  
weight 
>1000 g, 
mean 1800 
grams)  
 
Single-
centre RCT 
Unblinded  
 
Vapotherm 
device, 
Precision 
Flow or 
2000i 
 
NIPPV 
SLE 2000 
or 5000 
Treatment 
failure defined 
by requiring 
mechanical 
ventilation 
HFNC  11/38 
 
 
 
NIPPV 
13/38 
HFNC 
Vapotherm 
nasal 
prongs 
 
NIPPV  
nasal 
prongs   
Iranpour et 
al(123) 
 
2016 
 
Iran 
 
British 
Journal of 
Medicine & 
Medical 
Research 
 
60 infants 
 
Gestational 
age of 30 
to 35 
weeks 
(mean 31.8 
in NIMV 
and 31.83 
weeks in 
HFNC) 
 
 
HFNC- 
RT329 
(Fisher and 
Paykel 
Healthcare, 
Salter Lab, 
Arvin, 
California). 
The 
external 
diameter of 
the nasal 
cannula 
was 2 mm. 
 
NICU 
duration 
 
Post-NICU 
hospitalisation 
period 
 
Age when 
oral feeding 
began 
 
Age when full 
oral feeding 
established 
 
HFNC 
0/30 
 
 
NIMV 
0/29 
Treatment 
failure 
criteria not 
specified 
 
Sreenan et 
al study 
used to 
calculate 
HFNC 
flow rates  
NIMV –  
 
Device not 
specified 
 
 
 
Table 11 is a summary of two studies comparing HFNC versus NIPPV as a primary 
respiratory support mode for treatment of RDS in preterm infants. 
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Figure 11. Forest plot of comparison: HFNC versus NIPPV for primary respiratory 
support in RDS, Outcome: Treatment failure as defined by the studies. 
 
 
 
 
 
 
Figure 11 shows risk ratio with 95% confidence intervals in brackets when comparing HFNC 
versus NIPPV as the primary respiratory support mode for RDS in preterm neonates. 
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3.7 Post Extubation Respiratory Support – HFNC versus CPAP 
 
There are now more than 1000 preterm babies who have been studied regarding the efficacy 
of HFNC over CPAP in providing adequate post extubation respiratory support.  
A detailed description of each study and a table summarising key features has been presented. 
I performed meta-analysis of key outcomes and discuss the findings in relation to existing 
knowledge from previous systematic reviews.  
 
3.7.1 Descriptive review of studies evaluating HFNC for post extubation respiratory support 
compared to CPAP 
 
In a prospective, single-centre study involving 132 very preterm infants below 32 weeks’ 
gestation at birth Collins et al evaluated clinical efficacy of HFNC as post extubation 
respiratory support (96). The mean gestational age was 28 weeks and birth weight was 1100 
grams (96). The study groups were HFNC (Vapotherm 8 L/min) as treatment arm and nasal 
CPAP (Hudson Respiratory Care, 8 cmH2O) as control arm as per randomisation (96). They 
used nasal cannula with 1.5 mm outer diameter for HFNC and bi-nasal prongs with outer 
diameter of 3.7-4.6 for nasal CPAP. The primary outcome was extubation failure in the first 
seven days after extubation (96). Their pre-defined extubation failure criteria included 
episodes of apnoea occurring at a frequency of >6 episodes in 6 hours or severe enough to 
require intermittent positive pressure ventilation, acidosis (pH <7.25 and PCO2 >66 mmHg) 
and sustained increase in FiO2 of >15% from extubation (96). The study population included 
132 infants with 67 in HFNC arm and 65 in CPAP arm. The primary outcome rate was similar 
in both groups (96). The study conclusion was that the extubation failure rates are similar 
between HFNC and CPAP therapy at 7 days in premature infants (96).  
 
The study had several strengths with adequate randomisation process and clearly defined 
failure criteria. However, the study was non-blinded and extremely premature and extremely 
low birth weight babies were not included. The risks of bias in this study includes being an 
unregistered trial there may have been selective reporting.  
 
Manley et al conducted a multi-centre, non-inferiority study of 303 preterm infants (< 32 
weeks’ gestation at birth) and studied efficacy of HFNC versus CPAP post extubation in 
providing respiratory support (98). The mean gestational age was 27 weeks and mean birth 
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weight was 1000 grams (98). Infants were randomised to receive either HFNC (5 to 6 L/min) 
or CPAP (7 cmH2O) after extubation (98). The primary outcome was treatment failure within 
seven days of randomisation, based on prespecified criteria (98). Infants who failed HFNC 
were treated with CPAP (98).  
 
HFNC was noninferior to CPAP in terms of primary outcome (risk difference 8.4 percentage 
points; 95% confidence interval [CI] -1.9, 18.7 (98). There were no significant differences 
between HFNC and CPAP groups for treatment failure reasons although 48% of HFNC 
failure infants were rescued with CPAP without reintubation (98). There was no significant 
difference between the HFNC and CPAP groups for reintubation within 7 days of extubation 
(risk difference -7.4 percentage points; 95% CI -16.6, 1.8; p=0.12) (98). The nasal trauma rate 
was significantly less with HFNC (98). The study concluded that the efficacy and safety of 
respiratory support with HFNC and CPAP are similar in very preterm infants following 
extubation (98).  
 
This was a multi-centre trial with large numbers and therefore with adequate power to address 
their primary outcome measure. A pragmatic, real life approach to study protocol with HFNC 
failure babies being able to be offered period of CPAP was incorporated. However, the non-
inferiority margin was generous. Stricter interpretation i.e., 10% rather than 20% percentage 
points for non-inferiority would have shown that HFNC was not non-inferior to CPAP as a 
post extubation respiratory support strategy. The risks of bias in this study include non-
blinded study, selective reporting as not all the outcomes listed have been reported.  
 
Yoder et al conducted a multicentre study where HFNC was compared with CPAP as a 
respiratory support for neonatal respiratory distress. A subgroup analysis of babies in whom 
HFNC was used as primary support for respiratory distress and compared with CPAP was 
done (97). Over all 432 term and preterm infants of more than 28 weeks' GA who were 
planned to receive non-invasive respiratory support either as primary support after birth or 
post-extubation were enrolled onto the study (97). Of these, 351 infants were preterm and rest 
were term babies (97). The primary support subgroup had 125 preterm infants and post-
extubation subgroup had 226 preterm babies (97).  The respiratory support provided by 
HFNC was in the range of 3 to 5 L/min and nasal CPAP was 5 to 6 cmH2O and this was 
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administered after randomisation (97). The primary outcome was defined as the need for 
intubation within 72 hours of randomisation (97).   
 
There was no significant difference in the primary outcome between CPAP and HFNC in the 
subgroup analysis (97). More infants in the HFNC group crossed over to the alternative 
treatment after 72 hours (97). They concluded that in infants >28 weeks’ gestational age, 
HFNC appears to have similar clinical efficacy and safety to CPAP as a mode of non-invasive 
respiratory support (97). 
 
The study protocol had prespecified criteria for intubation and they used random number 
generation with opaque sealed envelopes for randomisation and like other studies included 
this review, it was non-blinded. The risks of bias include selective reporting and non-blinded 
study.  
 
In a prospective, multi-centre randomised control study, conducted in China, 255 infants (< 7 
days old) were studied (111). In this study 150 were preterm and the mean gestational age was 
35.5 weeks and mean birth weight was 2,472 ± 788 grams (111). A total of 128 infants were 
in the HFNC group, and 127 infants were in the CPAP group (111). Post extubation 
respiratory support was allotted following randomisation to either HFNC or CPAP (111). 
BPD or death in hospital, extubation failure defined by requiring reintubation within 7 day of 
study entry were the primary outcomes (111). During the first 72 hours of the study, cross-
over was not allowed between the two groups (111).  
 
The difference in the extubation failure for HFNC (12/128, 9.4%) versus nasal CPAP (12/127, 
9.4%) (P > 0.05), or in mortality for HFNC (12/128, 9.4%) versus nasal CPAP (15/127, 
11.8%) (P > 0.05) were not statistically significant (111). They concluded that among infants 
in the first week of postnatal age, HFNC appears to have efficacy and safety similar to those 
of CPAP group when used as post extubation respiratory support (111).   
 
Although this was a multicentre, prospective randomised controlled study, it included diverse 
mixture of infants where pathology is widely different ranging from RDS to meconium 
aspiration syndrome. Subgroup data was not given in detail to understand the distribution of 
outcome data among more vulnerable group i.e., preterm infants. The risks of bias include 
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non-blinded study, trial was not registered raising the possibility of reporting bias and also the 
random sequence generation method was not explicitly stated.  
 
Mostafa-Gharehbaghi et al conducted a single-centre randomised controlled study with 123 
preterm infants where 85 neonates who met inclusion criteria were enrolled (128). The mean 
gestational age was 32.15 ± 1.59 weeks and the birth weight was 1895 ± 438 grams (128). All 
the babies were given CPAP as well as surfactant with INSURE technique (128). After 
extubation they were then randomised to either HFNC (flow rate of 6 L/min) or nasal CPAP 
(pressures of 5 to 6 cmH2O) (128). The primary outcome was re-intubation according to 
prespecified criteria within three days of study entry (128). 
 
The primary outcome was noted in 8 patients (18.6%) in CPAP group and 5 (11.9%) in 
HFNC group (128). HFNC device manufacturer was not mentioned in the article and the 
CPAP device was Bubble CPAP System Fisher and Paykel Health Care, Inc (128). Their 
conclusion was that HFNC was as effective as nasal CPAP for respiratory support in preterm 
infants after INSURE treatment (128).  
 
This was a randomised controlled study with prespecified criteria for primary outcome. Since 
Vapotherm was not accessible in Iran, the country in which this study was done, they used bi-
nasal prongs for HFNC. However, it is not mentioned in the study whether they used a local 
custom-made assembly of heated humidified device or any other pre-tested commercial 
device. The risks of bias in this study includes non-blinded study and unclear methodology 
regarding primary outcome. The intubation criteria not specified.  
 
In a randomised, controlled study in preterm infants aged 26 to 31(+6 days) weeks with 
respiratory distress syndrome after extubation Kang et al studied 161 infants (125). The 
HFNC (n=79) was compared with CPAP (n=82) (125). They also made subgroup analysis of 
babies according to the gestational age (125). HFNC device was Fisher ＆ Paykel Healthcare 
and CPAP device was Infant Flow, VIASYS Healthcare (125). The treatment failure rate, 
reintubation rate within 7 days after extubation, incidence of complications, and mortality 
during hospitalization were the outcomes studied (125). The treatment failure rate and 
reintubation rate showed no significant differences between the HFNC and CPAP groups 
(125). They concluded that in preterm infants aged 29-31(+6) weeks, HFNC has a similar 
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efficacy as CPAP after extubation, while in those aged less than 29 weeks, HFNC should be 
used with caution (125). 
 
The main strength of this study is that it also included preterm infants of under 29 weeks’ 
gestation. However, the study was inadequately powered to provide definitive conclusion 
about the role of HFNC in comparison to CPAP control therapy. The risks of bias in this 
study includes non-blinded study.  
 
Kadivar et al in their randomised, controlled study compared the effect of HFNC with nasal 
CPAP in post-extubation of 54 preterm infants with RDS. They used INSURE method for all 
babies in their study (124). The primary outcome was remaining extubated for at least 3 days 
after INSURE method (124). The patient was reintubated if there was hypercapnia 
(pCO2≥60) with pH<7.25 and/or paO2<50 with FiO2>0.6(124). HFNC device used was 
Fisher & Paykel, Healthcare, Auckland, New Zealand and the CPAP device used was 
Dragger, Lubeck, Germany (124). Nasal prong details were not mentioned.  
 
The rate of reintubation was higher in the HFNC compared with the nasal CPAP group (124). 
The rate of either IVH or ROP, duration of oxygen requirement and hospitalization were not 
statistically different (124). There were no cases of BPD or mortality seen (124).  
 
Although the authors concluded that that preterm infants with RDS could be managed post-
extubation after INSURE method with either CPAP or HFNC, their primary outcome showed 
that the rate of reintubation was higher in the HFNC group (124). The study was randomised, 
controlled study with prespecified failure criteria in the protocol however, the flow rates used 
were below the conventional flow rates used in preterm infants.  
 
Soonsawad et al conducted a randomised, controlled, single centre study involving 49 preterm 
infants with gestational age <32 week or birth weight of <1500 g post extubation onto HFNC 
(n=24) or CPAP (n=25) (132). A block-of-four randomization stratified by gestational age  
(<28 week, 28 to 30 week and >30 week) and implemented with concealed, opaque envelopes 
with the computer generated sequence numbers (132). The primary outcome was extubation 
failure within 72 h after endotracheal tube removal (132). HFNC set up included binasal 
cannula (BC2425 model, Fisher and Paykel Healthcare, Auckland, New Zealand), 2.4 mm in 
outer diameter, occupying approximately half of the nares diameter. Fisher and Paykel 
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Healthcare humidifier was used (132). The CPAP support was by variable flow CPAP 
generator (Fabian, Acutronic, Hirzel, Switzerland) via nasal mask (132).  
 
There was no difference in the primary outcome between the two groups with 8 infants  in 
HFNC vs. 6  in CPAP group (p = 0.47) (132). However, 6 infants (75%) in HFNC and 4 
infants (66%) in CPAP group who met failed extubation criteria were rescued by bi-level 
CPAP (132). Therefore, the reintubation rate was similar [2 infants (8.3%) in HFNC vs. 2 
infants (8%) in CPAP group] (132). Study concluded that the extubation failure rate was not 
statistically different between infants who were on HFNC or CPAP support (132).  
 
The strength of the study includes adequate randomisation process although the overall 
numbers were small to make definitive conclusions about efficacy.  
 
Elkhwad et al conducted a single centre randomised controlled trial in Iran (112). The study 
included 60 preterm infants between 24 and 28 weeks’ gestation (mean 26.7 weeks) with 
respiratory distress syndrome (112). The mean birth weight was similar in two groups (112). 
They were randomized to either HFNC or CPAP (112). The primary outcome was failure of 
extubation defined by the need for re-intubation and mechanical ventilation within 5 days of 
initial extubation (112). HFNC machine used was Tri-Anim Vapotherm the Precision Flow 
and CPAP machine was Fisher and Paykel Healthcare, Bubble CPAP System (112). No 
information about nasal prongs used was given.  
 
Preterm infants who remained intubated for more than 24 hours were excluded from the study 
(112). They analysed 53 infants’ data with 24 in HFNC arm and 29 in CPAP arm (112). Their 
results showed that 17.2% of neonates placed on HFNC failed extubation and required re-
intubation within 5 days of initial extubation compared with 20.8% of neonates placed on 
CPAP (p value 1.000) (112). Similarly mean duration of respiratory support using HFNC was 
37.45 days compared to 40.04 days using CPAP (p value 0.66) and duration of oxygen 
requirement for infants placed on HFNC was 49.41 days compared to 43.75 days for infants 
placed on NCPAP (p value 0.58) (112). The study concluded that HFNC use was comparable 
to the use of CPAP in the immediate post-extubation period for preterm infants between 24 
and 28 weeks gestations with Respiratory Distress Syndrome and does not increase risk for 
co-morbid conditions (112). 
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This study included extremely preterm babies and study groups were randomised before 
allotment. However, there was no information about nasal prongs used and whether this 
allowed adequate leak at nasal interface. This is an important data as the study included 
babies with mean birth weight of under 1000 grams. The risks of bias include non-blinded 
study and unclear risk in terms of reporting bias.  
 
Chen et al evaluated 66 VLBW babies of less than 37 weeks gestational age in a single centre 
randomised controlled study to compare the clinical efficacy of HFNC versus nasal CPAP in 
treatment of respiratory distress syndrome. Babies received surfactant and conventional 
treatment initially after birth. The primary outcome was rate of re-intubation within 7 days of 
extubation was significantly lower in HFNC group. In addition, HFNC babies had 
significantly shorter oxygen exposure time and invasive ventilation time, and suffered lower 
incidences of nasal injury, air leak, and abdominal distention, as compared with the CPAP 
group. They recommended HFNC as the first choice of non-invasive ventilation in the 
treatment of RDS in VLBW infants.  
 
The article was in Chinese and Google Translate was used to understand the methods and 
results. The randomisation method was not clear.  
 
Chen et al conducted the only study which studied exclusively ELBW babies. In this single 
centre randomised, controlled study 129 ELBW infants born <34 weeks of gestation were 
allocated to HFNC or CPAP group. The primary outcome included the incidence of 
extubation failure, nasal injury, air leak, abdominal distension and bronchopulmonary 
dysplasia. The extubation failure rate was lower in HFNC group (25.8%) compared to the 
nasal CPAP group (47.6%) which was statistically significant. The BPD rates similar in two 
groups. They concluded that HFNC was an effective and safe method for prevention of 
extubation failure in ELBW infants. 
 
The article was in Chinese and Google Translate was used to understand the methods and 
results. The randomisation method was not clear.  
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3.7.2 Results and discussion 
 
A summary of the studies evaluating HFNC compared to CPAP as post extubation respiratory 
support is shown in table 12. 
 
I generated a pooled meta-analysis from the studies available up to date and compared with 
Cochrane review (1) from 2016 and another review published in 2017 (142). This is shown in 
figure 12.  
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Table 12. Summary of clinical studies comparing HFNC versus CPAP as post 
extubation respiratory support for RDS in preterm neonates 
 
 
 
 
Author, 
date, 
Country 
Publication 
journal 
 
Study 
population 
Type of 
study 
Equipment 
Primary 
outcome 
Results 
Additional 
information 
Yoder et 
al(97) 
 
2013 
 
USA 
 
Pediatrics 
291 
ventilated 
neonates 
 
28–42/40 
gestational 
weeks 
 
 
 
Multi-centre 
RCT 
Nonblinded  
 
 
Extubation 
failure any 
time after 
initiation of 
study support 
 
There were no 
predefined 
extubation 
criteria 
 
HFNC 
11/107 
 
 
CPAP 
9/119 
Pre-intervention 
respiratory 
support also 
included 
neonates who 
were initially on 
non-invasive 
support 
 
Pre-extubation 
caffeine use was 
not standardised 
Collins et 
al(96) 
 
2013 
 
Australia 
 
The Journal 
of Pediatrics 
132 very 
preterm 
infants (< 
32 weeks 
 
Mean 
gestational 
age & birth 
weight 
were 
28weeks & 
1100 grams 
Single centre 
RCT 
nonblinded 
 
 
HFNC 
Vapotherm 
CPAP 
Hudson 
Respiratory 
Care 
Extubation 
failure in the 
first seven 
days after 
extubation 
 
Apnoea 
>6 in 6 hours 
or an episode 
requiring  
IPPV  
HFNC 
15/67 
 
CPAP  
22/65 
Extubation 
failure  
Apnoea 
Acidosis  
pH <7.25 & 
PCO2>66mmHg 
Sustained 
increase in FiO2 
of >15% from 
extubation 
Manley et 
al(98) 
 
2013 
 
Australia 
 
NEJM 
303 
preterm 
infants 
<32 weeks 
Multi centre 
RCT 
nonblinded 
 
HFNC 
Optiflow  
CPAP 
mechanical 
ventilator or 
an 
underwater 
“bubble” 
system 
Treatment 
failure within 
seven days of 
randomisation, 
based on 
prespecified 
criteria 
HFNC  
52/152 
 
 
CPAP  
39/151 
HFNC-  binasal 
infant cannulae 
Fisher & Paykel 
Healthcare 
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Author, 
date, 
Country 
Publication 
journal 
(cont) 
 
Study 
population 
Type of 
study 
Equipment 
Primary 
outcome 
Results 
Additional 
information 
Liu et al(111) 
 
2014 
 
China 
 
Zhonghua Er 
Ke Za Zhi 
journal 
255 cases 
included,  
 
128 were in 
the HFNC 
group 
127 were in 
the NCPAP 
group 
Multi centre 
RCT 
nonblinded 
HFNC  
Fisher Paykel 
Optiflow  
CPAP 
Infant Flow 
Stepheni 
Extubation 
failure within 
7 days after 
study entry 
HFNC 
12/128 
 
CPAP 
12/127 
 
The study 
included late 
preterm and term 
infants 
Mostafa-
Gharehbaghi 
et al (128) 
 
2014 
 
Iran 
 
Zahedan 
Journal of 
Research in 
Medical 
Sciences 
85 neonates 
enrolled in 
the study 
 
The mean 
gestational 
age 32.15 ± 
1.59 weeks 
and mean 
birth 
weight was 
1895 ± 438 
grams 
Single centre 
RCT 
nonblinded 
 
HFNC 
Manufacturer 
was not 
mentioned 
 
Bubble 
CPAP 
System 
Fisher and 
Paykel  
Re-intubation 
according to 
prespecified 
criteria within 
three days of 
study entry 
HFNC  
5/42 
 
CPAP  
8/43 
The failure 
criteria:  
PaO2 <85% or 
PaO2 ≤ 50 mm 
Hg while 
receiving FiO2 ≥ 
0.4; PCO2 > 65 
mm Hg with a 
pH < 7.2; >4 
apnoeic episodes 
in the first hour 
or need for >2 
episodes of 
bagging per hour 
Chen et 
al(116) 
 
2015 
China 
Chin J 
Contemp 
Pediatr 
66 VLBW 
infants 
Gestational 
age <37 
weeks 
Weight 
<1500 
grams 
HFNC 
Fisher & 
Paykel) 
Optiflow 
 
CPAP 
Infant Flow 
System  
Re intubation 
within 3 days 
HFNC  
8/34 
 
CPAP 
7/32 
 
7- day re-
intubation rate 
was significantly 
higher in the 
CPAP group 
Chen et 
al(117) 
 
2016 
 
China 
 
Chinese 
Journal of 
Neonatology 
 
129 ELBW 
infants  
 
Gestational 
age ＜ 34 
weeks 
 
Birth 
weight  
＜1000 g 
HFNC 
Fisher & 
Paykel) 
Optiflow 
 
CPAP 
Infant Flow 
System  
Bubble 
CPAP 
Re intubation 
within 7 days 
HFNC  
17/66 
 
CPAP  
30/63 
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Author, 
date, 
Country 
Publication 
journal 
(cont) 
 
Study 
population 
Type of 
study 
Equipment 
Primary 
outcome 
Results 
Additional 
information 
Kang WQ    
(125) 
 
2016 
 
China 
Chinese 
journal of 
contemporary 
pediatrics 
161 
preterm 
infants  
HFNC 
(n=79)  
 
CPAP 
(n=82). 
Single centre 
RCT 
nonblinded 
 
HFNC- 
Fisher ＆ 
Paykel  
CPAP - 
Infant Flow 
Treatment 
failure within 
7 days after 
extubation. 
 
HFNC   
29/79 
 
CPAP  
19/82 
The failure rate 
(45%) in preterm 
infants treated 
with 26-
28 +6 weeks was 
higher than that 
in controls (21%) 
(χ 2 = 4.70, P = 
0.03) 
Kadivar(124) 
 
 
2016 
 
Iran 
Iranian 
Journal of 
Medical 
Sciences 
54 preterm 
infants 
 
27 in each 
group 
HFNC and 
CPAP 
Single centre 
RCT 
nonblinded 
 
 
 
 
Remaining 
extubated for 
at least 3 days 
after INSURE 
method.  
 
HFNC 
14/27 
 
CPAP 
4/27 
Nasal prong 
details were not 
mentioned.  
 
HFNC - Fisher & 
Paykel 
 
 
CPAP - Dragger, 
Germany 
Soonsawad et 
al(132) 
 
2017 
 
Indian 
Journal of 
Pediatrics 
 
Thailand 
49 infants 
enrolled  
 
24 in the 
HFNC  
 
25 in the 
CPAP 
group 
Single centre 
RCT 
nonblinded 
 
 
Extubation 
failure within 
72 h after 
endotracheal 
tube removal 
HFNC 
8/24 
 
 
 
CPAP 
6/25 
 
 
 
Binasal cannula 
(BC2425 model, 
Fisher and 
Paykel), 2.4 mm 
in outer diameter 
 
HFNC - Fisher 
and Paykel 
CPAP - Fabian, 
Acutronic 
Elkhwad et 
al(112) 
 
2017 
 
Qatar 
 
Neonat 
Pediatr Med 
60 preterm 
infants 
enrolled 
(54 
analysed) 
(mean 26.7 
weeks)  
Single centre 
RCT 
nonblinded 
Failure of 
extubation 
(need for re-
intubation) 
within 5 days 
of initial 
extubation 
HFNC  
5/29 
 
 
CPAP  
5/24 
The mean birth 
weight  
 
CPAP - 995.33 
(SD 201.66)  
 
HFNC- 994.54 
(SD 202.82) 
 
Table 12 shows a summary of 11 studies comparing HFNC versus CPAP as a post extubation 
respiratory support mode in preterm infants. 
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Figure 12. Forest plot of comparison: HFNC versus CPAP for post extubation 
respiratory support in RDS, Outcome: Treatment failure as defined by the studies. 
 
 
 
 
 
 
Figure 12 shows a Forest Plot analysis of risk ratio when comparing HFNC versus CPAP as a 
post extubation respiratory support mode. 
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HFNC resulted in a RR (95% CI) of 1.09 (0.90, 1.31) for treatment failure. This is similar to 
Cochrane review where treatment failure with HFNC as defined by the studies was similar to 
CPAP (1).   
 
A Cochrane review performed meta-analysis of the studies available until 2016 (1). However 
since then there have been number of RCT adding to the total number of babies where HFNC 
as post extubation respiratory support was studied (142). However the previous drawbacks of 
the studies remain that studies are varied in methodology, performed in different clinical 
settings, different levels of flow have been utilized (126). For example, Yoder et al used 
initial flows based on infants’ weight (3 L/min for 1,000–1,999 g, increased by a maximum of 
3 L/min) whereas Collins et al used an initial flow of 8 L/min and Manley et al used an initial 
flow of 5–6 L/min (126). 
 
The Cochrane Review authors noted that RCTs thus far have included relatively few 
extremely preterm infants (<28 weeks’ GA) (1). However in infants >28 weeks’ gestation 
they found that HFNC resulted in a RR (95% CI) of 0.80 (0.44, 1.44) for treatment failure, 
and 0.51 (0.27, 0.97) for intubation in comparison to CPAP (1). Therefore the review 
concluded that post-extubation HFNC may be an appropriate therapy in this group of infants 
with rescue CPAP being available (1).  
 
The studies by Soonsawad et al (132) and Kang et al (125) reached similar conclusions as 
Cochrane review. Study by Kadivar et al found a higher rate of intubation in HFNC infants 
(124). 
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3.8 HFNC for Weaning from CPAP/NIV 
 
3.8.1 Descriptive review of studies evaluating HFNC as a weaning mode 
 
Abdel Hady et al conducted a randomised, controlled, single-centre study involving 60 
preterm infants of gestational age 28 weeks and above (mean gestational age of 31 weeks and 
mean birth weight of 1600 grams) (113). The infants were eligible when they were stable on 
low levels of non-invasive respiratory support (CPAP 5 cmH2O and supplemental oxygen ≤ 
30%) (113). The two arms of the study were HFNC of 2 LPM and remaining on CPAP until 
they came off supplemental oxygen (113). The primary outcome in this study was the 
duration of supplemental oxygen and respiratory support (113). 
 
The two groups had 30 infants each and were similar in study entry characteristics (113). The 
CPAP group had fewer days on oxygen [median (interquartile range): 5 (1–8) vs 14 (7.5–
19.25) days, pb0.001] and shorter duration of respiratory support [10.5 (4–21) vs 18 (11.5–29) 
days, p=0.03] (113). There were no differences between groups regarding success of weaning 
from nasal CPAP (113). The study concluded that weaning preterm infants from nasal CPAP 
to HFNC will cause increase in exposure to oxygen and longer duration of respiratory support 
(113). 
 
Badiee et al also conducted a single centre randomised controlled study involving  88 preterm 
infants of gestational age 28 to 36 weeks (mean gestational age at birth of 31 weeks) who 
were stable on CPAP 5cmH2O and less than 30% supplemental oxygen (114). They were 
randomised to HFNC (2 L/min) or to remain on CPAP (114). The primary outcome in this 
study was the duration of supplemental oxygen (114). 
 
The mean duration of oxygen therapy (20.6 ± 16.8 h vs. 49.6 ± 25.3 h, P < 0.001) and mean 
length of hospital stay (11.3 ± 7.8 days vs. 14.8 ± 8.6 days, P = 0.04) was significantly lower 
in HFNC group compared to non‑HFNC group (114). However, the successful weaning rate 
was similar between two groups (114). The study concluded that by using HFNC as step 
down from CPAP, the duration of oxygen therapy and length of hospitalization in preterm 
infants can be reduced (114).  
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Soonsawad et al conducted a single centre, randomised, controlled study involving 101 
preterm infants with a gestational age of <32 weeks who met the predefined criteria of 
stability for weaning off CPAP. The study groups included one group weaning by using 
HFNC and the other group weaning directly from CPAP (141). The stable infants were 
defined by those requiring CPAP pressures of  ≤6 cm H2O and a FiO2 of ≤0.3 for at least 24 
h (141). The rate of weaning in HFNC was 1 litre/min every 24 h to 2-3 litters/min depending 
on body weight where <1000 grams babies 2 litres per minute and >1000 grams 3 litres per 
minute and in the CPAP group rate of weaning was by reducing pressure by 1 cm H2O every 
24 h until stable on CPAP 4 cm H2O (141). The HFNC or CPAP was weaned off after this 
stage was reached. The primary outcome was the time it took to wean off either CPAP or 
HFNC.  
 
There were 51 infants in the HFNC and 50 infants in the CPAP group (141). There was no 
difference in time to successfully wean between the 2 groups (141). Infants in the HFNC 
group had significantly less nasal trauma (20% vs. 42%; p = 0.01) (141). The study concluded 
that the time to wean off CPAP using HFNC was not different from when weaning directly 
from CPAP (141). 
 
Baozhi et al conducted a single centre randomised controlled study involving 82 preterm 
infants of gestational age ≤34wk and birth weight ≤2000g who were ready to wean CPAP 
(129). One group was HFNC and the control group received nasal cannula oxygen therapy 
(129). Primary outcomes were rate of one-time successful weaning CPAP, duration of 
respiratory support, weight gain rate, incidence of BPD and retinopathy of prematurity(ROP), 
nosocomial infection rate and air leak after weaning CPAP (129).  
 
They reported that one-time successful weaning CPAP and oxygen duration and respiratory 
support duration were lower and weight gain rate was higher (P<0.05) in HFNC group (129). 
Their conclusion was compared to nasal cannula oxygen therapy HFNC achieves higher rate 
of one-time successful weaning from CPAP (129).  
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3.8.2 Results and discussion 
 
A summary of the studies evaluating efficacy of HFNC as a weaning mode is presented in 
table 13.  
 
The earlier study by Abdel Hady used very low flow rates and unsurprisingly found babies 
weaned by HFNC did worse than those by CPAP. However surprisingly subsequent study in 
2015 by Badiee found favourable results for weaning by HFNC despite using similar flow 
rate. The mean duration of oxygen therapy in CPAP group in the Badiee study was about 2 
days compared to 5 days in the Abdel Hady study. This difference could partially be due to 
shorter maintenance on CPAP after initial stabilization in the Badiee study (6 h instead of 24 
h). The reduction in HFNC flow rate was faster in Badiee study (0.5 L/min every hour as 
compared to 0.5L/min every 6h by Abdel Hady.  
 
Finally, in 2016, Soonsawad study showed no difference when HFNC was used as a step 
down from CPAP as opposed to weaning directly from CPAP.  
 
Therefore, at present there is no evidence to suggest that HFNC helps in improving outcomes 
when used as a weaning method from respiratory support.  
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Table 13. Summary of clinical studies comparing HFNC versus CPAP alone as weaning 
from CPAP in preterm neonates 
 
 
 
Author, 
date, 
Country 
 
Study 
population 
Type of 
study 
 
Primary 
outcome 
Results Additional 
information 
Abdel Hady 
et al(113) 
 
2011 
 
Egypt 
60 preterm 
infants 
Gestational 
age >28 wk 
(mean 31), 
mean birth 
weight1600 
grams 
Randomized 
Open label 
Controlled 
trial  
 
Duration of 
oxygen 
requirement 
Non HFNC 
group had fewer 
days on oxygen 
and shorter 
duration of 
respiratory 
support 
HFNC flow 
rate was 2 
L/min with 
FIO2 = 0.30  
 
Badiee et 
al(114) 
 
2015 
 
Iran 
 
88 preterm 
infants of 
gestational 
age 28 to 
36 weeks 
(mean 31 
weeks) 
 
Randomized 
controlled 
trial  
 
The main 
outcome 
was the 
duration of 
oxygen 
requirement 
The duration of 
oxygen therapy 
and length of 
hospitalization in 
preterm infants 
can be reduced 
with weaning by 
HFNC 
HFNC –44 
babies 
CPAP – 44 
babies 
 
Soonsawad 
(141) 
 
2016 
 
Thailand 
 
101preterm 
infants 
with a 
gestational 
age of <32 
weeks 
 
Randomized 
controlled 
trial  
 
Time taken 
to wean off 
the use of 
the CPAP 
or HFNC 
devices 
 
Time to wean off 
CPAP using 
HFNC was not 
different from 
when weaning 
directly from 
CPAP 
Infants in the 
HFNC group 
had less nasal 
trauma 
 
HFNC – 51 
CPAP - 50 
Baozhi 
(129)  
 
2017 
 
China  
82 preterm 
infants of 
gestational 
age ≤34wk 
and birth 
weight 
≤2000g 
Randomized 
controlled 
trial  
 
Rate of 
one-time 
successful 
weaning 
CPAP 
One-time 
successful 
weaning CPAP 
was higher 
O2 duration, 
respiratory 
support duration 
was lower  
Weight gain rate 
was higher  
(P<0.05) in 
HFNC 
 
 
Table 13 is a summary of clinical studies comparing HFNC versus CPAP alone as weaning 
from CPAP in preterm neonates. 
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3.9 Other Clinical Outcomes with HFNC 
 
3.9.1 Bronchopulmonary Dysplasia (BPD) 
 
I performed a pooled analysis of the BPD data from the review of studies undertaken on two 
specific indications of HFNC. The BPD rates with risk ratio when HFNC was compared to 
CPAP as primary respiratory support for preterm neonate respiratory distress and a Forest 
Plot analysis is shown in figure 13.  
 
The BPD rates with risk ratio when HFNC was compared to CPAP as post extubation 
respiratory support for preterm neonate respiratory distress and a Forest Plot analysis is 
shown in figure 14.  
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Figure 13. Pooled estimate of BPD risk in preterm infants on HFNC compared with 
other modes of NIV as primary respiratory support 
 
 
 
 
Figure 13 is Forest plot analysis of BPD risk in preterm infants on HFNC compared with 
other modes of NIV for primary respiratory support. 
 
 
 
Figure 14. Pooled estimate of BPD risk in preterm infants supported post extubation on 
HFNC compared with other modes of NIV 
 
 
 
 
Figure 14 is a Forest plot analysis of BPD risk when HFNC is compared with other modes of 
NIV in preterm infants for post extubation respiratory support. 
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When I performed a meta-analysis for the outcome BPD, comparing HFNC with CPAP, the 
risk ratio was suggestive of no increased risk either when HFNC was used as primary 
respiratory support [RR 1.17 95% CI (0.72, 1.90)] or as post extubation respiratory support 
[RR 0.88 95% CI (0.74, 1.05)].  
 
The Cochrane Review reported a no increased risk when compared to CPAP in the clinical 
outcome of BPD (RD 0.96, 95% CI 0.78 to 1.18) from analysis of 893 infants pooled from 
post-extubation studies (1). 
 
Taha and his group conducted a retrospective data analysis from the Neonatal Database for a 
5-year period from January 2008. The inclusion criteria were that babies weighing ≤ 1000 g at 
birth, and having received HFNC or CPAP therapy (133). Their main objective was the rate of 
incidence of bronchopulmonary dysplasia (BPD) or death in extremely low birth weight 
infants who received HFNC versus CPAP (133). 
 
In their study, 2487 infants were included with 941 in CPAP group, 333 in HFNC group, and 
1546 in HFNC ± CPAP group (133). The BPD rate or mortality rate was significantly higher 
in the HFNC group (56.8%) compared with the CPAP group (50.4%, P < .05) (133). This was 
also seen in group receiving HFNC ± CPAP group compared with the CPAP group (133).  
 
Hoffman et al conducted a retrospective chart review with the objective to evaluate the effect 
of introducing HFNC on length of respiratory support and stay (139). They included 163 
patients in 24–32 weeks’ gestation requiring mid-level support (HFNC/nasal CPAP) 1year 
before and after HFNC implementation (139). Pre-HFNC group had eighty infants and the 
post-HFNC group had 83 infants (139). There was a trend towards higher BPD rates in post 
HFNC group whilst the rates of retinopathy of prematurity was significantly higher (139). The 
post-HFNC subjects had longer duration of non-invasive respiratory support (139). They 
concluded that HFNC introduction was significantly associated with a longer duration of non-
invasive respiratory support in addition to being associated with increased retinopathy of 
prematurity rates (139).   
 
There are methodological weaknesses in these studies. They have differing demographics in 
infants treated with HFNC, inconsistencies in the definition of BPD, and changes in practice 
during the study period and selection bias associated with any retrospective study (142). 
 109 
 
Therefore, it is not possible to make firm conclusions regarding association or causation of 
HFNC therapy and BPD.  
 
3.9.2 Mortality 
 
In this review, the mortality outcome showed no significant increased risk when HFNC was 
compared to CPAP. This was seen when HFNC was used as post extubation respiratory 
support [RR 0.62 95% CI (0.28, 1.39)] as well as when used as a primary respiratory support 
[RR 0.61 95% CI 0.08, 4.57)]. (See Figures 15 and 16) 
 
There was no statistically significant difference in the rate of deaths in the group of preterm 
infants randomly assigned to receive HFNC compared with other NIV in an earlier systematic 
review involving 922 infants (OR: 0.48 [0.18 to 1.24]) (110)  
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Figure 15. Pooled estimate of risk of death in preterm infants on HFNC compared with 
other modes of NIV as primary respiratory support 
 
 
 
 
Figure 15 shows Forest plot analysis of risk of death in preterm infants on HFNC compared 
with other modes of NIV as primary respiratory support. 
 
 
 
 
Figure 16. Pooled estimate of risks of death in preterm infants supported post 
extubation on HFNC compared with other modes of NIV 
 
 
 
 
Figure 16 shows Forest plot analysis of mortality risk with HFNC versus other NIV modes for 
post extubation respiratory support in preterm infants 
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3.9.3 Air leak complications 
 
In this review, the risk of air leak syndrome was significantly less with HFNC compared to 
CPAP. This was seen in both as primary respiratory support [RR 0.42, 95% CI (0.17, 1.02)] 
shown in figure 17 and as post extubation respiratory support [RR 0.28, 95% CI (0.15, 0.55)] 
shown in figure 18.  
 
There were some case reports and case series of air leak complications during HFNC (93-95). 
This has not been substantiated by prospective RCT involving more than 1000 babies 
collectively. The Cochrane Review reported a reduction in the rate of pneumothorax (RD 
−0.02, 95% CI −0.03 to −0.00) from analysis of infants from post-extubation studies (1, 142). 
The pooled analysis of air leak or pneumothorax data from primary respiratory support of 
neonatal respiratory distress have shown pneumothorax rates with (RD −0.02, 95% CI −0.02 
to 0.02) with HFNC and CPAP (142).  
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Figure 17. Pooled estimate of risk of air leak complications in preterm infants on HFNC 
compared with other modes of NIV as primary respiratory support 
 
 
 
 
 
 
Figure 17 shows estimate of risk of air leak complications in preterm infants on HFNC 
compared with other modes of NIV as primary respiratory support. 
 
 
 
 
Figure 18. Pooled estimate of risk of air leak complications in preterm infants supported 
post extubation on HFNC compared with other modes of NIV 
 
 
 
 
 
Figure 18 shows risk of air leak complications in preterm infants supported post extubation on 
HFNC compared with other modes of NIV. 
 
 
 113 
 
3.9.4 Patient Comfort 
 
In a randomised, crossover comparison of 24 h of treatment with CPAP or HFNC, followed 
by 24 h of the alternative therapy in infants with mild respiratory illness, patient comfort was 
the primary outcome. The study concluded that the parents preferred HFNC, but there were 
no significant differences in a patient comfort score (137). 
 
Preterm infants are thought to be more comfortable on HFNC compared with CPAP by 
neonatal nurses (91). 
 
In an observational cross-sectional study, 60 preterm infants, received CPAP (n=37) and 
HFNC (n=23)(138). Pain response was assessed using Premature Infant Pain Profile (PIPP), 
duration of first cry and salivary-cortisol concentrations (138). They reported PIPP scores 
were significantly higher in the CPAP compared with HFNC group and no infants in HFNC 
group had severe pain defined by PPP score >12 and salivary cortisol levels were higher in 
CPAP group (138). A lower incidence of cry was observed for infants in the HFNC group 
compared with the CPAP group (138). In addition, the respiratory rate was significantly lower 
with HFNC (138).  
 
3.9.5 Nasal trauma 
 
The risk of nasal trauma was significantly less when HFNC was compared with CPAP either 
as primary respiratory support [RR 0.50 95% CI (0.34, 0.72)] as shown in figure 19 or as post 
extubation respiratory support [RR 0.50 95% CI (0.40, 0.61)] as shown in figure 20.  
 
This is consistent with other reviews performed with earlier studies up to and including from 
2016 (1, 110). Nasal trauma was less common in HFNC group infants than infants treated 
with control (CPAP, SIPPV) means of respiratory support in majority of the studies including 
Nair (140), Iranpour (122), Collins (96), Manley (98), Yoder (97) and Mostafa-Gharehbaghi 
(128) and Soonsawad (132) but no difference was seen in two studies Liu (111) and 
Kugelman (126).  
 
An earlier meta-analysis of HFNC versus CPAP to prevent extubation failure with secondary 
outcome as nasal trauma showed a RR 0.64 (95% CI of 0.51-0.79) (1). 
 114 
 
 
Collins et al devised a nasal trauma score in a randomised controlled study comparing infants 
extubated to either HFNC or nasal CPAP (118). These infants were preterm <32 weeks’ 
gestation (118). The HFNC device used was Vapotherm and infants receiving this therapy 
used Sticky Whiskers type of nasal dressing and infants receiving nasal CPAP used either 
Sticky Whiskers or Cannualaide type of nasal dressings (118). The nasal trauma score 
consisted of six sites looking for erythema, bleeding or ulceration and were recorded three 
times daily during the first 7 days post extubation (118). The sum of these 21 scores was 
compared between the two groups. The scores in HFNC group (2.8 with SD 5.7) was much 
less compared to CPAP (11.7 with SD 10.4) group (118). They concluded that HFNC causes 
less nasal trauma compared to CPAP in the first 7 days post-extubation (118).  
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Figure 19. Pooled estimate of risk of nasal trauma in preterm infants on HFNC 
compared with other modes of NIV as primary respiratory support 
 
 
 
 
Figure 19 shows risk of nasal trauma in preterm infants on HFNC compared with other modes 
of NIV as primary respiratory support. 
 
 
 
Figure 20. Pooled estimate of risk of nasal trauma in preterm infants supported post 
extubation on HFNC compared with other modes of NIV 
 
 
 
 
Figure 20 shows estimate of risk of nasal trauma in preterm infants supported post extubation 
on HFNC compared with other modes of NIV. 
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3.10 Discussion 
 
3.10.1 Efficacy of HFNC 
 
In their review on HFNC, Kotecha et al equated the efficacy of HFNC to failure of therapy as 
defined by the authors (110). They conducted their analysis with focus on HFNC as a primary 
mode of respiratory support as well as a post extubation respiratory support.  
They included four studies involving 321 preterm infants (97, 143-145) comparing HFNC 
with other NIV as a primary mode of respiratory support. The OR for failure of therapy was 
1.02 (95% CI: 0.55 to 1.88). Since Kugelman et al study compared HFNC with NIPPV, 
excluding this yielded OR of 1.12 (0.51 to 2.50) (110). 
 
In this review, I included a large multicentre RCT (130) and a smaller study (131) published 
later thereby increasing the number of preterm babies in the analysis. A total of 1227 preterm 
babies distributed evenly in two arms of HFNC and CPAP were analysed.  
When HFNC was compared with CPAP as a primary respiratory support mode in preterm 
neonatal respiratory distress there was increased risk of treatment failure as shown in the 
Forest plot figure 10 with RR 1.57 95% CI (1.20, 2.05)].  
 
When larger number of babies including the later studies are included, the balance shifts 
towards CPAP favouring CPAP as a mode of respiratory support shows lesser risks of failure 
of therapy. This is consistent with the meta-analysis presented by Roberts et al excluding the 
relatively smaller Shin et al study (131, 142).   
 
Thus for practical application, primary mode of respiratory support in RDS the findings of 
Kotecha et al study is being challenged by the higher risks of failure found in this review 
(110). 
 
Similar to Kotecha et al study, the Cochrane review in 2016 presented their meta-analysis 
from studies up to 2016 (1, 110). They found a cumulative risk ratio of 1.30 (0.73, 2.34) 
based on 439 patients from 3 trials with 211 patients in HFNC arm and 228 patients in CPAP 
arm (1). They concluded that for preterm infants needing primary respiratory support after 
birth, there were no differences in the rates of primary or secondary outcomes between HFNC 
and CPAP (1).  
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The Cochrane review (1) had only half the numbers of Lavizzari et al (127) study published 
by Ciuffini et al prematurely whereas Kotecha et al (110) does not have the numbers from the 
later Shin et al (131) and Roberts et al (130) studies. These later studies are larger, more 
rigorous in terms of statement of criteria for treatment interventions and were pre-registered 
as clinical trials reducing the reporting bias.  
 
 
In this review, when HFNC was compared with NIPPV as a primary respiratory support 
mode, there was no significant increased risk of treatment failure, RR 0.85 95% CI (0.44, 
1.65).  
 
Cochrane review took into account data from one study and reported that there was no 
difference between HFNC and NIPPV in rates of treatment failure, death or CLD (1, 126). 
Also, from the same study it was noted that infants randomised to HFNC spent a longer 
period of time receiving non-invasive respiratory support (median 4 days vs median 2 days, P 
< 0.01) (1, 126).  
 
Since then there has been one more study from 2016 which did not find any further 
differentiating data with regards to primary outcome of treatment failure as defined by the 
study (123).  
 
There was no separate analysis of HFNC versus NIPPV as a primary mode of support in 
Kotecha et al paper (110). However they did include Kugelman et al study (143) for pooled 
analysis of estimation of odds of failure of therapy as a primary mode of respiratory support.  
 
As a post extubation respiratory support mode HFNC when compared to CPAP in a total of 
661 babies in three studies (96, 97, 146), Kotecha et al (110) found odds of failure of 
treatment of 1.09 (0.58 to 2.02). This means HFNC and CPAP showed no difference in risk of 
failure. In this review, a total of eleven studies containing 1513 babies showed that HFNC 
resulted in a RR (95% CI) of 1.09 (0.90, 1.31) for treatment failure when compared to CPAP 
when used as a post extubation respiratory support mode. This is similar to Cochrane review 
where treatment failure with HFNC as defined by the studies was similar to CPAP (1).   
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The earlier studies included in Kotecha et al review are varied in methodology, performed in 
different clinical settings and different levels of flow have been utilized (110, 126). For 
example, Yoder et al (97) used initial flows based on infants’ weight (3 L/min for 1,000–
1,999 g, increased by a maximum of 3 L/min) whereas Collins et al (96) used an initial flow 
of 8 L/min and Manley et al (146) used an initial flow of 5–6 L/min (126). These 
methodological inconsistencies continue in the later studies included in this review as well.  
Unlike the studies included in Kotecha et al review, a study by Kadivar et al, included in this 
review found a higher rate of intubation in HFNC infants (110, 124). 
 
The Cochrane Review authors noted that RCTs thus far have included relatively few 
extremely preterm infants (<28 weeks’ GA) (1). This finding is echoed in the paper by 
Kotecha et al as well and they concluded that no recommendations can be made in extremely 
premature babies as there have been no significant studies including these babies (110). 
However in infants >28 weeks’ gestation they found that HFNC resulted in a RR (95% CI) of 
0.80 (0.44, 1.44) for treatment failure, and 0.51 (0.27, 0.97) for intubation in comparison to 
CPAP (1). Therefore the review concluded that post-extubation HFNC may be an appropriate 
therapy in this group of infants with rescue CPAP being available (1).  
 
In this review three studies arrive at different conclusions in terms of efficacy of HFNC as a 
weaning mode. The Abdel Hady study (147) found babies weaned by HFNC did worse than 
those weaned by CPAP whereas study by Badiee et al (148) found the opposite. More 
recently study by Soonsawad et al study (141) showed no difference when HFNC was used as 
a step down from CPAP as opposed to weaning directly from CPAP. The Kotecha et al paper 
did not analyse this aspect of HFNC use (110). 
Therefore, at present there is no evidence to suggest that HFNC helps in improving outcomes 
when used as a weaning method from respiratory support.  
 
3.10.2 Other clinical outcomes 
 
In this review looking at the BPD outcome, comparing HFNC with CPAP, the risk ratio was 
suggestive of no increased risk either when HFNC was used as primary respiratory support 
[RR 1.17 95% CI (0.72, 1.90)] or as post extubation respiratory support [RR 0.88 95% CI 
(0.74, 1.05)].  
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Kotecha et al review had a total of 932 infants in the studies having data on BPD outcome 
with OR of 0.93 (CI 0.67 to 1.28) showing they were comparable in two groups (110). 
The Cochrane Review reported a no increased risk when compared to CPAP in the clinical 
outcome of BPD (RD 0.96, 95% CI 0.78 to 1.18) from analysis of 893 infants pooled from 
post-extubation studies (1). 
 
In this review, the mortality outcome showed no significant increased risk when HFNC was 
compared to CPAP. This was seen when HFNC was used as post extubation respiratory 
support [RR 0.62 95% CI (0.28, 1.39)] as well as when used as a primary respiratory support 
[RR 0.61 95% CI 0.08, 4.57)]. 
 
Similarly, there was no statistically significant difference in the rate of deaths in the group of 
preterm infants randomly assigned to receive HFNC compared with other NIV in an earlier 
systematic review by Kotecha et al involving 922 infants (OR: 0.48 [0.18 to 1.24]) (110)  
 
In this review, the risk of air leak syndrome was significantly less with HFNC compared to 
CPAP. This was seen in both as primary respiratory support [RR 0.42, 95% CI (0.17, 1.02)] 
and as post extubation respiratory support [RR 0.28, 95% CI (0.15, 0.55)]. 
Similarly, Kotecha et al (110) reported no increased odds of air leak with HFNC in their 
pooled data with total of 992 infants with OR of 0.72 (CI 0.28 to 1.83).  
 
There were some case reports and case series of air leak complications during HFNC (93-95). 
This has not been substantiated by prospective RCT involving more than 1000 babies 
collectively. The Cochrane Review reported a reduction in the rate of pneumothorax (RD 
−0.02, 95% CI −0.03 to −0.00) from analysis of infants from post-extubation studies (1, 142). 
The pooled analysis of air leak or pneumothorax data from primary respiratory support of 
neonatal respiratory distress have shown pneumothorax rates with (RD −0.02, 95% CI −0.02 
to 0.02) with HFNC and CPAP (142).  
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3.10.3 Safety and comfort 
 
The patient comfort scores have been reported variably in different studies (149, 150).  
However preterm infants are thought to be more comfortable on HFNC compared with CPAP 
by neonatal nurses (91) and parents (149). 
 
The risk of nasal trauma was significantly less when HFNC was compared with CPAP either 
as primary respiratory support [RR 0.50 95% CI (0.34, 0.72)] or as post extubation respiratory 
support [RR 0.50 95% CI (0.40, 0.61)].  
 
This is consistent with other reviews performed with earlier studies by Kotecha et al and 
Cochrane review (1, 110). Collins et al devised a nasal trauma score in a randomised 
controlled study comparing infants extubated to either HFNC or nasal CPAP (118). They 
concluded that HFNC causes less nasal trauma compared to CPAP in the first 7 days post-
extubation (118).  
 
3.11 Summary of descriptive review of studies evaluating clinical efficacy of HFNC  
 
HFNC therapy results in less risk of nasal trauma and air leak complications irrespective of 
whether it is used as primary support or as post extubation support. However, when it is used 
as primary respiratory support in preterm babies with RDS, more babies will end up meeting 
failure criteria and need intubation or other forms of escalation of respiratory support 
compared to CPAP. The same outcome is equivocal when two small studies are reviewed 
together comparing HFNC with NIPPV. There is no difference between HFNC and CPAP 
when used as post extubation support and in BPD and mortality outcomes. There are 
equivocal results from the three studies that examined whether HFNC improves outcomes if 
used as a weaning mode instead of weaning on CPAP.  
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Chapter 4. Materials and Methods 
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4.1 Study Design Development 
 
The study design was developed after undertaking a review of high flow therapy in infants(2) 
and conducting a retrospective neonatal data base study of use of HFNC in local neonatal unit 
(153).  
 
The study protocol was internally peer reviewed followed by an external peer review process. 
My research team held consultations with neonatal nurses, parents and neonatal medical staff. 
The ideas and current knowledge about safe margins of therapy and applicability of study 
pathway in the protocol was discussed in formal meetings within the neonatal unit.  
 
4.1.1 Study protocol 
 
I developed the full study protocol for a comprehensive evaluation of respiratory physiology 
during high flow therapy. A copy of the full study protocol is in Appendix number 1. 
The study had two phases- initial proof of concept phase to identify reliable, feasible, safe and 
repeatable methods of measuring various respiratory parameters. The second phase involves 
larger number of babies. The study was registered in Clinical Trials Registry, Number: 
NCT02200900.  
 
4.2 Ethics Approval 
 
I submitted a detailed ethics application through the IRAS platform for submission of clinical 
trials in United Kingdom. The IRAS application document is attached in Appendix number 2.  
I presented the study to ethics committee along with the study Chief Investigator. I prepared 
the answers for the queries posed by all members of the Ethics committee including medical, 
research and lay representatives.   
 
I made the required changes to the protocol and resubmitted to Ethics committee and received 
the approval with approval number14/NE/0093. A copy of the ethics approval is attached in 
appendix number 3. 
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4.3 Informed Consent 
 
I obtained informed written consent from parents after giving them a full verbal and written 
explanation of the study. In addition, the attending clinical team was also available to meet 
with the parents during the intervention period to ensure that they understood the study 
procedures and continue to consent to participate in the study. 
 
Some preliminary written and verbal information was, whenever possible, offered to the 
parents when the baby was likely to be eligible. Additional information was also given once 
the baby was stable on non-invasive respiratory support.  
 
A copy of the Participant Information Sheet has been presented in appendix number 4.  
 
Further information about the study continued to be given to parents as and when they 
requested it after the baby was enrolled into the study. They were also offered an early 
appointment with the senior clinician responsible for the baby’s care so they could discuss 
participation in greater detail. It was made clear to the parents that they remained free to 
withdraw their baby from the study at any time but if they did withdraw their baby, we would 
ask them for consent to analyse the data that has been already collected. 
Information about the study was continued to be offered to parents after their baby left the 
neonatal unit. 
  
4.4 Selection and Withdrawal of Study Participants  
 
In this proof of concept study, 6 infants were recruited and underwent measurements for the 
study.  In the next stage, approximately 45 babies would be recruited for the study. 
  
4.4.1 Inclusion criteria 
 
Infants were eligible if: 
1. They were less than 37 weeks’ gestation at birth  
2. Were on non-invasive respiratory support and 
3. The parent(s) were given written informed consent to their baby’s participation 
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4.4.2 Exclusion criteria 
 
1. Infants who were clinically unstable and unsuitable for non-invasive respiratory support as 
judged by attending neonatology consultant clinician. 
The infant must be clinically stable for preceding 12 hours on non-invasive respiratory 
support. Indications of clinical stability were, 
 Stable FiO2 requirement in the previous 12 hours – The FiO2 has not increased more 
than 0.2 from baseline 
 Tolerating feeds 
 Stable observations including heart rate (100-180 per minute), respiratory rate (30-60 
per minute), temperature (36.5- 37.5oC) 
 No signs of infection – evidence of blood culture positive infection and or treatment 
for active infection 
 
2. Participation in a concurrent study that prohibits inclusion in other trials 
3. Known major upper airway, lower respiratory tract, cardiac or gastrointestinal tract 
anomaly 
4. Co-existing complications such as pneumothorax. 
  
4.4.3 Withdrawal of participants 
 
 Babies could be withdrawn for any of the reasons detailed in the discontinuation criteria. The 
reason for withdrawal was recorded on the data collection form.  
 
4.5 Baseline Assessments 
 
For eligible babies, clinical details were collected at study entry. This included details to 
confirm eligibility including gestational age, type of respiratory support, and clinical stability 
over the previous 12 hours and confirmation of a signed parental consent form. (See 
Appendix 5 for a copy of consent form) 
   
 
 
 
 125 
 
4.6 Details of Study Design and Procedures 
 
This was a randomised, crossover study. I performed the proof of concept phase with the 
following study design. A larger study followed the same protocol and methods after 
completion of first phase. The study procedures are summarised in figure number 21 and 
described in more detail in subsequent sections.  
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Figure 21. HFNC Study Flow Chart 
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4.7 Description of Study Interventions 
  
Non-invasive respiratory support was given to preterm babies where clinically indicated by 
the clinical team. The device used were the standard devices used in participating neonatal 
unit (Fabian therapy, ACUTRONIC Medical Systems AG). The baby was given non-invasive 
respiratory support either by HFNC or CPAP as deemed appropriate by the attending 
clinician. The standard neonatal policy (See Appendix 6) in maintaining baby’s oxygen 
saturations and clinical stability were followed. 
  
The interventions were studied for total of about two hours as described below. After this 
time, the baby was returned to the non-invasive support that was originally administered by 
the clinical team. 
  
The internal nare diameter was measured with a tape measure. The nasal cannula outer 
diameter was obtained from product information on the cover provided by the manufacturer.   
The ratio of nasal cannula to nare diameter was documented. 
 
4.8 Airway pressure measurement – Gaeltec Catheter Tip Pressure Transducer  
 
There are different types of catheter tip pressure transducers used in the medical field. 
Gaeltec, Brown Medical Systems and Millar Instruments are some of the leading 
manufacturers I tested a Gaeltec catheter (Gaeltec, Dunvegan, UK) with transducer mounted 
at the tip to assess whether it was suitable for measurement of airway pressures. The Gaeltec 
Catheter tested by us is shown in figure 22.  
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Figure 22. Gaeltec catheter tip pressure transducer 
 
 
 
 
 
The Figure 22 shows the image of the Gaeltec catheter with catheter tip mounted transducer, 
catheter with cm markings and a connector assembly containing one tube with Luer lock end 
for gas analysis and the other containing electrical connection components to connect to the 
amplifier. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A – Electrical connection 
assembly  
 
B – Pressure transducer  
 
C – Gas sampling channel  
 
D – cm markings 
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4.8.1 Gaeltec catheter tip pressure transducer 
 
The Gaeltec catheter measures pressure at the site of catheter placement where the sensor is 
located at the distal tip of the catheter. The sensor is mounted on the side wall at the distal tip 
of the catheter.  
The Gaeltec catheters have the following parts -  
 Sensor assembly 
 Connector assembly 
 Silicone catheter with customised markings as needed 
 Customised additional channel if needed – As I needed an additional channel for 
sampling nasopharyngeal air the company manufactured a custom made catheter with 
a small channel with additional port with leur lock connection at the other end.  
 
The sensor was a resistive strain gauge type (55). This element was mounted in a catheter wall 
close to the tip as shown in figure 23.  
 
The sensor has a metal diaphragm which is very thin and works as a resistive strain gauge 
membrane and is housed in the catheter in a unique arrangement. There is an atmospheric 
reference pressure channel that connects the back of the sensing area to the ambient air 
pressure via a hole in the connector. Therefore, all measurements are differential with respect 
to ambient air.  
 
Apart from the sensor assembly, the catheter has a connector component. This has passive 
components to complete a full Wheatstone bridge circuit. This also has temperature 
compensation and a bridge balance network. Together, this connector assembly can be 
connected to most strain gauge amplifier systems. I used the Gaeltec S7d 4 channel amplifier. 
 
It is important that these amplifiers provide electrical isolation. The amplifier must be patient 
isolated. These pressure sensors require an excitation voltage of 1V or less DC or 5V r.m.s or 
less AC to avoid electrical damage when in use.  
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Figure 23. Catheter tip pressure transducer with strain gauge sensor at the tip 
 
 
 
 
 
 
 
The Figure 23 shows the sensor assembly (marked with arrow A) of the Gaeltec catheter. The 
sensor assembly as a silicon layered strain gauge component (marked with arrow C) an 
opening for the gas channel (marked with arrow B). The cm marking is shown with arrow D 
with first marking 3 cm from the tip of the catheter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A – Pressure transducer 
sensor assembly 
 
B – Gas sampling channel 
opening 
 
C –Strain gauge 
component 
 
D – cm markings 
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4.8.2 Dimensions 
 
The Gaeltec catheter CTO-L1 and CTO-L2 are general purpose catheters. The total length of 
the catheter was 76 cm measuring from the tip to the connecter assembly shoulder. The 
transducer assembly was located at the sidewall close to the tip of the catheter. There were 
markings at 1cm intervals from the tip of the catheter for measuring length of insertion.  
 
I used the endoscope cleaning suite at the hospital for sterilisation of the catheter following 
use. The catheter is designed for multiple use and it was clearly critical to avoid any risk of 
cross infection.  I extrapolated the cleaning process for bronchoscopes and liaised with the 
endoscopy cleaning service to set up a protocol to ensure there was no risk of cross infection. 
The catheter connector assembly part was protected by sealing with a silicone rubber cap 
provided by the company. This was done to prevent liquid from entering the small 
atmospheric reference pressure hole in the centre of the pins on the plug of the connector 
assembly. If liquid enters this channel then sensor may be permanently damaged and also will 
not be able to function as a differential transducer in relation to atmospheric pressure.  
 
4.8.3 Storage, safety and standards certification 
 
The catheter was stored in a plastic, crush proof transducer box and sent to cleaning and 
sterilisation in a transparent, plastic box labelled with date and time. The catheter like most 
medical equipment was subjected to The Health and Safety at Work Act (1974) and the 
Control of Substances Hazardous to Health (COSHH) regulations (1988). This means that 
equipment needs to be sterilised after use and used as per instructions for the safety of 
personnel handling it and patients in whom it is being used. CE 0120 EC Certificate was in 
place with full quality assurance system, Certificate GB 12/86323 and Gaeltec devices limited 
was assessed and certified as meeting the requirements of Directive 93/42/EEC on Medical 
Devices for medical pressure transducers.  
 
4.8.4 Catheter assembly 
 
This type of catheter needs an amplifier to process the transducer signals into readable 
analogue form as seen in figure 24.  
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Figure 24. Catheter tip pressure transducer assembly with amplifier in series 
 
 
 
 
 
 
 
Figure 24 shows the amplifier (marked with arrow A) connected to the Gaeltec catheter.  The 
sensor assembly (marked with arrow C) is located at the tip of the catheter and its signals are 
transferred as analogue output via the connector assembly (marked with arrow B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A – Amplifier 
 
B – Connector assembly  
 
C – Sensor assembly 
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4.8.5 Amplification 
 
I used the Gaeltec S7d a general-purpose amplifier for interfacing Gaeltec Pressure 
Transducers to the AD instruments chart recorder (analogue device) for recording the pressure 
data.  
 
This was a 4-channel device powered by a low voltage mains adaptor and it has a single 
output port for connection to the host device and a single input port for pressure transducer 
connection and also has a LCDE display for use during setup and configuration. It has 
electrical isolation with protection up to 5000 volts between the pressure transducer connected 
to a patient and the host analogue device. It was cleaned by alcohol wipes after each study. It 
was stored in normal environmental temperature, range between 5˚C and 30˚C.  
 
4.8.6 Calibration 
 
The transducer sensor is placed inside a calibration chamber provided by Gaeltec as shown in 
figure 25. This has a sealing compressible grommet that forms an airtight seal around the 
catheter.  
 
The calibration involves 2 stages, 
First, the Gaeltec S7d amplifier is calibrated followed by connecting to the host analogue 
device (Power lab, AD instruments, Oxford, UK) and calibrating to the likely range of 
pressures to be measured.  
 
The following steps are followed for the Gaeltec S7d amplifier calibration, Firstly, the 
transducer is connected to amplifier and the transducer sensor was placed and sealed inside 
the calibration chamber and then the calibration chamber was connected to the manometer 
and left open to atmosphere. Then the host analogue device was connected to the amplifier 
(S7d). Finally, mains connection was done via adaptor. The second step was to switch the 
amplifier (S7d) on followed by zeroing all the inputs followed by zeroing the selected channel 
input. The last step was amplifier calibration to the desired range of pressures. I used 2-point 
calibration to calibrate to ‘0’ and ‘20’ cm H2O pressures.  
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Figure 25. Schematic diagram and catheter mounted pressure transducer calibration 
 
 
             
  
 
 
 
                      
Figure 25 shows the schematic diagram of catheter mounted pressure transducer calibration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 135 
 
4.8.7 Linearity 
 
The linearity refers to the straightness of the output signal at various equally spaced pressure 
points applied in an increasing direction. 
 
According to the manufacturers, Gaeltec catheters should have linearity when used within the 
pressure ranges of 0- 300 mm Hg. The reported linearity and hysteresis error is ±1% FS BSL 
(Full Scale or Full Span stands for the difference between the lowest and highest measured 
point and BSL stands for Best Straight Line, a virtual line derived from a set of non-linear 
points).  
 
I tested the linearity for the air-way pressure range that is likely to be seen in preterm infants 
against a known source of pressure delivered by a CPAP machine (B&D Electro medical, 
Stratford-upon-Avon, UK) as control. The CPAP machine pressures were cross checked 
against a water manometer to confirm accuracy and linearity. The trend was linear and CPAP 
and water manometer recorded pressures were the same. This is shown in figure 26.  
 
. Then I tested the linearity of the two Gaeltec catheters by comparing them with CPAP 
delivered pressures. Both catheters had pressure measurements difference of up to 1.3 cm H20 
pressure in either direction compared to the control. This is shown in the figures 27 and 28. 
The difference between two measures (Gaeltec catheter versus the control) on Y axis was 
plotted against the mean of the two measures.  
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Figure 26. Linearity of the CPAP pressure checked with water manometer 
 
 
 
 
 
 
Figure 26 shows linearity and accuracy of CPAP machine when a series of pressures were 
plotted against the water manometer.  
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Figure 27. Linearity of the Gaeltec Catheter Tip Pressure transducer – CTO- L1 against 
the control (Bland Altman plot) 
 
 
 
 
 
 
 
Figure 27 shows the difference between the two pressures on Y axis plotted against the mean 
of the two measures along the X axis with Gaeltec catheter CTO-L1.   
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Figure 28. Linearity of the Gaeltec Catheter Tip Pressure transducer – CTO- L2 against 
the control (Bland Altman plot) 
 
 
 
 
 
Figure 28 shows the difference between the two pressures on Y axis plotted against the mean 
of the two measures along the X axis with Gaeltec catheter CTO-L2.   
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4.8.8 Frequency response 
 
The manufactures report excellent frequency response since the sensor and catheter assembly 
is small in size.  The frequency response of the pressure measurement instruments may 
degrade when additional equipment or catheters are connected in series. I tested the frequency 
response for the measuring unit with nasopharyngeal catheter attached to the amplifier.  
 
The frequency range of airway pressure wave signal is influenced by the breathing frequency. 
Small mammals or preterm neonates, when in respiratory distress can have respiratory rate in 
the range of 60-120 breaths per minute. This gives a frequency range of 1-2 Hz (Frequency in 
Hz = number of cycles/60 seconds). In order for the measurement systems to have adequate 
frequency response, they should be able to measure up to four times the normal frequency of 
the study population. For example, in neonates with frequency of 1-2 Hertz, the measurement 
systems should have a frequency characteristic of at least 4-8 Hertz. 
 
Frequency response of the pressure measuring systems was tested by ‘pop test’. In this test an 
inflated balloon is fitted over the pressure sensor and then burst, producing a sudden drop in 
input signals to the system(154). The time taken 10 to 90% of pressure change was noted 
from the laptop reading the electronic chart recorder data. Fourier transformation equation 
(fbw = (1/3Tr where Tr is in milliseconds) was used to calculate the frequency response of the 
system being checked, where fbw is the frequency response and Tr is the time taken for the 
pressure change from 10 to 90% of the final resting pressure.  
 
The response to an instantaneous change in pressure was recorded on a laptop computer using 
electronic chart recorder software (Power lab 16/35, AD instruments, Oxford, UK).  
The frequency response for airway pressure measurement included the airway pressure 
transducer, the connecting tubing (in case of B&D differential transducer and Thermal sensor 
transducer) and the amplifier (in case of Gaeltec catheter tip pressure transducer).  
 
The frequency response of the Gaeltec catheter tip pressure transducer (CTO-L1) and the 
amplifier was measured with the above technique and showed a 10-90% response time of 75 
milliseconds giving frequency response of 4.4 Hertz. A second catheter set was also tested 
(CTO-L2) which had response time of 63 milliseconds which equates to frequency response 
of 5.2 Hertz.  
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This was less than that reported by manufacturers as well as in other studies that used similar 
catheter systems (39, 155).  
 
4.8.9 Stability 
 
According to manufacturers, the Zero drift factor is typically less than 1mmHg over 24 hours. 
This amounts to about 1.35 cm H2O pressure. This can be considered as a significant pressure 
difference particularly in a very small premature baby. I performed stability of pressure 
readings over a period of time with 2 sets of Gaeltec catheters. The catheter tip with 
transducer was kept in the Gaeltec calibration tube. After calibration of the pressure 
transducer, different pressures were delivered to the calibration tube from the CPAP machine 
(B&D Electro medical, Stratford-upon-Avon, UK). The resulting analogue output from the 
transducer was recorded continuously on an electronic chart recorder (Power lab, AD 
instruments, Oxford, UK). The drift from baseline was noted over a period of 2 hours. The 
stability was ±1.3 cm H2O off baseline at lower pressures (3-6 cm H2O) and about ±0.3 cm 
off baseline at 20 cm H2O pressures.  
 
4.8.10 Factors influencing catheter performance 
 
According to manufacturers the catheter has a life of at least 10 years. However, this is 
affected by the care taken during its use. The catheter tip transducer system is affected by 
extreme pressures, thermal stress and if any liquid enters the channel communication between 
atmosphere and sensor chamber.  
 
4.8.11 Description of airway pressure measurement with Gaeltec Catheter 
 
A catheter (Gaeltec Devices Ltd, Dunvegan, UK) with pressure transducer and port for gas 
sampling at the tip was placed at the nasopharynx or oropharynx by using standard 
measurement for placing nasopharyngeal airways(27, 29). Distance between nare of the nose 
to tragus of ear was measured with a measuring tape. The nasopharyngeal catheter was 
introduced to about 1 cm less than this measurement to ensure adequate placement in 
nasopharynx and to avoid gagging or undue stimulation of cough reflex (27, 29). This was 
connected to an O2 and CO2 analyser (AD instruments Gas analyser) and electrically isolated 
excitation amplifier to measure pressure.  Where possible this was timed to coincide with 
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routine replacement of the feeding tube which was facilitated at the conclusion of the 
study.  The pressure recording was done when mouth was passive and also with mouth closed 
gently with a finger pressing on the chin. 
 
4.8.12 Results of Gaeltec catheter pressure measurement 
 
Nasopharyngeal pressure measurement was tried in two babies (Study ID 01 and 02) with 
Gaeltec catheter tip transducer. No accurate, acceptable airway pressure profile was obtained 
in both these measurements.  
The catheter however allowed sampling for airway gas concentration measurement.  
 
4.8.13 Summary of catheter mounted pressure transducer 
 
The catheter tip pressure transducer is an attractive option to measure airway pressures and 
has been cited as practical in a number of published series. The manufacturer also felt it was 
suitable for use in infants and that it would be capable of measuring pressures typical for a 
child on respiratory support.  The ability to measure pressure at the desired location in the 
airway without being affected by gravity and also any movement of the patient is attractive. 
However, the device is manufactured for a wide range of pressure measurement and its 
applicability to measure a small range of pressure at the lower end of its range is suspect. The 
stability of the measurements is another factor which needs to be more stable.  Despite 
previous published work my investigations have shown this technology lacks the necessary 
accuracy and stability for use in small infants.  Results from previous published series using 
this technique need to be interpreted with caution. 
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4.9 Airway Pressure Measurement - Thermal Sensor Pressure Transducer 
 
4.9.1 Introduction 
 
Thermal sensor pressure transducers work on a different principle to differential pressure 
sensors and find application in medical, automobile and other precision industries. They are 
small in size and have signal-conditioning circuit on a single microchip. There are different 
manufacturers (examples: Sensirion AG, Switzerland and First Sensor AG, Berlin, Germany).  
There are a range of products and a transducer suitable for the pressure range likely to be seen 
in this study is shown in figure 29. This device comes with a sensor component which is 
combined with the analogue and digital signal processing circuit on a small silicon chip.  
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Figure 29. Example of a Thermal micro sensor pressure transducer 
 
 
 
 
 
Figure 29 shows the thermal micro sensor pressure transducer and its constituent parts. The 
micro sensor is housed in a case (marked with arrow B) and is powered by an AC adopter 
(marked with arrow D). The gas flow ports Hi and Lo are indicated (arrow marked C) and the 
output is via BNC connector (marked with arrow A) 
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4.9.2 Measuring principle of a thermal flow sensor 
 
The microchip has a heating element. This releases heat into the medium through which the 
gas flows. Two temperature sensors are placed on either side of heating element. When the 
gas flows across the sensors it detects a difference in temperature with high sensitivity. This 
change in temperature is read as pre-calibrated flow signal by the micro sensor chip. This is 
shown in figure 30.  Since all the elements of this system are assembled on a single silicon 
chip the analogue sensor signals are amplified and processed without interference.  
 
4.9.3 Equipment details 
 
The thermal sensor is a small compact unit measuring 2cmX2cm in size. It has high and low 
flow ports and an analogue output cable with BNC connectors for connection to the electronic 
chart recorder.  
 
The sensor assembly was packaged in a heat resistant plastic container by the biomedical 
engineering department at our institute. This enabled cleaning with surface active cleaning 
agents used in the neonatal unit for equipment cleaning. The device was cleared for electrical 
safety as per the standards for medical equipment.  
 
4.9.4 Sensor assembly 
 
The nasopharyngeal catheter is connected to the ‘high’ flow port of the sensor assembly and 
the ‘low’ flow assembly is open to the atmosphere. The output from the sensor assembly is 
connected to the electronic chart recorder (Power lab, AD instruments, Oxford, UK) via BNC 
connector.  
 
4.9.5 Calibration 
 
I calibrated the transducer with a 2-point calibration against known pressure source delivered 
by a calibrated CPAP device. The calibration points were recorded by the electronic chart 
recorder (Power lab, AD instruments, Oxford, UK) and the calibrated voltage values were 
entered in the chart recorder to generate the pressure values.   
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Figure 30. Principle of thermal sensor (Obtained from Sensirion AG) 
 
 
 
 
 
The Figure 30 shows micro sensor chip with a heating element in the centre and two 
temperature sensors on either side allowing the gas to flow in a straight channel 
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4.9.6 Linearity 
 
The linearity of the pressure transducer was checked against a known source of pressure. The 
control was various levels of CPAP pressures delivered by a calibrated CPAP machine (B&D 
Electro medical, Stratford-upon-Avon, UK).  
 
In the linearity testing the pressure signals correlated well with control pressure as seen by the 
Bland Altman plot in the figure number 31 with pressures range from 3 cm H2O to 20 cm 
H2O closely following the bias line.  
 
4.9.7 Frequency response 
 
The frequency response of the thermal sensor type of transducer was tested with the ‘pop’ test 
method(154). This test was done when the transducer was connected in series with the 
nasopharyngeal catheter (Argyle Gentle Flow Suction Catheter, Size 8FR, Covidien Ltd, 
Ireland) used to measure pressure in the nasopharyngeal airway. The response time was 33 
milliseconds giving a frequency response of 9.9 Hertz.  
 
4.9.8 Factors influencing sensor performance 
 
The thermal sensor requires an uninterrupted flow of gas down the nasopharyngeal catheter 
enabling temperature changes at the sensor. Therefore, it is different from differential pressure 
transducer. The main limitation in using this in very small preterm babies is that flow can 
easily be interrupted by secretions and may not be uniform. There is no effect of gravity 
unlike the water filled catheter systems. However, the effect of local changes in temperature 
may be substantial as in-vitro calibration may not be applicable to in-vivo use.  
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Figure 31. Linearity of the thermal sensor pressure transducer against the control  
(Bland Altman plot) 
 
 
 
 
 
 
Figure 31 shows the two measures with thermal transducer and control along Y axis plotted 
against the mean of the two measures along the X axis showing good linearity. 
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4.9.9 Description of thermal sensor pressure measurement  
 
A catheter (Suction catheter size Fr 8) was placed at the nasopharynx or oropharynx by using 
standard measurement for placing nasopharyngeal airways (27, 29). Distance between nare of 
the nose to tragus of ear was measured with a measuring tape. The nasopharyngeal catheter 
was introduced to about 1 cm less than this measurement to ensure adequate placement in 
nasopharynx and to avoid gagging or undue stimulation of cough reflex (27, 29). This was 
connected to the ‘high’ flow port of the sensor assembly and the ‘low’ flow assembly is open 
to the atmosphere. The output from the sensor assembly is connected to the electronic chart 
recorder (Power lab, AD instruments, Oxford, UK) via BNC connector.  
 
Where possible this was timed to coincide with routine replacement of the feeding tube which 
was facilitated at the conclusion of the study.  The pressure recording was done when mouth 
was passive and also with mouth closed gently with a finger pressing on the chin. 
 
4.9.10 Results of thermal sensor pressure measurement 
 
Nasopharyngeal pressure measurement was tried in two babies (Study ID 03 and 05) with 
thermal sensor transducer. No accurate, acceptable airway pressure profile was obtained in 
both these measurements. A pressure profile obtained with this method is shown in figure 
number 32.  
 
4.9.11 Summary of thermal sensor pressure transducer 
 
The thermal sensor is technically sound with good frequency response, linearity and response 
times. However, in the case of preterm neonates it was difficult to receive consistent, valid 
pressure signals because of the presence of secretions blocking the catheter and interrupting 
free flow of gas.  
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Figure 32. Airway pressure recording with thermal sensor – HFNC 5LPM – Dampening 
signal with movements 
 
 
 
 
 
 
Figure 32 shows the pressure data obtained with thermal sensor transducer with varying 
amplitude and irregularity. 
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4.10 Airway Pressure Measurement - Differential Pressure Transducer  
 
Differential pressure transducers are widely used in industries, gas and engineering equipment 
and in medical equipment. They can be used to either measure pressure or flow by 
differentiating the pressure signal  
 
4.10.1 Principle of differential pressure transducer 
 
The differential pressure transducers convert change in pressure into an electrical signal. This 
is achieved by the sensor contained in these transducers. The sensor can be of different types. 
In the B&D differential transducer that I used, the sensor is made up of a diaphragm with 
strain gauges attached. The strain gauges deform on application of a pressure difference and 
these are transmitted as electrical signals by the Wheatstone bridge transmitting system 
attached to the diaphragm. This deformation is proportional to the pressure changes. In B&D 
differential transducer, one of the pressures is always atmospheric pressure as one surface of 
the diaphragm is subjected to the atmospheric pressure.   
 
4.10.2 Description of B&D differential transducer structure 
 
The differential transducer sensor has a diaphragm type of sensor as its core element. The 
other essential part is the transmitting unit which conveys the electrical signal generated due 
to pressure changes as an analogue signal to the recording equipment. The transducer was 
cleaned after each use as per existing neonatal unit policy of cleaning medical equipment.  
The product had electrical safety and standards certification for use as medical equipment. 
The B&D differential transducer used in this study is shown in figure 33. 
 
4.10.3 Transducer assembly 
 
The transducer is connected to the nasopharyngeal catheter (Argyle Gentle Flow Suction 
Catheter, Size 8FR, Covidien Ltd, Ireland) through a leur lock connector. The nasopharyngeal 
catheter was kept patent with a constant flow of air through a syringe pump containing 50 ml 
syringe flushing air at a constant rate of at 20ml/hr. The output signal was recorded in 
electronic chart recorder (Power lab 16/35, AD instruments, Oxford, UK) via BNC 
connectors.  
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Figure 33. Differential pressure transducer and its assembly with nasopharyngeal 
catheter in series 
 
 
 
 
 
Figure 33 shows the B&D differential transducer (arrow marked A) connected to the 
nasopharyngeal catheter (arrow marked D) through its port (arrow marked C). The output 
from B&D is shown digitally in this transducer but also collected as analogue output (arrow 
marked B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A –Differential 
transducer 
 
B – Analogue output 
 
C – Catheter connection 
port 
 
D – The nasopharyngeal 
catheter connected to the 
transducer 
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4.10.4 Calibration 
 
I calibrated the B&D transducer before each use with a known pressure source from a CPAP 
machine (B&D Electromedicals, Stratford-upon-Avon, UK). A 2-point calibration was done 
and voltages in the electronic chart recorders were appropriately adjusted.   
 
4.10.5 Linearity 
 
The linearity check gave satisfactory readings over the range 3-20 cm H2O when compared 
with control pressures delivered by calibrated CPAP device as illustrated in figure 34.  
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Figure 34. Linearity of the B&D Differential Pressure Transducer against the control 
(Trend line with Error Bars-Standard Error) 
 
 
 
 
 
 
The figure 34 shows the linearity profile for B&D differential pressure transducer plotted 
along the X axis against the control pressures along the Y axis for series of pressures ranging 
from 3 - 20 cm H2O. 
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4.10.6 Frequency response 
 
The frequency response of B&D differential transducer was tested when connected in series 
with nasopharyngeal catheter (Argyle Gentle Flow Suction Catheter, Size 8FR, Covidien Ltd, 
Ireland) by the ‘pop’ test method(154). The response time was 20 milliseconds giving a 
frequency response of 16.2 Hertz.  
 
4.10.7 Factors influencing differential transducer performance 
 
The differential transducer works on the physical principle of deformation of strain gauge 
elements in its sensor. Therefore, it can be influenced by the ambient temperature. The 
accurate pressure measurement is dependent on a patent catheter leading up to the site of 
interest but not necessarily an active flow.   
 
 
4.10.8 Description of Differential pressure transducer measurement  
 
Differential transducer method (B&D Electromedical, Stratford-upon-Avon, UK): A suction 
catheter was placed at the nasopharynx or oropharynx by using standard measurement for 
placing nasopharyngeal airways. Distance between nare of the nose to tragus of ear was 
measured with a measuring tape(26). The nasopharyngeal catheter was introduced to about 1 
cm less than this measurement to ensure adequate placement in nasopharynx and to avoid 
gagging or undue stimulation of cough reflex(26). This was connected to O2 and CO2 analyser 
and differential pressure transducer via a 3-way connection. The gas analysis sampling was 
done intermittently at flow rate changes as per the study pathway.  
 
4.10.9 Summary of differential pressure transducer 
 
The B&D differential transducer had very good accuracy, linearity and frequency response. It 
was also practicable to use in a small preterm baby due to the practical challenges of 
unpredictable flow into the measuring catheter. The results and discussion of airway pressure 
measurements done with this method are discussed in the results chapter –Chapter 5.  
 
 
 155 
 
4.11 Gas Analysers for Respiratory Gases 
 
There are different types of gas analysers available which are used predominantly in 
anaesthetic practice, intensive care and also by sports physiologists. I used a commercially 
available gas analyser (AD instruments, Oxford, UK), which provides analogue output for O2 
and CO2 concentration from the gas sample being analysed.  
 
4.11.1 Principle 
 
The AD instruments gas analyser is an electronic gas analyser with transducers for infrared 
carbon dioxide and visible spectrum oxygen detection. A schematic diagram illustrating the 
gas analyser components is shown in figure 35. 
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Figure 35. Schematic Diagram of Gas Analyser (From AD instruments, Oxford, UK) 
 
 
 
 
 
 
 
 
Figure 35 shows a schematic diagram of a gas analyser with its constituent parts. 
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4.11.2 Materials and device assembly 
 
The AD instruments gas analyser has a gas analyser unit, connecting tube called Nafion and 
output cable with BNC connectors for connection to electronic chart recorder. These are 
shown in figure 36. 
 
Nafion is a copolymer of tetrafluoroethylene (Teflon) and perfluoro-3, 6-dioxa-4-methyl-7-
octene-sulfonic acid i.e.a combination of Teflon with sulfonic acid group side chains 
interspersed in it. These side chains have a very high affinity to water, absorbing 13 molecules 
of water for every sulfonic acid group in the polymer and therefore Nafion tube absorbs 22% 
by weight of water. Unlike micro-porous membrane permeation, which transfers water 
through a relatively slow diffusion process, Nafion removes water by absorption. This 
absorption occurs as a first order kinetic reaction, so equilibrium is reached very quickly. 
Because this is a specific reaction with water, gases being dried or processed are not affected. 
 
The Nafion tube is 30 cm in length and 0.13 mm in diameter. The material allows water 
vapour to pass through its walls so that the water vapour content of the gas sample inside the 
tube equilibrates with that of the room air. This happens very quickly within milliseconds.  
 
The In-line Filter connects directly to the sampling port of the Gas Analyser to protect the 
transducers from moisture and damaging particulates. This has 0.45µm pore-size hydrophobic 
membrane and a disc size of 17mm.  
 
The gas analyser (AD instruments, Oxford, UK) has an infrared carbon dioxide sensor and 
optical oxygen detector. The analyser samples expired gas from a mixing chamber with a 
damped, micro-vacuum sampling pump. A flow control knob on the front of the unit provides 
sampling rates of 35 to 200 ml/min. The maximum flow values may vary for different sizes 
and lengths of tubing. The gas analyser has the following operating requirements- power 
supply of 85–250 VAC 50/60 Hz, temperature range should be 5–35 °C and humidity 
between 0–90% (non-condensing). The salient features are shown in table 14.  
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Figure 36. Gas analyser, Nafion connecting tube and In-line filter 
 
 
 
                   
 
 
 
 
Figure 36 shows a gas analyser with its different functionalities labelled, a nafion connecting 
tube and a bacterial filter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                     
 
 
 
 
 
 
 
 
 
Flow control Gas sample inlet 
port 
Power Pump switch indicator 
Nafion tube In-line filter 
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Table 14. Features of gas analyser (obtained from AD instruments, Oxford, UK) 
 
 
 
Features CO2 analyser 
 
O2 analyser 
 
Type of analyser Infrared, optical Visible spectrum (760 nm) 
absorption 
Range  0–10% CO2 5–100% O2 
Output Linear, 0–1 V (0–10% CO2) Linear, 0.05–1 V (5–100% O2) 
Resolution 0.1% CO2 0.01% O2 
Linearity ±0.1% CO2 ±0.2% O2 
Drift 0.1% CO2 over 8 hours 0.1% O2 over 2 hours 
Response time (10–90%) 90–130 ms @ 200–50 ml/min 
- transducer alone; 440 ms @ 
200 ml/min sample flow with 
Nafion tubing and 
hydrophobic filter connected 
to sample inlet port 
 
Transducer 130–300 ms 
between 200–50 ml/min 
 
 
Table 14 shows performance features of gas analyser components. 
 
 
 
The CO2 transducer works on the principle of infrared absorptiometry. It is a Servomex model 
1507 infrared transducer. It is calibrated so that output voltages in the range 0–1 V are 
proportional to CO2 concentrations in the range 0–10%.  
 
The O2 transducer works on the principle of optical absorptiometry. It is an Oxigraf X2004 
sensor which uses absorption spectroscopy in the visible spectrum (760 nm). The incoming 
gas sample is exposed to narrow-band light produced by a laser diode. The light is thermally 
tuned to a particular emission-line in the oxygen spectrum. A detector on the opposite side of 
the chamber detects changes or attenuation in the light intensity at the wavelength of the gas 
sample being studied. As the concentration of oxygen in the chamber increases, more energy 
is absorbed by the oxygen molecules in the gas and less light is received by the detector. 
 
The exterior of the gas analyser was cleaned as per neonatal unit policy for medical 
equipment. The device had all the electrical and safety standards certificates for use as a 
medical device.  
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4.11.3 Calibration 
 
The instrument was warmed up for at least 15 minutes prior to every test to minimize any 
possible electrical drift. Calibration of the O2 and CO2 analysers was performed immediately 
prior to every test using two-point calibration with two known gas mixtures.  
Oxygen analyser was calibrated with first calibration point being room air and the second was 
12.5% O2 cylinder with CO2 7.5% and balance N2 gas mixture. For CO2, first calibration point 
was room air (0.004) and the second was 7.5% CO2 from gas mixture cylinder (BOC Health 
care, UK).  
 
4.11.4 Obtaining measurements 
 
The machine was switched on for 15 minutes and then calibrated as per the protocol.  
Then the pump speed was set at 200ml/min. A nafion tube was connected to the gas inlet port. 
The nafion tube ensures optimising the water vapour content of the gas sample to the room air 
level. A bacterial filter was juxtaposed between nafion tube and patient catheter to prevent 
cross infection or contamination of the machine. The machine makes continuous 
measurements of the O2 and CO2 levels of the sampled gas sample which is recorded as an 
analogue signal on electronic chart recorder (Power lab, AD instruments, Oxford, UK) 
 
4.11.5 Factors influencing gas analyser performance 
 
The measured gases should be free of excessive water vapour. In addition, inadequate 
warming time might affect the results due to alteration in the electronic signals produced by 
the O2 and CO2 transducers.  
 
4.11.6 Summary of gas analyser for air way gas concentrations 
 
The features of the AD instruments gas analyser including the response time, range of 
measurement capability and ability to record continuous gas concentration in an analogue 
output were suitable for the purposes of this study.  
 
 
 
 161 
 
4.12 Tidal volume measurement - Volusense Technology 
 
4.12.1 Principle 
 
Volusense uses electromagnetic inductive plethysmography technique for evaluating tidal 
breathing indices in infants (81, 156). A vest with conductive coils is wrapped around the 
baby’s chest and abdomen. The resultant change in magnetic field generated by the coils due 
to movements of the chest and abdomen is picked up by an antenna placed at a height over the 
baby. This allows measurement of tidal volume, respiratory rate and by differentiating volume 
signals over time tidal flow indices can be measured.  A schematic diagram of Volusense 
principle is shown in figure 38.  
 
The measurements are depicted continuously in the Volusense screen as flow volume signals. 
The measurement quality can be visually checked by the shape of the waves as shown in 
figure 39. 
 
Thoraco abdominal asynchrony can be calculated from the Electromagnetic Inductance 
Plethysmography done via the Volusense software. The chest wall and abdominal movement 
signals have specific wave characteristics. The phase angle provides a quantitative estimation 
of Thoraco-abdominal asynchrony. In addition, the shape of the flow volume loop can give 
clues about airway obstruction to flow.  
 
Volusense machine has been validated for tidal breathing indices measurement in both term 
and preterm infants in the earlier studies (157, 158). 
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Figure 37. Schematic representation of Volusense Electromagnetic Inductance 
Plethysmography (157) 
 
 
 
 
 
 
 
Figure 37 shows a schematic representation of Volusense machine. The key components are 
labelled (157). 
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Figure 38. Volusense machine and measurement display on the machine screen 
 
 
 
 
 
Figure 38 shows the Volusense machine with its main components labelled. 
 
 
 
 
 
 
 
 
 
 
 
Tidal breathing  
display 
 
Antenna 
 
Volusense machine 
with display screen 
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4.12.2 Materials and device assembly 
 
The Volusense machine comes with a standalone unit consisting of a base unit with device 
computer for onscreen instructions and conducting the calibration and test. The device 
extends onto an antenna. The device also comes with a calibration unit consisting of a 
metallic cylinder with known volume against which the calibration has to be performed in the 
area of interest. This test site specific calibration is crucial as the magnetic fields in an area 
that might interfere is specific to that area. 
  
The vest containing conductive coils comes in 5 different sizes. These are colour coded and 
are ranging from vests suitable for a less than 1000 grams baby to a larger infant. Accurate 
size selection is done after measuring the distance between the armpit to hip in the baby and 
comparing it with the colour coded scale and colour coded vests provided by the company.   
 
4.12.3 Factors influencing Volusense performance 
 
The presence of a strong magnetic field or instruments that might generate electromagnetic 
field are likely to interfere with measurements. The baby needs to be quiet and not moving 
vigorously as movements will lead to artefacts. The size of the vest should be appropriate for 
the baby’s size as too loose or too tight vests will not accurately measure the actual tidal 
breathing indices. The calibration has to be done according to the guidelines and height of 
antenna needs to be as per guidance.  
 
4.12.4 Measurement of tidal volumes 
 
The Volusense vest was placed over the infant’s torso. Respiratory measurements are derived 
from changes in electromagnetic inductance in this wrap-around vest worn by the baby. The 
vest is disposable and used for one patient only to avoid cross-infection. Thorax and 
abdominal volumes and volume changes are measured and stored digitally by the Volusense 
device shown in figure 38. The device was used to record tidal volume, tidal flow volume 
loop, respiratory rate and to calculate tidal breathing indices.  The device has the ability to 
export analogue signals of tidal volume and flow for simultaneous recording in the 
multichannel recorder for synchronous recording. 
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4.13 Transcutaneous CO2 measurement 
 
Transcutaneous (Radiometer UK Limited, Crawley, UK) sensor was applied to the baby’s 
skin to measure carbon dioxide (CO2) levels. 
 
4.14 Transcutaneous O2 saturation measurement 
 
Transcutaneous oxygen saturation percentage was measured by placing pulse oximetry probe 
on foot and connecting it to Masimo SET Pulse Oximetry machine (Masimo Europe Limited, 
Basingstoke, UK).  
 
4.15 Data recording 
 
All the above measurements were connected to a multi-channel recorder (Power lab chart 
recorder, AD Instruments, Oxford, UK) that allowed synchronised recording and graphical 
presentation of all the above parameters. These are saved as files allowing future 
analysis.   The following measurements were attempted at a sampling frequency of 100Hz. 
  
 Transcutaneous oxygen saturations. 
 Transcutaneous CO2 levels. 
 Nasopharyngeal pressures. 
 Concentration of CO2 and O2 in nasopharyngeal space during inspiration and 
expiration. 
 Tidal volume, flow, respiratory rate and FRC baseline. 
 
Clinical observations were done as per unit policy (Appendix Number 6). 
 
A screenshot of simultaneous multichannel recording of respiratory physiology parameters is 
shown in the figure 39. The different channels are colour coded to identify different inputs 
from measuring equipment.  
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Figure 39. Example of simultaneous recording of physiology parameters in Lab Chart 
recorder –Study ID – 06 
 
 
 
 
 
 
 
Figure 39 is a screenshot from the simultaneous multichannel recording of the all the 
physiological parameters measured in this study. The individual parameters are represented in 
colour coded waveforms and the analogue measurements are displayed onscreen as well. 
 
 
 
A study trolley was assembled containing the following devices as shown in figure 40 and a 
list of equipment used in the study is given in Table Number 15. 
 
 
 
 
 
 
 
 
 
 
 
 
O2 
CO2 
TV 
TcPCO2 
Pressure 
HR 
SPO2 
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Figure 40. Study Trolley 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40 shows the study trolley assembly with its components.   
 
 
 
 
 
 
 
 
 
 
Study laptop 
 
B&D differential 
transducer 
 
AD instruments chart 
recorder 
 
TOSCA Radiometer 
 
Gas analyser 
 
Pulse oximeter 
 
Storage areas 
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Table 15. Equipment used in the study 
 
 
 
Equipment 
 
 
Manufacturer 
 
Standards 
 
 
Features 
The HFNC and 
CPAP devices 
Fabian therapy: 
ACUTRONIC 
Medical 
Systems AG 
 
CE 0124. Fabian Therapy 
is an Equipment Class IIb 
ventilator per European 
directive. 
It can provide both 
CPAP and HFNC 
therapy 
Pressure monitoring 
and gas sampling 
Gaeltec catheter 
tip pressure 
transducer: 
Gaeltec Devices 
Ltd 
CE 0120 
EC Certificate full quality 
assurance system: 
Certificate GB 12/86323, 
Directive 93/42/EEC on 
Medical Devices for 
medical pressure 
transducers. 
Single equipment 
with incorporated 
pressure transducer 
and a channel for 
aspirating gas 
sample for analysis 
Pressure monitoring Differential 
pressure 
transducer  
B&D 
Electromedical 
Ltd 
CE 0120 
Electrical safety 
certificate 
Compact device 
easily portable for 
bedside 
measurements 
Gas analyser   AD instruments, 
Oxford, UK 
 
CE 0120 
Electrical safety 
certificate 
Needs calibration 
against known gas 
concentration before 
use 
Tidal breathing 
indices 
Volusense 
Pediatrics, 
Bergen, Norway 
Class II A according to 
MDD. 
Electrical Classification: 
Class I, type B according 
to IEC 60601-1 
Safety standards: EN/IEC 
60601-1: 2005 and 
EN/IEC 60601-1-6 
Bulky instrument, 
it’s a standalone 
device with its own 
software input from 
device laptop. 
However, data can 
be exported in 
analogue form to 
multichannel chart 
recorder 
Transcutaneous 
carbon dioxide 
monitoring. 
Radiometer UK 
Limited, 
Crawley, UK 
CE 0123 
Instrument Class 1, type 
BF, defibrillator proof, 
fulfils the requirements of 
MDD 93/42 
 
Compact device, 
amenable for 
bedside 
measurement 
Transcutaneous O2 
saturation 
monitoring 
Masimo Europe 
Limited, 
Basingstoke, 
UK 
CE 0120 
Electrical Safety 
certificates 
Compact device for 
continuous 
measurements 
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4.16 Study Treatment 
 
4.16.1 Adjustment of FiO2 
 
FiO2 was continued at the same level as pre-study entry level. Any desaturations outside the 
standard target range (91-95%) were dealt with as per standard neonatal practice (FiO2 
increased or decreased by 5% aliquots). A sustained increase (more than 15 minutes) in FiO2 
by 0.2 above baseline or FiO2 > 0.6 was used as the cut-off to restore the infant to previous 
flow rate with no further reduction in flow.  The study was continued but these infants were 
studied over a reduced range of flow rates.  
 
4.16.2 Study Duration 
 
Total study duration was around 120 minutes. I was directly observing the baby throughout 
the study. 
 
4.16.3 Minimisation of Bias 
 
The recordings were done simultaneously on an electronic chart recorder with no possibility 
of observer bias. The stability of pressure traces was based on the presence of a clean artefact 
free respiratory waveforms after recording.  Only those segments with no noise and artefact 
were analysed and all artefact free data in its entirety was exported for analysis to avoid 
observer bias. 
  
4.16.4 Discontinuation Criteria 
 
The attending clinician had the powers to withdraw the baby at any time in the interests of the 
baby’s health and well-being. Babies would have been discontinued from study if (any of):  
 Inadequate ventilation - pH <7.20 and pCO2 >10 kPa, 
 Inadequate oxygenation - FiO2 >0.6 and/or increase in FiO2 of 0.2 from baseline to 
maintain SpO2 >91% (28), 
 Recurrent unprovoked minor apnoea requiring intervention (not self-resolving; >2 per 
hour during study) or one major apnoea requiring positive pressure ventilation (28). 
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4.16.5 Concomitant Treatments 
 
Throughout the study, the babies continued to receive prescribed concomitant treatments 
deemed necessary to provide adequate supportive care. 
 
4.17 Research Governance 
 
Babies recruited to the HFNC Study spent about two hours participating in the study. I 
monitored the babies closely throughout the study.  In addition, babies continued to have 
routine neonatal observations as per the neonatal unit policy by the clinical team. There was 
no transfer of babies between neonatal units during this study as it was a short study of two 
hours duration. Timeline of proof of concept project development is given below in Table 
number 16. 
 
Table 16. Timeline of various physiology studies in the proof of concept study 
 
 
Respiratory physiology study development 
 
Timeline 
HFNC Review of evidence 
 
July 2013-September2013 
Protocol development 
 
October 2013-January2014 
Study Trolley assembly 
 
July 2014 
Gas analyser calibration set up 
 
August 2014 
Pressure monitoring calibration set up 
 
August 2014 
Volusense equipment training  
 
December 2014 
Airway pressure monitoring– Gaeltec catheter 
 
February 2015 
Airway pressure monitoring with thermal sensor  
 
February 2015 
Airway pressure monitoring with differential transducer 
 
March 2015 
Airway gas concentration 
 
February-March 2015 
Tidal breathing indices- Volusense 
 
February –March 2015 
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4.18 Source data 
 
Source data was obtained from: 
• Hospital records for the baby’s clinical condition before study. 
• Data downloaded from the electronic multi-channel recorder (Power lab, AD   
   Instruments, Oxford, UK). 
 
4.19 Assessment of efficacy  
 
The primary outcome measures were recorded during the study on electronic chart recorder. 
The mechanism for recording any significant respiratory deterioration resulting in exit criteria 
being met was analysed on a case by case basis by the study team and the data monitoring 
committee. Each baby was monitored as per the current neonatal unit standards (Appendix 6). 
  
4.20 Assessment of safety  
 
Safety was assessed continuously during each baby’s study in the neonatal unit. Standard 
system was in place to address any adverse event.  
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4.21 Discussion and summary 
 
I undertook investigation of the techniques available to measure respiratory physiology in 
preterm infants accurately, safely and also wanted to demonstrate that it was feasible in 
preterm infants.  
 
Out of the three pressure measuring systems, though they all had specific advantages, the 
stability of the Gaeltec pressure catheter mounted pressure transducer was not optimal over a 
two-hour period at the pressure range we expected to see in preterm infants. I decided to test 
the quality of pressure tracings with these methods before choosing the most appropriate 
technique for larger randomised crossover study.  
 
The gas analyser selection for measuring airway gas concentration was based on the features 
described namely response rate, accuracy and feasibility for ease of use at bed side in a 
neonatal unit.  
 
I explored the features of a novel tidal volume measuring device called Volusense. This 
electromagnetic inductance plethysmographic device has been tested in neonates including 
preterm neonates but never during HFNC therapy situation (81, 160). The technical aspects of 
the machine when I examined in depth seemed to be suitable for the purposes of this study 
i.e., measuring tidal volumes continuously whilst measuring other physiological parameters in 
babies who were receiving varying flow rates of HFNC.  
 
These devices in addition to the already standardised transcutaneous CO2 and oximetry 
devices in use made up the core elements of the equipment used in this study.  
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Chapter 5.  Results 
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5.1 Introduction 
 
The body of literature on HFNC therapy in various clinical conditions is growing. Its use in 
the neonatal population has been increasing and it has been the subject of several studies as 
discussed in my literature review (96, 98, 130).  
 
However, the key mechanism of action of HFNC is yet to be elucidated. Out of the several 
mechanisms of action proposed the predominant feature is not known (14). Without this 
knowledge, it is difficult and empirical to make guidelines and treatment protocols for its 
initiation, maintenance weaning and stopping the therapy (99).  
 
In order to understand the role of airway distending pressure, dead space wash out effect and 
influence on tidal volume and hence minute ventilation, we planned a comprehensive 
physiological study. I undertook the initial study evaluating the equipment to be used in this 
study as above.  I chose and built the cart that all the equipment was mounted on and wired all 
items up to the chart recorder.  I established a protocol whereby the equipment could be 
calibrated then wheeled to the patient’s bedside in order to start the investigation.   
 
I also performed proof of concept studies to assess feasibility and safety before undertaking a 
larger study involving a larger number of babies. A detailed study protocol (See Appendix 
Number 1) as described earlier was developed followed by approvals from North East Ethics 
Committee-2(See Appendix Number 3), Special Trustees at Newcastle Hospitals for funding 
(See Appendix Number 7) and finally Newcastle Hospitals NHS foundation Trust research 
governance for site specific research (See Appendix Number 8).   
 
5.2 Baseline characteristics of study population 
 
The median (IQR) gestational age at birth was 27 (25.71-29.28) weeks and the median (IQR) 
birth weight was 872.5 (705-1160) grams.  The gender distribution was equal (3 male, 3 
female). 5 babies were >1500 grams in weight at the time of the study. There was one baby 
<1000 grams in weight at the time of the study.  The median (IQR) age at the time of study 
was 34.78 (32.86-36.14) weeks and the median (IQR) study weight was 1785 (1580-1980) 
grams. The participant summary and study entry characteristics are summarised in tables 17 
and 18.  
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Table 17. Participant Summary 
 
 
 
Recruitment Number of babies 
 
Respiratory support 
starting mode 
 
 
Consented 
 
 
9 
 
 
Studies undertaken 
 
 
6 
 
1 CPAP 
5 HFNC 
 
Reasons for exclusion 
 
 2 babies came off high 
flow therapy soon after 
consent before study could 
commence. 
 
 
 1 baby - Volusense only 
started – Baby active and 
unsettled- data not 
obtained consistently.  
 
 
 
 
Table 17 shows a summary of the participants in this pilot study. 
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Table 18. Description of baseline characteristics at study entry 
 
 
 
 
Participants Gender 
Gestational  
Age 
 in weeks 
Age at the time 
 of study 
in weeks 
Birth Weight 
grams 
Weight at the  
time of study 
in grams 
1 F 27+6 36+1 675 1980 
2 F 29+2 34+4 1160 1700 
3 M 
26+1 
 
28 
 
905 
 
975 
 
4 F 24+6 35 705 1870 
5 M 25+5 37+1 840 2280 
6 M 31+3 32+6 1400 1580 
Median  
27 
 
34.78 872.5 1785 
IQR range   (25.71-29.28) (32.86-36.14) (705-1160) (1580-1980) 
 
 
Table 18 shows the baseline characteristics of the study population. 
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5.3 Airway Pressure Recordings 
 
Two babies had a range of pressure measurement across different HFNC flows with the B&D 
differential transducer.  
 
A pressure recording was taken as valid and real if it showed the typical wave pattern and 
without interference and was of uniform amplitude across several respiratory cycles. In this 
study, at least 10 breaths were needed to accept measurements from that epoch. Various 
pressure data were collected and the segment represented by each pressure parameter is 
shown in a valid pressure signal in figure 41.  
 
 
 
 
 
Figure 41. Valid Pressure tracing with respiratory waveform for at least 10 breaths 
 
 
 
 
 
 
 
 
Figure 41 shows a valid pressure waveform that would be accepted for analysis. 
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The range of pressures seen during HFNC in a preterm neonate is shown in table 19 and 
figure 42. In this example, maximum pressure in air ways was seen during HFNC of 8 LPM. 
In the HFNC flow range of 2-8 LPM, there was a flow dependent increase in mean air way 
pressures and maximum airway pressures.  
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Table 19. Airway pressure profile recorded with B&D differential transducer with 
HFNC varying flow rates (Study ID 04 and 06) 
 
 
Respiratory 
Support 
Pressure 
Minimum 
cm H2O 
Pressure 
Mean 
cm H2O 
Pressure 
Maximum 
cm H2O 
Study ID 04 06 04 06 04 06 
CPAP 6cm H2O 1.69 3.56 4.01 5.59 5.81 7.34 
HFNC 8 LPM 2.39 5.62 4.15 7.14 4.83 8.01 
HFNC 7 LPM 0.34 4.31 3.27 5.74 6.4 6.77 
HFNC 6 LPM 0.09 3.36 3.51 5.18 6.7 6.30 
HFNC 5 LPM 0.00 0.80 2.19 3.48 4.94 5.18 
HFNC 4 LPM 0.07 0.97 0.7 2.63 1.1 4.92 
HFNC 3 LPM 0.42 0.22 0.98 2.64 1.44 4.21 
HFNC 2LPM 0.20 0.52 1.44 1.60 2.21 3.39 
 
 
Table 19 shows the complete range of various pressure parameters across all HFNC flow 
ranges and CPAP control mode. 
 
 
Figure 42.  Mean Airway pressure profile recorded with B&D differential transducer 
with HFNC varying flow rates (Study ID 04 and 06) 
 
 
 
 
 
 
Figure 42 is a scatter plot of the mean airway pressures across HFNC flow ranges and CPAP. 
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5.4 Gas concentration measurement 
 
5.4.1 In-vivo measurement of airway O2 and CO2 concentrations 
 
The O2 and CO2 concentration in nasopharyngeal gas sample was sampled intermittently 
during each flow rate from 2-8 LPM and during CPAP of 6 cm H2O pressures. The FiO2 
being administered was noted down at the same time. The transcutaneous CO2 was 
continuously recorded throughout the study.  
 
In the figure number 43, a snapshot of gas concentration analysis of nasopharyngeal space is 
illustrated with blue wave form from CO2 transducer and red wave form from O2 transducer 
of the gas analyser. The points in CO2 curves which stands for End Inspiratory and End 
Expiratory CO2 levels are indicated by black arrows.  
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Figure 43. Recording of nasopharyngeal airway O2 and CO2 concentrations during 
CPAP with FiO2 34% 
 
 
 
 
 
 
Figure 43 shows the recording of O2 and CO2 (marked with arrows) in nasopharynx during 
HFNC therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Administered FiO2 34% 
Recorded O2 concentration 27.5% 
 
Recorded CO2 concentrations 
End inspiratory 
End expiratory 
 
Airway O2  
Airway CO2  
Tidal volume  
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5.4.2 Gas concentration measurements in this proof of concept study 
 
Valid gas concentration measurement was available from Study ID 2, 3, 4 and 6 for different 
flow rates. The range of values seen is shown in table 20.   
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Table 20. Maximum, mean, minimum CO2 and O2 concentrations in nasopharyngeal 
airway at various HFNC flow rates 
 
 
 
Study 
ID 
 
Mode 
O2 
Average 
Minimum 
% 
O2 
Average 
Maximum 
% 
O2 
Mean 
% 
 
CO2 
Average 
Minimum 
% 
 
CO2 
Average 
Maximum 
% 
CO2 
Mean 
% 
2 CPAP 6 25.7 28.4 27.0 0.42 2.38 1.31 
3 CPAP 6 33.2 36.0 34.5 1.90 4.40 3.05 
4 HFNC 8 18.6 21.8 20.3 0.28 3.12 1.50 
6 HFNC 8 16.8 20.8 19.4 0.33 4.05 1.50 
3 HFNC 7 33.3 36.4 34.8 1.01 3.64 2.22 
6 HFNC 7 17.2 20.7 19.0 0.25 3.11 1.49 
3 HFNC 6 31.0 35.1 32.7 0.81 3.46 1.46 
4 HFNC 6 21.0 26.0 23.2 1.18 3.80 2.52 
4 HFNC 4 20.0 23.1 21.5 0.79 3.12 1.95 
6 HFNC 4 17.1 20.9 19.7 0.06 3.85 1.10 
3 HFNC 3 32.3 36.8 34.4 0.98 4.35 2.51 
6 HFNC 3 15.8 20.8 19.0 0.22 4.91 1.64 
3 HFNC 2 34.6 37.5 35.8 1.36 3.52 2.53 
4 HFNC 2 22.3 25.0 23.6 0.44 2.68 1.48 
6 HFNC 2 15.9 20.7 18.5 0.46 5.38 2.54 
      
HFNC  
2-4 LPM 
versus  
6-8 LPM 
P = 0.54 
 
                                                                                                                              
 
P value calculated using the t-test (Difference -0.183; Standard error 0.294; 95% CI-
0.8289 to 0.4636; t-statistic -0.622; DF 11; Significance level P = 0.5466) 
 
Table 20 shows maximum, mean, minimum CO2 and O2 concentrations in nasopharyngeal 
airway at various HFNC flow rates. There was no difference between CO2 levels between 
HFNC flow rates of 6-8 LPM compared to 2-4 LPM (P = 0.55 95% 95% CI -0.83 to 0.46; t-
statistic). 
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5.4.3 Relationship of administered O2 to recorded O2 concentration in nasopharyngeal 
airway 
 
The administered FiO2 by HFNC was slightly higher than the measured O2 levels in the 
nasopharyngeal gas sample. Thus, the HFNC prescribed oxygen concentration is likely to 
deliver a slightly lesser FiO2 concentration to the upper airways. The mean nasopharyngeal O2 
levels at different HFNC flow rates and CPAP 6 cm H2O respiratory support, recorded from 
nasopharyngeal gas samples is shown in table 21. 
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Table 21. Relationship of administered O2 to recorded O2 concentration in 
nasopharyngeal airway during HFNC 
 
 
 
 
Study ID 
 
 
Respiratory 
support mode 
 
Administered 
FiO2 
 
Mean 
Nasopharyngeal 
O2 % 
 
2 CPAP 6 34.0% 27.0 
3 CPAP 6 37.0% 34.5 
4 HFNC 8 24.0% 20.3 
6 HFNC 8 21.0% 19.4 
3 HFNC 7 37.0% 34.8 
6 HFNC 7 21.0% 19.0 
3 HFNC 6 37.0% 32.7 
4 HFNC 6 24.0% 23.2 
4 HFNC 4 26.0% 21.5 
6 HFNC 4 21.0% 19.7 
3 HFNC 3 45.0% 34.4 
6 HFNC 3 21.0% 19.0 
3 HFNC 2 45.0% 35.8 
4 HFNC 2 29.0% 23.6 
6 HFNC 2 21.0% 18.5 
 
Mean (SD) 
 
29.53(8.87) 
 
25.56(6.88) 
 
 
 
 
Table 21 shows relationship of administered O2 to recorded O2 concentration in 
nasopharyngeal airway during HFNC. 
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5.5 Tidal breathing indices measurements by Volusense method 
 
Tidal breathing indices were measured as per the study protocol during CPAP of 6 cm H2O 
and HFNC flow rate from 2-8 LPM. These were measured in all the 6 babies in the study.  
 
5.5.1 Tidal volumes in HFNC 
 
The mean tidal volumes at each flow rate was within the range of 3.1-3.9 ml/kg. However, the 
relationship of tidal volume and flow rate was not linear. There was no significant difference 
between the tidal volume seen at CPAP of 6 cm H2O and each of the flow rates 2-8 LPM. The 
mean tidal volume in ml/kg is shown in table 22. 
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Table 22. Tidal volumes in ml/kg determined by Volusense method at CPAP 6 cm H2O 
and varying HFNC flow rates 
 
 
 
Study 
ID 
CPAP 
6 cm 
H2O 
HFNC 
8 LPM 
HFNC 
7 LPM 
HFNC 
6 LPM 
HFNC 
5 LPM 
HFNC 
4 LPM 
HFNC 
3 LPM 
 
HFNC 
2 LPM 
 
01 2.49 NA NA 2.36 2.35 2.33 2.77 3.5 
02 4.54 4.12 4.41 3.45 3.76 4.11 3.1 5.17 
03 7.62 3.77 3.10 3.75 4.24 3.17 4.63 6.19 
04 1.77 2.38 2.07 2.08 1.72 2.05 2.02 1.60 
05 2.10 1.76 1.87 1.83 1.65 1.82 1.20 1.11 
06 3.76 3.44 4.63 5.17 4.63 5.62 5.34 5.82 
MEAN 3.71 3.10 3.22 3.11 3.06 3.18 3.18 
 
3.90 
 
STD 
DEV 
2.18 0.99 1.28 1.26 1.31 1.45 1.56 
 
2.17 
 
 
 
 
Table 22 shows Tidal volumes in ml/kg determined by Volusense method at CPAP 6 cm H2O 
and varying HFNC flow rates.  
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5.5.2 Tidal breathing indices including flow derivatives from Volusense 
 
The Volusense generated flow volume loops from the chest and abdominal wall movements.  
The various flow values are derived by differentiating the volume curves. This is shown in 
table 24. There were no statistically significant differences in either tidal volumes or flow 
indices derived from the flow volume loops when HFNC of 8 LPM was compared with CPAP 
of 6 cm of H2O.  
 
The mean peak tidal expiratory flow (PTEF) in mL/s during HFNC 8 LPM and CPAP 6 cm 
H2O was similar with no statistically significant difference (p=0.9150). Similarly, time to 
peak tidal expiratory flow as a ratio of total expiratory time, referred as Tptef/Te, was also 
similar (p=0.8111) between the two respiratory support modalities of HFNC 8 LPM and 
CPAP 6 cm H2O.  
 
The phase angle obtained from the difference in thoracic and abdominal wall movements was 
similar (p= 0.7962) indicating effect of HFNC and CPAP on thoracoabdominal asynchrony 
was the same in this instance.  
 
The expiratory flow volume loop centre of gravity, referred as FVg, was also similar (p= 
0.3706) in the two modalities of respiratory support.  
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Table 23. Tidal breathing indices with tidal flow derivatives 
 
 
 
 
Indices 
HFNC 8 LPM 
(n=5) 
 
CPAP 6cm H2O 
(n=5) 
 
Weight at study in 
grams 
Mean (range) 
1737 (975-2280) 1737 (975-2280) 
Vt (ml)/kg 
Mean(SD) 
2.82 
(1.51) 
3.14 
(2.62) 
RR(/min) 
Mean(SD) 
62.69 
(21.45) 
57.93 
(18.90) 
V'E(mL)/kg 
Mean(SD) 
184.84 
(127.53) 
193.01 
(207.80) 
PTEF (mL/s) 
Mean(SD) 
14.69 
(2.94) 
14.33 
(6.69) 
Tptef/Te (%) 
Mean(SD) 
62.61 
(16.00) 
65.11 
(16.00) 
Te/Ti 
203.20 
(122.18) 
188.62 
(41.91) 
Phase angle (Degree) 
mean (SD) 
101.08 
(62.46) 
90.3 
(65.19) 
FVg (dimensionless) 
Mean (SD) 
0.48 
(0.07) 
0.45 
(0.01) 
 
 
 
Table 23 shows tidal flow indices derived from the Volusense flow volume loops. 
 
Vt (mL)/kg - Tidal volume per kilogram body weight 
RR - Respiratory rate 
V’E (mL)/kg - minute ventilation 
PTEF - Peak tidal expiratory flow 
Tptef/Te - Time to peak tidal expiratory flow as a ratio of total expiratory time  
FVg - Expiratory flow volume loop centre of gravity (dimensionless) 
 
 
 
 
 
 
 
 190 
 
5.6 Gas exchange profile of patients during the study 
 
5.6.1 Heart rate, respiratory rate, transcutaneous O2 and CO2 levels   
 
All the babies had continuous heart rate, respiratory rate, transcutaneous O2 concentration and 
transcutaneous CO2 levels measured as shown in Table 24, Table 25, Table 26 and Table 27 
and figure 44, figure 45, figure 46, figure 47 respectively. The mean values of these basic 
respiratory parameters were recorded throughout the study across all HFNC flow ranges.  
 
The mean heart rate and mean respiratory rates were stable across the flow ranges of HFNC 
as well as CPAP of 6 cm H2O during the study period.  
 
The oxygen saturation profile was stable within the limits agreed in the protocol (FiO2 not 
exceeding more than 0.2 from baseline) throughout the study and 3 babies needed increase in 
FiO2 in 5% aliquots.  
 
The transcutaneous CO2 mean values were within the acceptable range during the entire study 
period in all the babies. This shows that there were no transient elevations of TcPCO2 levels 
during the various HFNC flow levels during the study period.  
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Table 24. Heart Rate (mean) during the study 
 
 
 
 
Study 
ID 
CPAP 
6 cm 
H2O 
HFNC 
8 LPM 
HFNC 
7 LPM 
HFNC 
6 LPM 
HFNC 
5 LPM 
HFNC 
4 LPM 
HFNC 
3 LPM 
HFNC 
2 LPM 
 
Total 
study 
Mean 
HR 
1 154   142 148 146 151 144 155 
2 154 160 157 151 153 147 157 161 160 
3 174 177 161 164 161 162 163 166 169 
4 160 175 162 165 167 159 156 152 164 
5 159 155 144 154 155 149 158 148 162 
6 161 151 149 149 157 152 148 151 161 
 
 
 
Table 24 shows the mean heart rate measured during the study. 
 
 
 
 
Figure 44. Heart Rate (mean) during the study 
 
 
 
 
 
 
 
 
Figure 44 is a scatter plot of the mean heart rate measured during the study. 
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Table 25. Respiratory rate (mean) during the study 
 
 
 
 
Study 
ID 
CPAP 
6 cm 
H2O 
HFNC 
8 LPM 
HFNC 
7 LPM 
HFNC 
6 LPM 
HFNC 
5 LPM 
HFNC 
4 LPM 
HFNC 
3 LPM 
HFNC 
2 LPM 
 
Total 
study 
Mean 
RR 
1 58   69 55 77 81 82 69 
2 44 74 75 57 51 67 75 64 63 
3 82 75 69 72 81 71 62 71 74 
4 71 49 46 60 56 64 72 73 63 
5 41 49 37 65 52 81 60 42 62 
6 40 64 51 65 78 81 72 46 62 
 
 
 
Table 25 shows the mean respiratory rate measured during the study. 
 
 
 
Figure 45. Respiratory rate (mean) during the study 
 
 
 
 
 
 
 
 
Figure 45 is a scatter plot of the mean respiratory rate measured during the study. 
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Table 26. Transcutaneous O2 saturation levels (mean %) during the study 
 
 
 
Study 
ID 
CPAP 
6 cm 
H2O 
HFNC 
8 LPM 
HFNC 
7 LPM 
HFNC 
6 LPM 
HFNC 
5 LPM 
HFNC 
4 LPM 
HFNC 
3 LPM 
HFNC 
2 LPM 
 
Total 
study 
Mean 
SPO2 
1 97.2   98.6 97.5 98.7 88.9 99.7 96.3 
2 99.5 95.6 97.1 95.1 97 95 96.5 89.4 94.7 
3 92 90 91.8 89.8 93.6 93 89 89.5 89.7 
4 95.3 97.3 90.4 84 97.4 94 86 96.9 91.5 
5 99.2 99.3 98.8 99.5 99.3 98.4 97.6 99 98.7 
6 99.7 99.6 99.1 98.8 99.4 99 98.5 98.5 98.7 
 
 
Table 26 shows the mean O2 saturation levels at different flow levels during the study. 
 
 
 
 
Figure 46. Transcutaneous O2 saturation levels (mean %) during the study 
 
 
 
 
 
 
 
 
Figure 46 shows the mean O2 saturation levels at different flow levels during the study. 
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Table 27. Transcutaneous CO2 (mean) levels during the study 
 
 
 
 
Study 
ID 
CPAP  
6 cm 
H2O 
HFNC 
8 LPM 
HFNC 
7 LPM 
HFNC 
6 LPM 
HFNC 
5 LPM 
HFNC 
4 LPM 
HFNC 
3 LPM 
HFNC 
2 LPM 
 
Total 
study 
Mean 
TcPCO2 
 
1 8   7.2 7.5 7.4 6.7 7.2 6.8 
2 9.7 9.4 9.1 9.0 9.1 8.9 9.6 8.8 9.3 
3 7.1 8.3 7.4 7.7 7.4 7.3 7.1 7.3 7.1 
4 7.4 6.9 6.6 6.7 6.7 7.1 6.8 7.1 6.4 
5 5.6 5.3 4.5 5.6 5.7 5.6 5.3 5.5 5.0 
6 5.8 6.8 5.9 6.0 5.7 5.9 5.9 5.7 5.6 
 
 
Table 27 shows the mean transcutaneous CO2 levels measured during the study. 
 
 
 
 
Figure 47. Transcutaneous CO2 (mean) levels during the study 
 
 
 
 
 
Figure 47 shows the mean transcutaneous CO2 levels measured during the study. 
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5.6.2 Physiology parameters during respiratory support cross- over (CPAP to HFNC and 
vice versa) 
 
The following FiO2 increments had to be made during the study. These changes were within 
the limits of the protocol and did not warrant withdrawal from continuing the study.  
Study ID 01, 05 and 06 –No FiO2 changes were needed.  
Study ID 02 - FiO2 – Increased once by 5% as per protocol (one O2 desaturation to low 80s). 
Study ID 03 - FiO2 increased on two occasions as per protocol-O2 desaturations to mid-80s 
(FiO2 returned to base line level at the end of the study) 
Study ID 04 - FiO2 increased twice as per protocol – back to the baseline post study.  
 
A detailed analysis of physiology parameters profile 10 minute prior to and 10 minutes after 
cross over to other mode of respiratory support showed that the physiological status of the 
baby was back to baseline within 10 minutes of the change. This indicates that the wash out 
time of 30 minutes time adopted in the study protocol after cross over was probably sufficient. 
This is illustrated in figure 48.  
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Figure 48. The physiology parameters trend with change in respiratory support mode 
(CPAP to HFNC and HFNC to CPAP) 
 
 
 
 
 
 
 
 
 
Figure 48 shows the basic respiratory physiology parameters status 10 minute before and after 
respiratory support mode crossover. 
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5.7 Safety and adverse events 
 
None of the babies had apnoeic episodes requiring intervention.  
There were no episodes of major oxygen desaturations seen during any part of the study or 
handling.  
One baby had one episode of oxygen desaturation with bradycardia which resolved without 
intervention within seconds. This episode was similar to the baby’s pre-study entry episodes 
but not frequent enough to meet exclusion criteria.  
None of the babies had nasal trauma, air leak episode, escalation of respiratory support 
immediately after the study or deterioration of blood gases suggesting decompensation 
immediately following the study.  
 
5.8 Conclusions 
 
In this proof of concept physiology study, I was able to identify a suitable measuring 
technique and measure satisfactory nasopharyngeal pressure in preterm infants safely. The 
ability to measure nasopharyngeal gas concentrations for O2 and CO2 with the same catheter 
enabled assessment of this study outcome without additional instrumentation. I was able to 
use a novel tidal breathing measurement device in preterm infants during HFNC therapy and 
obtain consistent measurements across all flow levels for a period of about two hours. I was 
continuously monitoring the babies and was able to ensure safe conduct of the study and with 
minimal interference to neonatal care needs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 198 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6. General Discussion 
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6.1 Thesis Results and Current Literature 
 
6.1.1 Retrospective study of HFNC use over a 5-year period in Royal Victoria Infirmary 
tertiary neonatal unit 
 
This retrospective study involved a large number of babies (282 patients) treated with HFNC 
and CPAP over a 5-year period and the babies who received HFNC showed worse outcomes 
in terms of NIV days (22 days±15 SD in CPAP versus 49 days ±23 SDin HFNC group)  and 
BPD rate (1.08% in CPAP versus 13.63% in HFNC group). 
 
Though the study has inherent limitations due to being a retrospective study, any possible role 
of HFNC resulting in worse lung health outcomes needs to be considered and warrants further 
research.   
 
More recently further studies have raised similar concerns. The study by Hoffman et al 
covered 2 different time epochs and was a retrospective chart review of HFNC use and 
outcomes(139). They reported a trend towards a higher rate of BPD in HFNC group compared 
to CPAP/BiPAP group (139). The study by Taha et al was a large retrospective review of a 
neonatal database and reported that babies who received HFNC either as lone NIV or in 
association with some CPAP use at some period had worse outcomes in terms of BPD (133).  
 
The possible explanation for worse BPD outcomes noted in retrospective studies could be 
because of selection bias. The sicker babies might have required prolonged NIV and since 
HFNC has been increasingly used as a respiratory support often in place of CPAP there might 
have been higher representation of BPD in HFNC group.  
 
Interestingly BPD outcomes in prospective randomised, controlled trials involving HFNC as 
either as primary respiratory support or as post extubation support or as a weaning mode of 
therapy instead of CPAP have not shown increased rates of BPD in HFNC group(1, 96-98, 
114, 127, 130).  
 
The mechanism of any lung damage due to HFNC is largely speculative. It is more likely to 
be due to under filled lung volumes rather than due to over distension since the air leak 
syndromes in HFNC are less frequent compared to CPAP as indicated in some RCTs (1). The 
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under ventilated lung may be prone to atelectotrauma. The possibility of episodic supra 
therapeutic levels of mean airway pressures is a theory that needs to be tested. The effects of 
transient rises in pressure are not known both in terms of duration or magnitude of higher 
pressures.   
 
In light of the findings in this retrospective review it was decided to appraise available 
literature regarding safety and efficacy of HFNC in preterm neonates.  
 
6.1.2 Evidence for efficacy and safety of HFNC in preterm neonates 
 
In this review, I reviewed RCTs comparing efficacy and safety of HFNC to CPAP or other 
forms of NIV. The risk of treatment failure (needing escalation of respiratory support or 
intubation, as defined by study authors) with HFNC was similar to CPAP when used as post 
extubation support [RR (95% CI) of 1.09 (0.90, 1.31)].  
 
A similar risk compared with CPAP was seen for clinical outcomes like BPD when HFNC 
was used as primary respiratory support, RR 1.17 95% CI (0.72, 1.90); as post extubation 
respiratory support, RR 0.88 95% CI (0.74, 1.05)] and mortality [as primary respiratory 
support, RR 0.61 95% CI (0.08, 4.57); as post extubation respiratory support, RR 0.62 95% 
CI (0.28, 1.39)].  
 
Unlike CPAP, HFNC proved better when it came to complications of therapy. The 
complication risk of air leak syndromes as primary respiratory support, RR 0.42, 95% CI 
(0.17, 1.02); as post extubation respiratory support, RR 0.28, 95% CI (0.15, 0.55)] as well as 
nasal trauma [as primary respiratory support, RR 0.50 95% CI (0.34, 0.72); as post extubation 
respiratory support, RR 0.50 95% CI (0.40, 0.61)]. 
 
However, as a primary respiratory support, the risk of treatment failure was higher compared 
to CPAP [RR 1.57 95% CI (1.20, 2.05)]. The reason for this difference in outcome is unclear. 
The behaviour of lungs in the setting of initial RDS is likely to be different to that of the lungs 
in infants who are ready to be extubated. It may be because HFNC is inherently less 
efficacious in the setting of progressively worsening respiratory distress as compared to 
respiratory distress which is progressively improving. The degree of respiratory support or 
how much off-loading of work of breathing HFNC does has not been answered yet in the few 
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physiology studies done so far(73, 74).  
 
In summary, on combining the studies performed to date, I conclude that HFNC is unlikely to 
be harmful in the short term because it’s not associated with increased mortality or BPD and 
has beneficial effect on nasal trauma and air leak syndromes rates. It does not appear to be as 
effective in primary respiratory support.  The long-term consequences of this support remain 
uncertain and need further research.  
 
6.1.3 Airway pressure measurement methods 
 
In this study, I evaluated the accuracy, range and feasibility of three types of pressure 
transducers.  
 
The Gaeltec catheter tip pressure transducer has been used in earlier studies investigating 
HFNC and various pressure ranges have been reported by different groups of researchers (27, 
29). Earlier Lampland et al used saline filled catheters (24, 31) and Locke et al used an air 
filled balloon catheter(30) for measuring oesophageal pressure as an indicator of pleural 
pressure. These have the disadvantage of being influenced by gravity or height of the 
transducer in relation to the measuring site and in addition the transducer is outside the body, 
away from the measuring site. There is also the added effect of length of the catheter, catheter 
diameter, body movements leading to artefacts on the pressure wave form and they need 
considerable technical skill and expertise to reliably perform. Therefore, catheter mounted 
pressure transducers became an attractive option.  
 
The Gaeltec catheter when tested in vitro showed drift in baseline occurring within minutes 
and attained levels of ± 1.3 cm H2O pressure off baseline at the end of two hours. The drift in 
baseline was larger when pressures at the lower end were tested for stability. A second 
catheter that was available was also tested and produced similar results. This problem 
persisted despite it being sent back to the company and sensor components being re-laid and 
retested in factory conditions. The linearity although was reasonable, the performance of 
pressure recording was not stable at any given pressure point. Ultimately, attempts at 
recording pressure in two babies did not produce reliable pressure recording.  
The likely reasons for our experience with the Gaeltec catheter tip mounted pressure 
transducer include firstly, a faulty batch which is less likely as it was returned to the company 
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for repair. Secondly, these sensors have a very wide pressure range from 0-300 mm Hg (or 0-
407.8 cm H2O). This range is 40 times larger than our intended pressure range. Thus, at the 
very extreme ends of its range it may not be accurate enough. Thirdly, the influence of flow 
dynamics in a complex anatomical space like the nasopharynx on these sensors have not been 
well studied. A lateral wall mounted pressure sensor may not truly catch the pressure 
dynamics in the nasopharynx. Therefore, we concluded that Gaeltec catheter was not fit for 
purpose in this setting.  
 
A thermal sensor was tested in vitro and found to be accurate with good linearity and 
frequency response. However, the main limiting factor in using these sensors is they are 
dependent on a flow of gas across their sensor surface in order to detect changes in 
temperature and then provide an analogue output of the likely pressure. Thus, it was tested in 
two babies’ in vivo and I could not get reliable pressure traces since in preterm babies the flow 
through the nasopharyngeal catheter tends to be intermittent and unreliable.  
 
The B&D pressure transducer works with a simple technique of the transducer being exposed 
to two different pressure areas and the differential is picked up by a strain gage type of sensor 
and an electrical signal is generated based on pressure differential and provided as an 
analogue output. Thus, one pressure area is atmospheric and the other is the nasopharynx 
accessed through a nasopharyngeal catheter. It does not depend on flow and as long as the 
catheter is patent, the pressure differential is appreciated by the sensor. The transducer 
showed excellent linearity, stability over time and adequate frequency response for neonatal 
breathing frequency. I used this in two babies and obtained reliable pressure traces across all 
flow rates and CPAP in one baby and across some flow rates in the second baby.  
To conclude, from these measurements, the B&D differential pressure transducer provided a 
consistently valid pressure signals with valid data across all flow ranges. This pressure 
transducer was found to be suitable to study the nasopharyngeal airway pressures in the 
context of preterm neonatal age group.  
 
6.1.4 Airway gas concentration measurement methods during HFNC 
 
The airway dead space wash out effect is one of the proposed mechanisms of action of HFNC. 
This has been noted by tracheal gas insufflation studies earlier and subsequently by 
observational clinical studies (71, 72). However, it’s not been confirmed or its relative 
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contribution to the efficacy of HFNC has not been studied. We hypothesised that 
simultaneous recording of transcutaneous CO2 and airway CO2 levels would help us 
understand whether HFNC has any significant role in washing out the airway dead space of 
expired air CO2 content.  
 
Firstly, in this study, I showed that it is possible to measure the nasopharyngeal airway gas 
concentration quickly with breath-to-breath almost instantaneous data allowing us to compare 
the other respiratory parameters at the same time. We used the same nasopharyngeal catheter 
used to record pressure thus eliminating the need for invasive instrumentation.  
 
Secondly, the relationship of transcutaneous CO2 to the nasopharyngeal CO2 measured in this 
study was interesting. It has been shown in earlier studies that the End tidal CO2 measurment 
trends correlate well with transcutaneous CO2 (159). The measured value of average 
maximum CO2 in the nasopharyngeal space in this pilot study was always much lower than 
that seen in transcutaneous CO2 simultaneously. It could be because of the wash out effect.  
This effect is in the process of being tested in a larger study sample.  
 
Finally, the shape of the CO2 trace obtained needs to be explained. The CO2 trace obtained 
during high flow has smooth edges unlike that seen during capnometry during tidal breathing 
obtained at pneumotach or during ventilation (160) (See Figure 49). The expired CO2 
waveform can provide important information concerning airway obstruction and endotracheal 
tube leak. Similarly, the shape seen in CO2 analysis from the nasopharyngeal airway during 
high flow may be because of increased elimination of CO2 due to high flow and leak. Indeed, 
it was seen in one study where they introduced varying amounts of leak during HFNC, the 
CO2 clearance improved in the presence of leak at increasing flow levels (22). During high 
flow therapy, at any given litre of flow, the volume of dead space to be flushed is determined 
by the time allotted by end-expiration and the expiratory pause (22). Therefore, greater gas 
flows will flush more dead space until a flow rate is reached that can flush all of the available 
anatomical dead space in the available time (22).  
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Figure 49. CO2 trace during high flow, during mechanical ventilation preterm neonate 
(160) and facemask ventilation via pneumotachograph (160, 161) 
 
 
 
 
 
 
Figure 49 shows shape of the CO2 trace during high flow, during mechanical ventilation 
preterm neonate and facemask ventilation via pneumotachograph. 
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The normal end tidal capnometry has a square shape and the plateau phase is truly alveolar 
CO2 only when there is no obstruction in airways distal to site of CO2 measurement or there is 
no washout from conducting airways allowing steady state (either of these scenarios, if 
present, there will be a reduction in end tidal CO2). Therefore, a possible reason for this shape 
during HFNC could be because of CO2 wash out effect of HFNC.    
 
HFNC therapy has been postulated to provide the prescribed FiO2 concentration in view of 
the high inspiratory flows well above the inspiratroy flow demands of the neonate(162). Thus 
there is less room for entrainment of room air during inspiration, diluting the FiO2 in the 
inspiratory limb of HFNC circuit. However, from the available gas concentration test results 
in Table Number 21, there was slightly lower measured O2 concentration compared to the 
administered FiO2.  
 
 6.1.5 Tidal breathing indices evaluation using Volusense in preterm neonates  
 
There has been a renewed interest in measurement of tidal breathing indices in assessment of 
respiratory function. There is a pressing need for robust infant lung function testing in view of 
increasing interventions in infants for various respiratory conditions. However, the main 
limiting factor in infant lung function testing has been the need for sedation or need for 
instrumentation involving the face. The contact of measuring devices or a face mask on the 
facial skin elicits possible reflex neurologic responses altering the breathing characteristics 
and ventilation indices(78). In addition, pneumotach adds to the dead space and resistance 
component. Therefore, non-invasive measurement techniques like Respiratory Inductance 
Plethysmography have come into vogue. Electromagnetic Inductance Plethysmography by 
Volusense being a recent method of evaluating tidal breathing indices, I evaluated the 
feasibility of performing measurements using this technique in preterm neonates on HFNC 
support.  
 
The tidal breathing indices were reliably obtained in all 6 infants. The measurement was easy 
to implement with minimal disruption to the neonates’ daily routine. The instrumentation did 
not interfere with respiratory care, feeding and other nursing care of a preterm neonate. There 
were no adverse events related to use of this device.  
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To my knowledge, there has been no similar study reported using Volusense electromagnetic 
inductance plethysmography (EIP) on preterm neonates during HFNC therapy.   
 
In a study on preterm babies of gestation 28±2 weeks with respiratory support on CPAP and 
bi-level and when breathing was unsupported, Pickerd et al measured tidal breathing indices 
(154). They also measured weekly measurements using electromagnetic inductance 
plethysmography EIP. They could obtain consistent trends in respiratory rate and tidal volume 
per kg with varying respiratory support levels in preterm neonates (154). Earlier the same 
group measured tidal breathing indices using electromagnetic inductance plethysmography 
(EIP) in 49 healthy spontaneously breathing infants between 32 and 42 weeks gestational 
age(81).  
 
Olden compared tidal breathing indices using electromagnetic inductance plethysmography 
(EIP) in normal infants with that seen in infants with BPD(163) and concluded that it is 
possible to measure tidal breathing parameters accurately, in healthy newborn infants, without 
prior calibration on the infant(163).  
 
Bentsen and colleagues measured tidal breathing indices by electromagnetic inductance 
plethysmography (EIP) in 10 preterm infants weighing about 1500 grams and 10 term infants 
with trained nurse performing the measurements. They concluded that measurements were 
well tolerated by the infants and the repeatability was better for term infants and the 
repeatability was as reported in other infant lung function tests being relatively poor compared 
to older children and adults (164).  
 
The same group compared tidal breathing indices obtained from Volusense to that obtained 
via a facemask using an ultrasonic flowmeter. They found agreement within ±5.5% except for 
peak tidal expiratory flow (PTEF)(157). They found that the application of the facemask 
significantly increased tidal volume, minute ventilation, PTEF, the ratio of inspiratory to 
expiratory time and the ratio of expiratory flow at 50% of expired volume to PTEF (157). 
They concluded that Volusense electromagnetic inductance plethysmography (EIP) was well 
suited for tidal breathing measurements in infants where facemask cannot be used (157).  
 
In conclusion, I found that application of Volusense vests was easy, well tolerated by infants, 
the assembling of equipment was achieved with little hindrance to routine care and the 
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procedure was well tolerated by preterm neonates. Although I did not confirm the tidal 
volume accuracy with that obtained by face mask and pneumotach method, the range of tidal 
volumes I obtained was within the range expected in preterm neonates.  
 
6.2 Safety Aspects of a Respiratory Physiology Study in Preterm Neonates 
  
The basic respiratory physiology parameters namely, respiratory rate, gas exchange 
parameters including SPO2 and TcPCO2 levels were stable during the study in all cases.  
Only 3 babies out of 6 needed adjustment of FiO2. This was well within the limits agreed in 
the protocol for safety reasons and did not require the study to be terminated.  
There were no nasal trauma or air leak complications. There were no immediate respiratory 
decompensation following the study.  
 
There were no concerns raised by clinical team, nursing staff or parents during the conduct of 
the study.  
 
6.3 Strengths and Limitations of the Study  
 
This main strength of this study is an extensive exploration of evidences and methods of 
evaluation of respiratory physiology parameters including airway pressures and gas 
concentrations in nasopharyngeal airway as well as a novel method of determining tidal 
breathing indices. The study showed the likely valid tools for measuring airway pressures 
safely and accurately.  
 
The airway pressures were measured with a catheter placed in nasopharyngeal airway 
connected to a differential pressure transducer. This method was shown to be feasible and the 
system had good agreement when checked in vitro against a control pressure source. The 
continuous measurement of pressures is an ideal goal but difficult to achieve. The main reason 
is because of the small size of preterm neonates; the instruments have to be of smaller calibre 
and hence are prone for blockage with secretions. Therefore, one has to rely on a consistent 
epoch of valid measurements at each level of respiratory support mode of interest. The 
segment that one chooses to report needs to be standardised, otherwise it is prone for 
reporting bias.  
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The measurement of gas concentration is an interesting aspect which has not been looked into 
much by other physiology studies on HFNC therapy. One of the strengths of this study is that 
I showed it is possible to rapidly obtain and record continuous gas concentration status in 
these preterm neonates. The simultaneous measurement of transcutaneous CO2 gives added 
information about the gas exchange status or ventilation efficacy at that point in time. A larger 
study with adequate data points will help us quantify any CO2 wash out from air way dead 
space during HFNC therapy.  
 
A novel method determining tidal volumes non-invasively using Volusense was shown to be 
feasible and well tolerated by preterm infants. This machine though bulky, could fit within the 
space available in the neonatal unit. The study methods were demonstrated to be safe and 
tolerable by this vulnerable group of preterm neonates.  
 
The study is limited by lack of some control measurements particularly with Volusense tidal 
breathing assessments. However, that would have added time and burden of instrumentation 
to the babies which was the reason for not including it in the protocol. Moreover, there has 
been published evidence that Volusense electromagnetic inductance plethysmography (EIP) is 
a valid tool to evaluate tidal breathing indices.  
 
Since this is a proof of concept study the number of samples obtained with pressure and air 
way gas concentration techniques are not sufficient to make quantitative judgments.  
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6.4 Future Research  
 
This study will be followed up with a larger randomised cross over study involving same 
protocol to obtain sufficient numbers of data points. Then it will be possible to make 
quantitative conclusions of the relative role of different mechanisms of HFNC in providing 
respiratory support in addition to humidification and oxygenation. 
 
The non-invasive tidal volume measuring technique used in this study can be used for follow 
up measurements of tidal breathing indices serially for preterm infants with significant 
chronic neonatal lung disease. It can also be used to study changes in pulmonary function 
with different respiratory support modes and in different physiologic states such as sleep and 
awake. It can also be used to evaluate tidal breathing indices in various pulmonary disease 
states and response to therapy such as in bronchiolitis.   
 
The areas where there are considerable lacunae in HFNC therapy are identifying best weaning 
strategy with HFNC, whether HFNC cause harm to ELBW babies and some other areas such 
as in improving quality of life to palliative patients by enabling home therapy and whether it 
is possible to deliver aerosol medications effectively during HFNC. There is also need for 
long term follow up of babies who received HFNC in the neonatal unit and post term babies 
with severe BPD who sometimes spend weeks on HFNC to assess effects on lung function 
and respiratory health.  
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6.5 My Personal Reflections about This Work 
 
Personally, I have gained several important skills in conducting research from this project. 
The process of conceptualising the ideas into an ethically acceptable and practically 
implementable methodology in a protocol was an educational experience. I found that it is 
important to learn the skills of ‘thinking ahead’ to work out the likely issues, problems and 
seeking solutions to these issues. I had many long hours of physiology discussion with my 
supervisors, which helped improve my understanding of some of the difficult concepts 
involved.  
 
The rigorous ethical approval process helped in improving my own understanding of what 
these investigations would mean to the ultimate stake holders in the study ‘the preterm 
neonates’.  The research equipment and materials can be expensive and I learned that the 
process of convincing a funding source to provide financial support can be quite challenging. 
I needed to clearly know the likely benefits this research would give, to convince a committee 
to part with some of their money. The support structure and monitoring process of hospital 
trust showed me that at the core of this hospitals’ aim was patient safety and the research 
governance team was thorough in their evaluation before giving the permission to conduct 
this research.   
 
The respiratory physiology investigations, especially in small preterm babies are challenging 
to conduct. I feel there is an immense need in developing miniature diagnostic tools 
particularly sensors and transducers which can be incorporated to the routine devices such as 
nasogastric tube for example, to measure oesophageal pressures. I read during my literature 
review the versatility of optical fibres and felt it was applicable for some of the equipment we 
needed. There is also need for developing the technology and improve the quality of data in 
non-invasive lung function measuring methods in infants.  
 
By doing this project, I have improved my skills in research and I feel more confident with 
my research skills to pursue my interest, respiratory physiology and lung function in infants.  
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